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ABSTRACT
The conjunctival wound healing response remains the major barrier to achieving long 
term intraocular pressure control after glaucoma filtration surgery (GFS). Current anti­
scarring agents improve the outcome of surgery but act by causing widespread cell death 
and can be associated with potentially blinding complications. In addition, some 
individuals still fail surgery. A more physiological and targeted approach to wound 
healing control and scarring prevention is required.
Of all the growth factors, TGF p has been shown to play a pivotal role in wound healing 
throughout the body, and has been identified as a potent stimulant of the scarring process 
in the eye. Modulation of TGF P has been highlighted as a possible mechanism by which 
ocular scarring may be reduced. This thesis has investigated the role of TGF p 
modulation as a potential anti-scarring strategy in glaucoma surgery.
In vitro, I have demonstrated that the anti- TGF p2 monoclonal antibody, CAT-152, 
inhibits Tenon’s fibroblast collagen production and myofibroblast transformation at 
physiological concentrations. It appears that these are the key histological changes 
associated with bleb failure following experimental GFS.
In vivo, subconjunctival administration of CAT-152, given at the time of surgery and in 
the immediate post-operative period, successfully improves surgical outcome, reduces 
subconjunctival fibrosis and is safe and well tolerated. Isolated post-operative 
administration of subconjunctival CAT-152 can prevent late bleb failure and prolonged 
dosing with CAT-152 appears to modulate the long-term scarring response after GFS. In 
addition, the anti-scarring effects of CAT-152 have compared favourably to one of the 
gold standard anti-scarring agents in clinical use. Finally, I have shown that antisense
2
oligonucleotides directed against TGF (3 may also have a role in the prevention of 
conjunctival scarring.
In summary, the work supports the hypothesis that TGF (3 modulation may represent a 
novel potential anti-scarring strategy in glaucoma surgery.
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CHAPTER 1. INTRODUCTION
1.1 GLAUCOMA
1.1.1 Overview
Glaucoma (derived from the Greek word Glaukos describing dull greyish-green or blue 
colouring) can be defined as a progressive optic neuropathy, which is characterised by a 
distinct pattern of visual field loss and has elevated intraocular pressure (IOP) as the 
major risk factor. The glaucomas are not a single disease process but a large group of 
disorders in which optic nerve head damage is the common pathological process. 
Glaucoma is a leading cause of irreversible blindness in the developed and developing 
world and is estimated to account for 15% of world blindness (Foster et al., 1990; 
Thylefors et al., 1994). In addition, due to the insidious nature of the disease many cases 
remain undiagnosed or patients present late with advanced irreversible glaucomatous 
visual loss (Grant et al., 1982). It is estimated that only 50% of cases are diagnosed in the 
developing world (Quigley, 1996).
Glaucoma can be broadly classified according to aetiology. In primary glaucoma 
developmental or intrinsic degenerative processes occurring in the eye give rise to raised 
pressure and optic nerve damage. In secondary glaucoma, however, the pathological 
changes are driven by other recognisable ophthalmic or systemic diseases. Glaucoma can 
be further subdivided into open angle or closed angle glaucoma. These terms relate to the 
anatomy of the drainage angle of the eye and the mechanism by which the outflow of 
fluid from the eye is impaired (Figure 1).
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Figure 1 Schematic diagram to illustrate the anatomy of the
anterior chamber and the normal passage of aqueous humour
CORNEA
'  CILIARY LENS
Site of trabeculectomy trap door to 
direct aqueous flow through the sclera 
and into the subconjunctival space
Outflow through 
Schlemms canal
CONJUNCTIV
Direction of aqueous flow
TRABECULAR MESHWORK
Aqueous is produced by the ciliary body epithelium and flows predominantly 
anteriorly around the lens into the anterior chamber. When the angle is open 
aqueous drains from the eye via the trabecular meshwork and is reabsorbed 
into the circulation through Schlemms canal and the aqueous veins. In angle 
closure the anterior chamber shallows and the iris becomes opposed to the 
peripheral inner corneal blocking the ability of fluid to drain into the 
trabecular meshwork. Following glaucoma filtration surgery an alternate 
route is created to direct aqueous transconjunctivally under less resistance
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Primary open angle glaucoma (POAG) is the commonest form of glaucoma in Britain and 
the USA affecting approximately 1 in 100 of the general population over 40 years and 
will be the focus of this discussion.
1.1.2 Intraocular pressure, glaucomatous damage and disease progression
Appreciation of elevated IOP as a risk factor for glaucoma dates back to the middle of the 
nineteenth century when Von Graefe reported its association with a characteristic type of 
optic nerve damage leading to blindness. Population based studies have confirmed that 
increased IOP is associated with increased prevalence and incidence of glaucoma 
(Armaly et al., 1980; Leske et al., 1995; Sommer et al., 1991). Raised pressure induces 
compression, stretching and remodelling of optic nerve head which results in direct 
mechanical axonal damage, compromised blood flow and reduced delivery of nutrients. 
Progressive loss of retinal nerve fibre axons leads to reduced visual function (Hernandez. 
M et al., 1997).
It is logical to predict and some evidence shows that reduction of the intraocular pressure 
will slow the progression of the disease (Grant et al., 1982; Group, 1989; Group, 1996; 
Mao et al., 1991; Odberg, 1987). More conclusive evidence has been provided recently 
by large, long term randomised clinical trials that were specifically designed to address 
this issue. In the advanced glaucoma intervention study (AGIS) individuals in which 
intraocular pressure was maintained below 18mmHg on all occasions, with an average of 
12.3mmHg, showed minimal disease progression, over 8 years of follow up (AGIS 
Investigators, 2001). The early manifest glaucoma trial was designed to identify risk 
factors and investigate the effect of treatment on glaucomatous progression. The results 
showed that each 1 mmHg reduction in IOP was associated with a 10% reduction in 
disease progression (Leske et al., 2003). Finally the ocular hypertension study showed
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that reduction of the IOP was effective in delaying or preventing the onset of optic nerve 
damage in individuals with raised pressure.
1.1.3 Management of glaucoma
Although other risk factors are recognised to be involved in the development of 
glaucomatous optic neuropathy, the control of IOP is the principal goal of current 
glaucoma treatment. IOP can be reduced by either limiting the production, or increasing 
the outflow, of aqueous humour from the eye. This can be achieved by medical, surgical 
or laser therapy.
Medical treatment in the form of topical eye drops is the most commonly used method to 
control IOP. Numerous formularies exist which act via different pathways, and can be 
used in isolation or as combined therapy. Despite topical administration, medical 
treatment can cause both local and systemic side effects. For example, the topical beta 
blockers can be associated with bronchospasm and heart failure (Diggory et al., 1996). 
Secondly, this mode of treatment is expensive, particularly the newer agents, which 
precludes use in the developing world. In addition, they require frequent and regular 
application for prolonged periods. This can lead to problems with administration and 
compliance particularly in the elderly, who make up a large percentage of the population 
needing treatment. Finally, studies have shown that long term use of eye drops can limit 
the success of glaucoma filtration surgery (Broadway et al., 1993a; Broadway et al., 
1993b; Broadway et al., 1994a; Broadway et al., 1994b; Lavin et al., 1990).
Laser treatment for primary glaucoma was introduced in the 1980s when the technique of 
argon laser trabeculectomy (application of laser bums to the trabecular meshwork) was 
first described. More recently selective laser trabeculectomy using application of Nd
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YAG laser has been introduced, which causes less tissue destruction. This treatment 
modality is effective in the short term, in certain types of secondary glaucoma (Robin et 
al., 1983), and in individuals of Afro-Caribbean origin (AGIS Investigators, 2001). 
However, long term IOP control is rarely achieved (Migdal, 1995). It is commonly 
adopted as a primary treatment in the USA but its use in the UK is normally limited to 
patients in which a conservative approach to treatment is deemed appropriate.
In cyclodiode laser therapy the ciliary body (site of aqueous production) is ablated. Its use 
is advocated in cases of severe refractory glaucoma, where other approaches have failed, 
and is proving to be a very useful tool (Bloom et al., 1997).
1.1.4 Glaucoma filtration surgery
Of all available therapies, surgery has been shown to be the most effective at controlling 
IOP and preventing visual loss (Hitchings et al., 1994; Jay, 1989; Jay, 1992; Migdal et al., 
1994). In addition, glaucoma filtration surgery results in a better quality of life for 
patients than medical therapy and in the developing world it is the only practical 
treatment (Sherwood et al., 1998).
The principle of glaucoma surgery is to provide an alternative channel for aqueous to 
drain out of the eye and thus lower the IOP. Filtration procedures have been performed 
since the early twentieth century and have evolved from early ‘unguarded’ techniques, 
where a full thickness hole in the sclera provided a direct fistula between the anterior 
chamber and the conjunctival space, to the Cairns ‘guarded trabeculectomy’ procedure, 
which is now the operation of choice (Cairns, 1968).
In a trabeculectomy, the conjunctiva is incised along the limbus and blunt dissection of 
the conjunctival space is performed creating a conjunctival flap. A partial thickness 
scleral flap is then fashioned as far anteriorly as the comeo-scleral junction. A full
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thickness sclerostomy involving either removal of a portion of the anterior trabecular 
meshwork (as originally described, hence the term trabecul(um) ectomy), or a block of 
comeo-scleral tissue is then carried out (Watson’s modification of Caim’s trabeculectomy 
(Watson, 1972). A block of peripheral iris tissue is also excised (peripheral iridectomy) 
and this completes the creation of the new drainage channel. Finally, the scleral flap is 
sutured down and the conjunctiva is closed. Aqueous flows subconjunctivally forming an 
elevated bleb, and is then reabsorbed back into the circulatory system via aqueous veins, 
lymphatic channels and diffusely by the conjunctival tissue (Benedikt. O, 1975) (Figure 
2).
Alternative filtration techniques are occasionally performed in severe and refractory 
cases, where individuals have a poor surgical prognosis or have failed previous surgery. 
Silicone tubes are inserted into the eye to maintain a permanent drainage channel. The 
tubes are attached to an external plate that maintains a large potential space between the 
conjunctiva and the sclera and increases the route of transconjunctival aqueous passage 
(Molteno et al., 1976).
1.1.5 Outcome of GFS
Trabeculectomy has been show to successfully reduce IOP below 21 mmHg in 85% of 
cases (Watson et al., 1981). However, some individuals fail surgery. The post-operative 
wound healing response is the major determinant of surgical outcome after glaucoma 
filtration surgery (Hitchings et al., 1983). Scarring occurs at the level of the sclera and 
with in the subconjunctival tissue, thereby creating a barrier to aqueous flow and results 
in a subsequent rise in IOP following surgery (Doyle et al., 1993a; Khaw et al., 1992b; 
Miller et al., 1989). Figure 3 shows the appearance of filtration blebs after filtration 
surgery. Successful surgery is associated with a diffuse elevated bleb with normal
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Figure 2 The technique of glaucoma filtration surgery
A traction suture is placed in the cornea to provide good exposure to the superior 
conjunctiva (A). The conjunctiva is incised and undermined (B). Cautery is applied 
to bleeding scleral vessels to ensure a bloodless field (C). Residual Tenon's and 
episcleral tissue is cleared. A 45 degree blade is used to make an incision tangential 
to the limbus to 1/3 to 1/2 scleral thickness (E) and a crescent blade is used to create 
a partial thickness scleral flap (F). The sides of the flap are cut to convert the partial 
thickness tunnel into a rectangular flap (G). The eye is entered anterior to the 
surgical limbus (H) which minimises the risk of complications such as iris plugging 
of sclerostomy and inadvertant damage to the lens or ciliary body.
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Figure 2 The technique of glaucoma filtration surgery (cont)
Sclerostomy is made with a scleral punch (I). The removed block of sclera is 
visible on the shelf of the punch, and the hole left by it is semicircular. A 
peripheral iridectomy is made to provide a route for aqueous to move from the 
posterior to the anterior chamber (J). The scleral flap is sutured using a 
combination of permanent and releasable sutures (L,M). Finally the conunctival is 
reflected back and a water tight closure is performed (N).
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Figure 3 Subconjunctival bleb morphology following glaucoma
filtration surgery
Successful glaucoma filtration surgery produces an elevated diffuse 
conjunctival bleb (A). Scarring, however, results in contraction and 
flattening of the bleb with increased vascularisation and reduced fluid flow 
through the subconjunctival tissues (B).
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conjunctival vasculature. Subconjunctival scarring leads to the presence of a flattened 
contracted bleb reduced drainage at the filtration site.
Increased scar deposition is associated with poor control of postoperative IOP. The 
subject has become even more important with the realisation that simply lowering the 
IOP to below 21 is inadequate and that optimal lowering of the IOP should be achieved in 
all patients undergoing surgery for glaucoma. The healing response varies in each 
individual patient (Figure 4). Ultimately IOP control and long term preservation of vision 
can only be achieved if the wound healing response is controlled in all patients.
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Figure 4 Healing profiles after GFS
( C) Persistent healing response
W)G (B) Exaggerated healing response
Excessive healing line
o
H (A) Normal healing response
Inadequate healing line
Time after injury
The healing response varies in each individual patient. The two healing 
lines represent imaginary boundaries; below the inadequate healing line 
a patient may suffer from complications related to low pressure 
(hypotony), whilst above the excessive healing line poor IOP control and 
surgical failure are likely. The normal healing response peaks then 
quickly plateaus but remains within the two healing boundaries (A). A 
patient with an exaggerated healing response who for example has 
received multiple topical treatments starts slightly higher and reaches a 
greater peak compared with normal (B). Persistent healing can be 
associated with chronic inflammatory conditions which constantly 
stimulate the healing response. Healing in this situation is associated 
with a dramatic initial response which is maintained over time (C). 
{Modified from Khaw et al Khaw, 1994b)
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1.2 CONJUNCTIVAL WOUND HEALING
Wound healing is a complex, dynamic process that can be simplified in to three main 
phases; the inflammatory, the proliferative and the remodelling phase. The sequence of 
cellular events following glaucoma surgery can be summarised diagrammatically as 
shown in Figure 5.
1.2.1 Conjunctival insult
Conjunctival, episcleral and scleral incisions result in both connective tissue and blood 
vessel injury. This stimulates the release of plasma proteins, blood cells and extracellular 
matrix (ECM) components into the damaged site, which in turn activates the clotting 
system and a clot forms around the damaged area. Blood loss is initially reduced by the 
aggregation of platelets forming haemostatic plugs. This process is stimulated by the 
presence of various factors including thrombin, adenosine phosphate, fibrinogen, 
collagen, thrombospondin and Von Willebrand factor VIII.
These events are similar to cutaneous wounding; however, the glaucoma filtration 
surgical wound site is unique in that it is constantly bathed by aqueous humour, which has 
a significant effect on the healing response. The aqueous contains factors which account 
for differences in subconjunctival scarring (Radius et al., 1980). Dissected conjunctiva 
normally scars down rapidly without aqueous, which has led to the suggestion that 
aqueous contains inhibitory factors (Herschler, 1990). However, aqueous also exhibits 
stimulatory effects on fibroblasts in vitro and in vivo (Joseph et al., 1987; Joseph et al., 
1989). On entering the eye a degree of breakdown of the BAB occurs, with release of 
stimulatory growth factors into the aqueous and the wound site (Krause et al., 1971; 
Snaders et al., 1982). Rapid scarring and subsequent surgical failure is often seen in eyes
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Figure 5 The sequence of events in wound healing after GFS
Conjunctival, scleral incision
Aqueous released 
from eye
Release of plasma 
proteins and blood
Damage to Connective tissue
Activation of complement and clotting cascade
Formation of blood clot
R
Migration and proliferation of PMN,
macrophages and lymphocyes
Release of growth factors from the blood
Fibroblast migration and activation
Fibroblast migration and wound contraction
Fibroblast synthesis of extracellular matrix
Angiogenesis
D Enzymatic degredation and 
remodelling of ECM
Resolution of wound healing 
Fibroblast apoptosis
Conjunctival scar
The molecular and cellular events leading to subconjunctival scarring and potential areas of wound 
modulation after glaucoma filtration surgery. A-D represents the wounding, inflammatory, 
proliferative and remodelling phases of wound healing.
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with co-existing inflammatory disease, which is thought to be a result of the high 
concentration of stimulatory factors in the aqueous of these patients (Reddan et al., 1979).
1.2.2 The inflammatory phase
This is characterised by the influx of polymorphonuclear cells (neutrophils), followed by 
lymphocytes and macrophages into the damaged area. These cells eliminate infection by 
phagocytosis, scavenge tissue debris and secrete growth factors which stimulate 
fibroblasts migration to the wound site. The inflammatory reaction is further enhanced by 
activation of platelets and the blood clotting cascade resulting in the release of growth 
factors, proteases, arachidonic acid metabolites, 5-hydroxytryptamine and lectins. In 
addition, the formation of fibrin, derived from plasma fibrinogen, provides a scaffold 
bridging the wound edges (Clark et al., 1988). Initiation of the classic complement 
pathway generates inflammatory cell chemoattractant molecules. As cells migrate they 
exert tractional forces on the extracellular matrix which causes contraction of the tissue.
1.2.3 The proliferative phase
This stage of wound healing is heralded by the formation of granulation tissue, which is 
mediated by an increase in fibroblast cell number and activity. Fibroblasts normally exist 
in low numbers within the subconjunctival tissue as undifferentiated mesenchymal cells, 
the fibrocytes. Upon stimulation by local factors at the wound site, fibrocytes become 
activated into fibroblasts, which carry out the key cellular functions of wound healing. 
These are migration, proliferation, tissue contraction and extracellular matrix synthesis 
(Khaw et al., 1994b). Re-epithelialisation and angiogenesis also occur (Figure 6).
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Figure 6 Effect of stimulatory factors at the wound site
Quiescent conjunctival fibrocyte
ECM Components
Fibronectin
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Fibroblast Growth Factor 
Epidermal Growth Factor (controversial) 
Transforming Growth Factor pi and p2 
Insulin like Growth Factor 
Interleukin 6
Complement
Activated fibroblast
Migration
ECM Deposition
Proliferation
Contraction
ECM Remodelling
The key cell in mediating the scar formation is the fibroblast. Various factors at the 
wound site can stimulate fibroblasts to become activated and commence the cellular 
functions of migration, proliferation, contraction, ECM deposition and remodelling.
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1.2.3.1 Fibroblast migration
Environmental factors derived from the locally damaged tissue, blood, inflammatory cells 
and the aqueous humour stimulate the migration of fibroblasts through the surrounding 
extracellular matrix towards site of damage. The complement component C5a, 
leukotriene, extracellular matrix molecules such as fibronectin, collagen fragments, 
elastin are all implicated in this process (Postlethwaite et al., 1976; Postlethwaite et al., 
1981; Postlethwaite et al., 1978; Postlethwaite et al., 1979). Research into the role of 
growth factors has also shown that transforming growth factor beta (TGF (3), basic 
fibroblast growth factor ((3 FGF), epidermal growth factor (EGF) and insulin like growth 
factor (IGF-I) all influence fibroblast migration to the wound site (Postlethwaite et al., 
1987); and in corneal fibroblasts TGF (31 has been shown to maximally stimulate this 
process at much lower concentrations than EGF and (3 FGF (Khaw et al., 1994a).
1.2.3.2 Fibroblast proliferation
Fibroblasts proliferate to generate sufficient cells to carry out the various wound healing 
process in a short time. This process peaks at about two weeks after the initial insult and 
again is regulated by growth factors (Miller et al., 1989; Ross et al., 1968).
TGF (31 has been shown to be a potent stimulator of human Tenon’s fibroblast 
proliferation, stimulating proliferation at much lower concentrations (10-12 M) and to a 
much greater degree (2-3 times greater) than (3 FGF, EGF and IGF-1 (Khaw et al., 
1994a).
1.2.3.3 Extracellular matrix synthesis
Fibroblasts secrete extracellular matrix components such as fibronectin, 
glycosaminoglycans and tropocollagen, which are ultimately enzymatically cross linked 
to form collagen. A fibrin scaffold is formed at the wound site which is initially replaced
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by collagen type HI and then by collagen type I (Figure 7). Type I collagen is laid down 
in large parallel bundles perpendicular to the basement membrane providing tensile 
strength to the mature wound (Thomas et al., 1995). The production of collagen is 
regulated by growth factors. TGF p has been identified as the most potent stimulator of 
ocular fibroblast mediated ECM production (Khaw, 1994). Type 1 collagen is the major 
component of scar tissue and collagen accumulation is a prominent feature in 
experimental surgical failure in the rabbit and monkey (Desjardins et al., 1986; Miller et 
al., 1989). Collagen accumulation is also a prominent feature of failing blebs in man 
(Hitchings et al., 1983). Fibroblasts actively participate in the synthesis of other 
extracellular components such as fibronectin and tenascin.
1.2.3.4 Wound contraction: Fibroblast and myofibroblast cell phenotypes 
The phenomenon of wound contraction is one of the essential steps of subconjunctival 
wound healing. Excessive or abnormal contraction of granulation tissue leads to 
pathological scarring.
The contractile force has been shown to reside in the granulation tissue, however, exact 
mechanisms underlying tissue contraction remain unclear (Grinnell, 1994). Two theories 
have been put forward to explain the contractile forces in wounds and scars, in which 
either cell locomotion or cell contraction act as the predominant mechanism. The first 
theory proposes that fibroblasts exert a tractional force by continual extension and 
retraction of filipodia as they propel themselves forward. Therefore, as cells migrate they 
exert tractional forces on their substratum which results in contraction of the tissue. This 
was elegantly investigated by Harris et al, who seeded fibroblasts onto ultra thin 
polymerised silicon, demonstrated tractional forces and proposed that rearrangement of 
extracellular matrices was the primary function of fibroblast traction (Harris et al., 1981).
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Figure 7 Scar tissue formation in subconjunctival bleb tissue
FIBROBLAST PROTEIN SYNTHESIS
++ Growth Factor
▼
Fibrin Scaffold
++ Tropocollagen
Collagen Type III
i
Collagen Type I 
SCAR
Fibroblasts synthesize tropocollagen, glycosaminoglycans and fibronectin. An 
initial fibronectin and fibrin scaffold is laid down in the wound. Collagen type III 
and then type I are sequentially deposited in a highly ordered arrangement of 
parallel bundles to form the main component of the subconjunctival scar.
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Additional information has been generated from extensive in vitro studies of contraction 
using a model of first described by Bell et al (Bell et al., 1979). Cultured fibroblasts 
suspended in a rapidly polymerizing collagen matrix produce a fibroblast-populated 
collagen lattice and with time, this lattice undergoes a reduction in size referred to as 
lattice contraction. This contractile process has been shown to be dependent on a number 
of factors including cell number, an intact actin skeleton, collagen concentration, cell- 
matrix attraction and protein synthesis (Guidry, 1993; Hunt et al., 1994; Nishiyama et al., 
1988; Pitaru et al., 1987). The mechanism of collagen fibre movement in 3 dimensional 
lattices is not fully understood. Meshel et al have recently demonstrated that fibroblast 
lamellipodia extend along held collagen fibres, bind, and retract them in a 'hand-over­
hand' cycle, involving alpha2betal integrin. Wild-type fibroblasts move collagen fibres 
three to four times farther per cycle than fibroblasts lacking myosin II-B (myosin II-B(-/- 
)).Green fluorescent protein (GFP)-tagged myosin II-B, but not II-A, restores normal 
function in knockout cells and localizes to cell processes. This data suggests that cyclic 
myosin II-B assembly and contraction in lamellipodia power 3D fibre movements 
(Meshel et al., 2005).
Ehrlich et al demonstrated that during lattice contraction two distinct cell populations 
develop (Ehrlich et al., 1990). At the periphery of the lattice, highly oriented sheets of 
cells, referred to as myofibroblasts, show cell-to-cell contacts and thick, actin-rich 
staining cytoplasmic stress fibers. It is proposed that these cells undergoing cell 
contraction produce a multicellular contractile unit which re-orientates the collagen fibrils 
associated with them. The cells in the central region, referred to as fibroblasts, are 
randomly orientated, with few cell to cell contacts and faintly staining actin cytoplasmic 
filaments. In contrast it is proposed that cells working as single units use cell locomotion 
forces to re-orientate the collagen fibrils associated with them.
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This has lead to the second theory of wound contraction which proposes that a specialised 
cell the myofibroblast is responsible for generating the contractile force associated with 
wound closure. Myofibroblasts are present transiently during tissue repair and are 
mesenchymal cells that exhibit morphological and biochemical features of both a 
fibroblast and a smooth muscle cell (Lorena et al., 2002). They are characterised by the 
presence of a contractile apparatus, that contains actin microfilaments with associated 
contractile proteins (non muscle myosin), and a specialised adhesion complex, the 
fibronexus, where the actin bundles terminate on the cell surface and attach the cell to 
extracellular fibronectin fibrils. These two elements generate a mechanotransduction 
system. Another characteristic of myofibroblasts is that they are connected directly to 
each other through gap junctions, indicating that they might form multicellular contractile 
units. Finally, myofibroblasts express a  smooth muscle actin in the stress fibres, in 
addition to (3 and y cytoplasmic actins found in fibroblasts. Contractile force is exerted on 
the ECM by stress fibre contraction mediated through cell cell and cell ECM contact. 
Fibroblasts respond to signals in the ECM and differentiate into the myofibroblast 
phenotype. Myofibroblastic differentiation represents an adaptive response to 
modification of the extracellular matrix environment and is modulated by cytokines. TGF 
(3 has been shown to be a direct inducer of the myofibroblast phenotype and is capable of 
up regulating a  SMA both in vivo and in vitro (Kelley et al., 1993; Li et al., 1999, 
Ronnov-Jessen et al., 1993, Vaughan et al., 2000). TGF pi stimulates the expression of a  
SMA in granulation tissue myofibroblasts. Furthermore, the expression of a  SMA protein 
and mRNA by TGF-pi is induced in both growing and quiescent cultured fibroblastic 
populations (Desmouliere et al., 1993). Serini and Gabianni have also shown that TGF 
P2, like TGF pi induces myofibroblast formation in vitro and in vivo (Serini et al., 1996).
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TGF P3 acts as a negative regulator of the myofibroblastic phenotype in vivo but not in 
vitro. In vitro the three different TGF P isoforms are equally able to induce a  SMA 
mRNA and protein expression in cultured human and rat subcutaneous fibroblasts. 
However, in vivo, TGF p isoforms may play different but complementary roles in 
myofibroblast modulation in wound repair.
A two stage model of myofibroblast differentiation has been proposed (Figure 8). In vivo, 
fibroblasts contain cortical actin but they neither show stress fibres nor do they form 
adhesion complexes with the ECM. In the presence of mechanical stress, fibroblasts 
differentiate into proto-myofibroblasts, which form cytoplasmic actin containing stress 
fibres that terminate in fibronexus adhesion complexes (Dugina et al., 2001, Grinnell et 
al., 1994, Hinz et al., 2001, Berry et al., 1998). Functionally, these cells can generate 
contractile force. In the presence of mechanical stress, TGF P and ED- fibronectin 
promote modulation of the proto-myofibroblasts into fully differentiated myofibroblasts 
(Serini, 1998). These cells are characterised by the de novo expression of a  SMA in stress 
fibres and by large fibronexus adhesion complexes, and functionally generate greater 
contractile force.
In summary myofibroblasts represent the main cellular type present in granulation tissue 
(Gabbiani, 1998) and appear to play an integral role in tissue contraction through 
generation of a mechanotransduction system. In addition, they are implicated in ECM 
deposition during tissue repair and actively participate in the synthesis of ECM 
components such as tenascin, fibronectin and collagens I and III to replace the damaged 
tissue (Zhang et al., 1994). Myofibroblasts are also responsible for the synthesis of 
enzymes involved in matrix degradation. The differentiation from fibroblasts in to the 
myofibroblast phenotype is carefully regulated according to the local environment and an
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Figure 8 Myofibroblast transformation
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Fibroblasts become activated by growth factors and ECM components inducing proliferation, migration to the 
wound site and provisional matrix deposition. Fibroblasts adapt to the local environment and in the presence of 
mechanical tension and TGF p they differentiate into a more contractile phenotype: the myofibroblast which is a key 
cell in pathological scarring.
abnormal predominance of myofibroblasts results in exaggerated and abnormal wound 
healing. Figure 9 provides a model of the evolution of contractile forces during wound 
healing.
1.2.4 Remodelling phase and scar formation
Scar tissue formation requires re-epithelialisation, granulation tissue remodelling with 
ECM degradation, and decreased tissue cellularity. The newly laid down connective 
tissue is remodelled continuously over several months (Peacock, 1984). In normal wound 
healing there is a careful balance between fibroblast and myofibroblasts mediated 
synthesis and degradation of the ECM which leads to the repair and restoration of normal 
tissue architecture. During repair of injured tissues, the mass of granulation tissue must be 
controlled and limited to prevent anarchic remodelling and the development of fibrosis. In 
aberrant wound healing there is an alteration in the balance and excess connective tissue 
is deposited which results in a fibrous scar.
The matrix metalloproteinases (MMP’s) are a family of over 20 proteolytic enzymes that 
degrade the extracellular matrix (Wong et al., 2002). They can be divided into four 
classes on the basis of their preferred substrate: collagenases, gelatinases, stromelysins, 
and membrane type (MT) MMP’s. Collagenases specifically degrade connective tissue 
collagens, mainly I, II and El by unwinding the helical fibre. This results in a denatured 
gelatin form which is susceptible to enzymatic cleavage by other MMP’s and proteases. 
Gelatinases, also known as type IV collagenases, degrade the basement membrane and 
have high enzymatic activity to denatured collagen. Stromelysins have broader substrate 
specificity, as they are able to degrade ECM components such as fibronectin, 
proteoglycans, laminin and type IV collagen of the basement membrane (Baramova et 
al.,1995). The membrane-type MMP’s differ in that they have an additional domain and
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Figure 9 Contractile forces during wound contraction and scarring
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A model to illustrate the evolution of contractile forces during wound healing. One 
of the pivotal differences between wound that proceed to normal compared to 
excessive scarring is the lack of myofibroblat cell death.
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cytoplasmic tail of 25 amino acids that anchors the enzyme to the extracellular side of the 
cell membrane. During repair many different MMP’s are produced by multiple cell types 
residing in the wound environment, including myofibroblasts. Pro teases may impede 
wound healing by degrading ECM proteins, but also by degrading peptide growth factors 
and cell surface receptors. Tissue inhibitors of the metalloproteinases (TIMP’s) a gene 
family of tissue derived metalloproteinase inhibitors, control, at least in part, the catalytic 
activity of MMP’s. The degree of ECM at the wound site is dependent upon the balance 
between MMP’s and TIMP’s, which in turn are regulated by several chemical mediators. 
The final process in normal wound healing is resolution of the scar. Once the wound is 
filled with collagenous matrix, angiogenesis ceases, and the fibroblasts and 
myofibroblasts within the matrix undergo apoptosis (Desmouliere et al., 1995). 
Persistence of these cells in the wound can lead to abnormal scarring and wound 
contracture. The induction of fibroblast apoptosis and their clearance by phagocytes is 
essential for normal wound healing and prevention of scarring. However, little is known 
about the clearance of apoptotic fibroblasts and whether apoptotic cells are active 
participants in the recruitment and activation of phagocytes. Evidence suggests that 
apoptotic fibroblasts may actively release increased amounts of thrombospondin (TSP1) 
to actively recruit macrophages (Moodley et al., 2003). Thromobospondins (TSPs) 1 and 
2 are extracellular modular glycoproteins that are best known for their anti-angiogenic 
properties and their ability to modulate cell-matrix interactions (Adams et al., 2004). 
Knowledge is evolving the role of TSP-1 and TSP-2 in wound-healing. Pericellular levels 
of the matrix metalloproteinase, MMP2, appear to be controlled by TSP2 (and potentially 
also by TSP1) (Bomstein et al., 2004) and Thrombospondin-1 promotes fibroblast- 
mediated collagen gel contraction caused by activation of latent transforming growth
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factor beta-1 (Sakai et al., 2003). TSP-2 may also play a key role in keratocyte/collagen 
matrix interactions during corneal stromal repair (Armstrong et al., 2003).
Successful glaucoma surgery is usually associated restoration of the normal conjunctival 
architecture at surgical site, which allows subconjunctival accumulation of aqueous 
humour (The bleb). However, in failed filtration surgery a dense scar is formed in the 
subconjunctival space which prevents aqueous flow and intraocular pressure lowering. 
Subconjunctival scarring represents the major barrier to achieving long term intraocular 
pressure control.
1.3 TRANSFORMING GROWTH FACTOR BETA AND CONJUNCTIVAL 
WOUND HEALING
Wound healing consists of a series of co-ordinated events which are driven by locally 
released mediators. The growth factor proteins involved in the scarring response are 
summarised in figure 10.
Transforming growth factor beta (TGF P) is a multifunctional growth factor with 
diverse effects throughout the body. The term was initially used to describe a protein 
produced by retro-virally transformed cells, which induced phenotypic changes in normal 
rat fibroblasts (Roberts et al., 1980; Spom et al., 1986). TGF P was identified in platelets 
and subsequently found to be produced by a variety of cells (lymphocytes, monocytes, 
macrophages) and tissues such as kidney, placenta lung and hepatic (Assoian et al., 1983; 
Roberts et al., 1981). Its actions depend upon target cell type, the extracellular 
environment, the cellular state of differentiation and the presence of other growth factors. 
It therefore displays diverse and opposing effects on many cell processes.
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Figure 10 The role of growth factors in wound healing
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1.3.1 TGF P superfamily
TGF P belongs to large superfamily of polypeptide molecules involved in growth, 
differentiation and morphogenesis. There are over 30 members which are grouped into 
four families according to their degree of structural and functional relationship (Kingsey, 
1994) (Table 1).
The TGF p superfamily displays high inter and intra species conservation through 
evolution. Most of the amino acid sequence similarity is in the C terminal of the precursor 
molecule. The degree of sequence identity in this domain ranges from 25 to 90% between 
different family members. At least 7 of the 9 cysteine residues in the C domain are 
conserved in all members of the superfamily and all 9 are conserved in the TGF p and the 
inhibin P chain (Roberts et al., 1990).
1.3.2 Molecular Structure
Three different mammalian 25,000 Da isoforms of TGF P have been identified; TGF pi, 
p2 and p3. TGF p is secreted in a latent form from an inactive precursor, which is then 
activated to mature form. The TGF p precursor has the characteristics of a secretory 
propeptide molecule and consists of an N-terminal signal sequence, glycosylated pro 
region and C-terminal domain bioactive domain. The precursor sequence site consists of 
four basic amino acids immediately preceding the bioactive domain. The mature 112 
amino acid C -terminal domain encodes 9 cysteine residues, which are conserved across 
the 3 mammalian isoforms. One of these cysteine residues forms an intermolecular bond 
to form a biologically active dimer molecule (Cheifetz et al., 1988; Schlunegger et al., 
1992). The mature C-terminal amino acid sequences display great conservation across the 
mammalian isoforms. TGF P2 is 70-74% similar to TGF pi, TGF p3 is 78-80% similar to
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Table 1 The TGF P superfamily
GROUP FUNCTION SUBFAMILY
MEMBERS MEMBERS
TGF P
Embry ongenesis 
Growth and 
differentiation 
Inflammation 
wound healing
TGF p
TGF b 1,2,3 
mammals 
TGF b4 chick 
TGF b5 frog
ACTIVIN Hormone secretion 
regulation, growth 
and development
Activins 
and inhibins
Activins mammal 
Inhibin A mammal 
Inhibin B mammal
DECAPENT
APLEGIC
Development of 
cartilage and bone
Bone morphogenic 
proteins BMP
Decapentaplegic
BMP2
mammal
BMP4
mammal
DPP
Drosophila
60 A Development of 
cartilage and bone
60 X
Bone morphogenic 
proteins
BMP 5,6,7,8
Mammal
60a  Drosophila
MISC Growth and 
differentiation
Growth 
differentiation 
factors (GDF)
Mullerian inhibiting 
substance (MIS)
GDF 1,3,9 
mammal 
MIS mammal 
Dorsalin chick 
Nodal mice
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TGF pi and 80-82% similar to TGF p2. The precursor sequences are less well conserved 
with TGF pi having a G-C rich sequence, p2 A-T rich and p3 displays a combination. 
TGF p i was the first protein to be isolated and acts as the structural prototype for the 
superfamily. Mature TGF pi is a dimer of two identical 112 amino acids chains, 
synthesised from a 390 amino acid precursor (Derynck et al., 1985). The TGF pi gene is 
located at 19ql3 in the human and chromosome 7 in the mouse (Roberts et al., 1990). The 
structure of TGF pi is shown in Figure 11. TGF p2 is also a homodimer of 112 amino 
acids cleaved from a 442 or 414 amino acid precursor (Webb et al., 1988). The gene is at 
chromosome lq41 in the human and at chromosome 1 in the mouse. TGF p3 was first 
identified at the cDNA level and has a 410 amino acid precursor, which forms a 
homodimeric 112 amino acid mature form (Derynck et al., 1985). The TGF p3 gene is at 
chromosome 14q24 in the human and 2 in the mouse.
There is over 97% identity between the mature TGF pi sequences from various 
mammalian and avian species. The same is true for the other two isoforms (Figures 12 
and 13)
Knockouts of the three isoforms produce different phenotypes. An auto immune 
inflammatory reaction is evident in TGF pi null mice. TGF P2 null mice exhibit perinatal 
mortality and a wide range of developmental defects for a single gene disruption. These 
include cardiac, lung, craniofacial, limb, spinal column, eye, inner ear and urogenital 
defects. The developmental processes most commonly involved in the affected tissues 
include epithelial-mesenchymal interactions, cell growth, extracellular matrix production 
and tissue remodelling (Sanford et al., 1997). TGF p3 null mice die with unique and 
consistent phenotypic features including delayed pulmonary development and defective 
palatogenesis (Kaartinen et al., 1995)
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Figure 11 Precursor latent and bioactive forms of TGF (31 
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I
ACTIVATION
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The precursor consists of an N terminal signal sequence, a pro-region and the 
bioactive domain. After secretion the cleaved pro-region remains associated with the 
TGF p dimer forming the biologically latent complex. In platelets and certain cell 
lines the latent complex also contains a 125-190 kd glycoprotein of unknown 
function. Bioactive TGF pi is released by disassembly of the complex.
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Figure 12 Optimal alignment of TGF-pl amino acid sequences
between species
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LASPPSQGEVPPGPLPEAVLALYNSTRDRVAGESADPEPEPEADYYAKEVTRVLMVDRNN
EIYDKFKQSTHSIYMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNS
KIYKKYKESRHSVYMLFNTSELREAVPEPVLLSRAELRLQRLKLQQEQHVELYQKYSNDS
AIYEKTKDISHSIYMFFNTSDIREAVPEPPLLSRAELRLQRLKSSVEQHVELYQKYSNNS
WRYLSNRLLAPSDS PEWLS FDVTGWRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDING 
WRYLSNRLLAPSNTAEWLS FDVTGWRQWLSHGEEIEGFRLSAHCSCDNKDNVLQVDING 
WRYLGNRLLTPTDTPEWLSFDVTGWRQWLNQGDGIQGFRFSAHCSCDSKDNKLHVEING
Box I
MPPSGLRLLL--LLLPLLWLLVLTPGRPAAG 
MPPSGLRLLLPLLLLPLLWLLVLTPGRPAAG 
MPPSGLRLLP--LLLPLPWLLVLTPGRPAAG
FTTGE
ISSGF
ISPKE
RGDLATIHGMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQL
RGDLATIHSMNRPFLLLMATPLERAQHLHSSRHRRALDTNYCFSSTEKNCCVRQL
RGDLGTIHDMNRPFLLLMATPLERAOHLHSSRHRRALDTNYCFSSTEKNCCVROL
YIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVP
YIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVP
YIDFRKDLGWKWIHEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASASPCCVP
QALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS
QALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS
QALEPLPIVYYVGRKPKVEQLSNMIVRSCKCS
Alignment of amino acid sequences for TGF-pl precursors translated from human, rat 
and mouse mRNAs. Box I indicates the signal sequences and Box II indicates the 
mature protein sequences. The nine cysteine are highlighted in red and show 
conserved aligment.
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Figure 13 Optimal alignment of TGF-p2 amino acid sequences
between species
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LSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEP
EEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPP
EEVPPEVISIYNSTRDLLQEEASRRAAACERERSDEEYYAKEVYKIDMPSYFPSENAIPP
DEVPPEVISIYNSTRDLLQEKASRRAAACERERSEQEYYAKEVYKIDMPSHLPSENAIPP
TFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSP 
TFYRPYFRIVRFDVSTMEKNASNLVKAEFRVFRLQNPKARVAEQRIELYQILKSKDLTSP 
T FYRP YFRIVRFDVSTMEKNASNLVKAEFRVFRLQNPKARVAEQRI EliYQILKSKDLTSP
TQRYIDSKWKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIP 
TQRYIDSKWKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNY11P 
TQRY IDS KWKTRAEGEWLS FDVTDAVQEWLHHKDRNLGFKI SLHCPCCTFVPSNNY IIP
NKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRK
NKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQSNRRK
NKSEELEARFAGIDGTSTYASGDQKTIKSTRKKTSGKTPHLLLMLLPSYRLESQQSSRRK
KRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQH
KRALDAAYCFRNVQDNCCLRPLYIDFRRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQH
KRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQH
RVLSLYNT INPEAS AS PCCVSQDLEPLTIL YYIGKTPKIEQLSNMIVKS CKCS *
SRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS*
TKVLSLYNTINPEASASPCCVSQDLEPLTILYYIGNTPKIEQLSNMIVKSCKCS*
Alignment of amino acid sequences for TGF-p2 precursors translated from human, rat 
and mouse mRNAs. Box I indicates the signal sequences and Box II indicates the 
mature protein sequences. The nine cysteine are underlined and show conserved 
aligment.
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1.3.3 Regulation and expression of TGF (3
In general, the pattern of TGF (3 expression varies with each cell type and does not appear 
to be uniform among cells of the same lineage. Given that most cells types in the body 
have been shown to produce TGF (3, the activity of this growth factor must be carefully 
regulated to prevent disease. The mechanisms of regulation of TGF p are extensive and 
complex.
1.3.3.1 Gene transcription regulation Transcription of the TGF pi gene can be 
stimulated by phorbol esters via a protein kinase C pathway and by itself (Van 
Obberghen-Schilling et al., 1988). The 5; region of the TGF pi gene contains two 
transcriptional start sites, one promotor region, 1400 base pairs up from the 
transcriptional start site, and second located between the two start sites (Kim et al., 1989). 
Four regions have been identified within the upstream promoter, two negative regulatory 
regions, an enhancer like element and a positive regulatory region, which contains 
binding sites for known transcription factors (API, Spl and NF1). The ability of TGF pi 
to positively regulate its own expression is thought to be via the transcriptional enhancer 
elements in both promoters that respond to induction by the TGF pi protein as well as 
API and phorbol ester. Activation via these elements is mediated by binding of the (Jun- 
Fos) AP-1 complex (Kim et al., 1990). Since the expression and activity of jun and fos 
genes are modulated by numerous factors including their own products and TGF p 1, these 
mechanisms have the capacity to finely tune TGF pi expression in response to diverse 
stimuli.
The three TGF p genes appear to be under differential transcriptional regulation, even 
thought the protein products are functionally very similar. Each promoter region is 
different; TGF pi is rich in G-C with SP1 and AP2-like binding sites but no TATA or
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CAAT boxes whilst TGF p2 and TGF p3 both have a TATA box and a functional 
CRE/ATF binding site. TGF p3 also has a non functional AP2 and several potential Spl 
binding sites. Therefore TGF p i and p3 both display stimulation by Spl transcription 
factor, whereas TGF p2 does not.
There is evidence that different cells may have different responsive elements in the 
promoter region of the p i gene. Spom and Roberts showed that the retinoblastoma gene 
product, RB, significantly stimulated the TGF p i promoter in mink lung epithelial cells 
but inhibited it in fibroblast cells (Kim et al., 1991). These differences in promoter 
activity may help to explain the variable TGF p effects seen on different cell lines.
1.3.3.2 Release and activation In most cells TGF p is released as part of a biologically 
inactive complex which is unable to interact with cell surface receptors. The latent 
complex consists of a dimer of the N terminal pro region (Latency associated peptide: 
LAP) non covalently associated with the dimeric C-terminal mature protein. The latent 
complexes of the three TGF p isoforms significantly differ from one another in that their 
precursor sequences display variation in glycosylation sites, the number of cysteine 
residues and the presence or absence of a peptide RGD (Arg-Gly-Asp) sequence.
In some cases the latent complex also contains a latent TGF p binding protein of 125-160 
kDa in platelets and 170-190 kDa in fibroblasts (LTBP), which is disulphide linked to 
LAP and non covalently associated with mature TGF pi (Kanzaki et al., 1990; Wakefield 
et al., 1988).The amino acid sequence contains multiple EGF like repeats as the main 
distinctive feature (Kanzaki et al., 1990). The function of this protein is not fully known 
in that it does not prevent binding of activated TGF pi to cells and has no detectable 
proteolytic activity. However, the LAP lacking LTBP is secreted more slowly from cells
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and release of latent TGF (31 from the ECM is as a consequence of proteolytic cleavage of 
LTBP (McMahon et al., 1996; Taipale et al., 1994).
For TGF (3 to become biologically active the LAP has to be released from its association 
with latent TGF (3 or must undergo a conformational change to expose the binding site. 
Evidence suggests that proteolytic action of plasmin (Grainger et al., 1995) or Cathepsin 
D on the pro region, the action of extremes of pH , chaotropic denaturing agents (sodium 
dodecyl sulfate, urea) or deglycosylation with glycosidases may contribute to the 
activation of TGF (3 in vivo (Lyons et al., 1988).In addition, non enzyme catalyst 
activation can occur with thrombospondin (McMahon et al., 1996). The TGF pi 
proregion can bind to mannose-6-phosphate receptors which may also contribute to the 
activation of the latent molecule (Dennis et al., 1991). Platelets have been shown to 
contain a furin-like enzyme which is released during platelet degranulation and may act 
as an alternate means of activating latent TGF p (Blakytny et al., 2004)
1.3.3.3 Sequestration Once released from the latent complex active TGF pi is bound by 
various ECM components and serum proteins. Clearance of circulating activated TGF P 
is extremely rapid (< 3 minutes)(Coffey et al., 1987) and binding a2 macroglobulin 
maybe involved in this process (Wakefield et al., 1987). High affinity binding to the core 
protein of proteoglycan and betaglycan or lower affinity interactions with matrix 
components acts to protect TGF p from degradation, provide a means of sustained release 
or act as a TGF p clearance system.
1.3.4 Signal transduction
TGF p has diverse effects on cellular function via its binding to specific cell surface 
protein receptors. Two glycoproteins (Receptors I and II) and a membrane proteoglycan,
57
designated betaglycan (type HI receptor) have been identified as the most widespread 
high affinity TGF (3 binding components. Most cell types simultaneously express all three 
of these receptors simultaneously although each is functionally very different. The 
receptor characteristics are summarised in Figure 14.
Type I (TBR I) and type II human TGF (3 receptor (TBR II) are classified as 
serine/threonin membrane kinase receptors, in which the signal transduction is dependent 
on phosphorylation of the hydroxyl site of serine or threonin on the target cell. Both 
receptors have an extracellular ligand domain and an enzymatic region located 
intracellularly within the cytoplasm. In comparison with TBR n, TBR I is smaller and 
displays a diminished intracellular domain. The extracellular domain of both receptors 
share sequence homology and are rich in cysteine residues believed to be important in 
determination of the correct three dimensional structure needed for specific binding 
(Ebner et al., 1993).
Both receptors are essential for signal transduction and form a receptor complex. TGF-(3 
binds directly to receptor II, the constitutively active kinase. Bound TGF-p is then 
recognized by receptor I which is recruited into the complex and becomes phosphorylated 
by receptor II. Phosphorylation allows receptor I to propagate the signal to downstream 
substrates. This provides the mechanism by which a cytokine can generate the first step of 
a signalling cascade (Wrana et al., 1994). A GS-rich region with glycine/serine repeats 
lies in front of the kinase domain intracellularly and this contains the phosphorylation 
sites necessary for activation of the TBRI/TBRII complex (Wrana et al., 1994)(Figure 
15). The Type ID human TGF (3 receptor, betaglycan, is a proteoglycan that binds to all 
TGF p isoforms. It forms a stable ternary complex by presenting the TGF p ligand to the 
type II receptor. The type III receptor is thought to have no role in TGF p signalling
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Figure 14 The molecular structure of TGF p receptors
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because deletion of the short cytoplasmic domain has no effect on association with the 
type II receptor, or with the presentation role of the type III receptor. However, Blobe et 
al have recently demonstrated that the cytoplasmic domains of the type III and type II 
receptors can interact specifically, in a manner dependent on the kinase activity of the 
type II receptor and the ability of the type II receptor to autophosphorylate. This indicates 
that the cytoplasmic domain of the type III receptor may infact play an important 
functional role in the regulation TGF (3 signalling (Blobe et al., 2001)
The biological significance of the type IV receptor is unknown. The final TGF (3 receptor, 
endoglin, is abundant on endothelial cells. It contains a transmembrane region and 
cytoplasmic tail homologous to the TBR III receptor. This receptor is mutated in patients 
suffering from hereditary haemorrhagic telangiectasia (Blobe et al., 2000).
Signal transduction by TGF (31 has been well characterised and is summarised in Figure 
15. Briefly TBR I phosphorylation results in activation its kinase, this in turns leads to 
phosphorylation of transcription factors known as Smads (derived from the Sma and 
MAD gene homologues in Caenorhabditis elegans and Drosophila melanogaster). These 
in turn initiate intracellular signalling. Of the 10 smad proteins that have been identified, 
TBR I receptors specifically phosphorylate smad2 or smad3 which then binds to smad4. 
The resulting smad complex moves into the nucleus where it interacts in a cell specific 
manner with various transcription factors to regulate gene transcription. Smad6 and 7 
have been shown to block the phosphorylation of smad2, and therefore inhibit TGF p 
signalling (Massague et al., 2000; Nakao et al., 1997). Although this pathway is 
inherently simple, interactions in the heteromeric receptor and Smad complexes, receptor- 
interacting and Smad-interacting proteins, and cooperation with sequence-specific 
transcription factors allow substantial versatility and diversification of TGF p family
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Figure 15 TGF p interaction with its receptors and signal
transduction
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The basic signalling engine: The ligand assembles a receptor complex that 
phosphorylates Smads, and the Smads assemble a transcriptional complex that 
regulates target genes. The type II receptors are activators of the type I 
receptor. Smads are direct substrates of type I receptors. The assembly of 
receptor-phosphorylated Smads with co-Smads is essential for many 
transcriptional responses. Smads gain access to target genes by synergistically 
binding to DNA with cell-specific cofactors, many of which remain unknown. 
The Smad complex can recruit co-activators or co-repressors that determine 
the outcome.
61
responses. Other signalling pathways further regulate Smad activation and function. In 
addition, TGF-beta receptors activate Smad-independent pathways that not only regulate 
Smad signalling, but also allow Smad-independent TGF p responses (Derynck et al., 
2003).
Receptor binding and activation by the TGF P2 isoform is not as clearly defined. A 
spliced variant of TBR II named TBRII-B has been identified as a TGF P2 binding 
receptor which mediates signalling via the smad pathway. The expression of TBRII-B is 
restricted to cells originating from mesenchymal tissues such as bone where the isoform 
TGF p2 has a predominant role (Rotzer D, 2001).
1.3.5 Biological effects of TGF p
TGF p has the ability to control the differential potential of many cells and therefore 
plays an important role in embryogenesis and development. By influencing cell 
proliferation and activation it is also implicated in the inflammatory and immune response 
and in tumourgenesis. Finally, it is a potent stimulator of scarring in the body.
The ability of TGF p to elicit multiple and often opposing cellular responses is a subject 
of great interest. The paradigm of TGF p as a dual factor arose from initial studies in 
which it was found that depending on the conditions, TGF P can either stimulate or 
inhibit proliferation (Roberts et al., 1985). The diverse effects on different cell lines has 
been summarised in Table 2.
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Table 2 Effects of TGF P on cell function according to cell type
Cellular function FIBROBLASTS EPITHELIUM ENDOTHELIUM SMOOTH
MUSCLE
CELLS
LYMPHOCYTES MONOCYTES
Proliferation
t i i t i ?  f
Migration
t t i r t t
Collagen
contraction i t i t
?
t
ECM deposition
t t t
?
?  t
ECM
degradation i t i i t ? t
OsU)
Inhibited by TGF p 
Stimulated by TGF p
Derived (from Roberts and Sporn, 1990)
1.3.5.1 Effect of TGF P on Cell Proliferation All forms of TGF P display 
reversible growth inhibitory activity in normal as well as transformed epithelial, 
endothelial, neuronal and haematopoietic cells (Cheifetz et al., 1987; Roberts et al., 1985; 
Shipley et al., 1986; Tucker et al., 1984). In certain cell lineages TGF P acts indirectly 
and reduces proliferation by opposing the action of specific mitogens such as EGF in 
keratinocytes and IL-1 and IL-2 in lymphocytes. The extent of the growth inhibitory 
response to TGF p depends on the cell type. TGF P acts by lengthening or arresting the 
G1 phase of the cell cycle (Heimark RL et al., 1986; Shipley et al., 1985). This is 
achieved by stimulating production of the cyclin dependent protein kinase inhibitor pl5 
which thereby inhibits the function or production of essential cell cyle regulators (Ravitz 
et al., 1997).
TGF p can also stimulate cell proliferation particularly in cells of mesenchymal origin. 
The mechanism by which this is achieved is not well described although expression of the 
oncogene c-fos appears to be important as does the regulation of the G1 cyclin dependent 
protein kinases (Ravitz et al., 1997).
1.3.5.2 Effect of TGF P on cell differentiation The differentiative potential of many 
cell lineages can be affected by TGF p in vitro. TGF P has inhibitory effects on 
preadipoctye, myoblast, haematopoietic progenitor cell and megakaryocyte differentiation 
(Ignotz et al., 1986; Massague et al., 1986; Ohta et al., 1987). Induction of differentiation 
is blocked in the presence of picomolar concentrations of TGF p, however once cells are 
committed to differentiate, they become refractory to inhibition. Inhibition does not 
appear to be secondary to the effects of TGF P on cell proliferation, it is reversible once 
the TGF p is removed, and correlates with a marked alteration in the expression of 
extracellular matrix proteins and cell adhesion receptors (Ignotz et al., 1985).
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TGF p has stimulatory effects on prechondroblasts, osteoblasts and epithelial cell 
differentiation (Masui et al., 1986). The TGF p isoforms differ in their effects, whilst 
TGF p i and TGF P2 are equally potent at inhibiting epithelial cell proliferation and 
adipogenic differentiation, only TGF P 1 is a potent inhibitor of haematopoietic 
progenitor cell proliferation (Ohta et al., 1987).
1.3.5.3 TGF p interactions with the ECM The marked and generalised effect of 
TGF P on the ECM plays a major role in tissue repair processes and the pathogenesis of 
fibrotic disease
ECM production and remodelling TGF P increases the expression of fibronectin in 
mesenchymal and epithelial cell types, which can result in up ten fold elevation in 
fibronectin matrix accumulation (Dean et al., 1988; Ignotz et al., 1986). TGF p also 
regulates the expression of type 1 collagen a l  and a2 chains, collagen types III, IV and X 
(Ignotz et al., 1986; Roberts et al., 1986). Other matrix proteins whose synthesis is 
elevated in response to TGF p include tenasin, thrombospondin, and the 
chondroitin/dermatan sulphate proteoglycans, biglycan and decorin (Bassols A, 1988; 
Penttinen et al., 1988). Elevated levels of mRNA for these proteins are seen within 3-5 
hours and result from elevated transcription of the corresponding genes combined with 
increased mRNA stability (Dean et al., 1988, Ignotz et al., 1987).
Not only does TGF P increase the expression of proteoglycan core proteins, it also 
increases the size of the glycosaminoglycan (GAG) chains attached to them (Bassols A, 
1988). Overall TGF P acts to an accumulation and qualitative changes in the composition 
of ECM.
TGF P simultaneously acts to suppress ECM breakdown. TGF P is intrinsically involved 
in the balance between the two enzyme systems that control matrix degradation, MMP’s
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and their inhibitors the TIMP’s. It is thought that TGF p down regulates the expression of 
MMP 1, MMP 3 and plasminogen activators (Overall CM et al., 1988). MMP 3 inhibition 
has been demonstrated to be at the level of transin/stomelysin gene expression (Kerr LD 
et al., 1990). TGF p also induces the expression of protease inhibitors such as 
plasminogen activator inhibitor, TIMP land TIMP 2, thereby increasing the deposition of 
ECM (Edwards et al., 1987; Lund et al., 1987).
Cell matrix and cell cell adhesion Cell migration during tissue repair is guided by a 
complex set of adhesive interactions between cells and extracellular matrices. The 
integrin family of cell adhesion receptors have been examined as targets as the 
mechanism by which TGF P treated cells have a greater ability to bind fibronectin and 
collagen. Integrins are heterodimeric membrane glycoproteins that consist of a a  and P 
subunit. At least 4 distinct P integrin subunits exist in human cells, each one able to pair 
with various a subunits, resulting in a aP integrin complex. Many integrins function as 
adhesion receptors for ECM components including fibronectin, collagen, laminin, 
vitreonectin and fibrogen.
TFG P induces marked alterations in repertoire of integrin expression by increasing the 
mRNA expression of the individual subunits (Ignotz et al., 1987).TGF p has been shown 
to alter the expression of all the integrin subunits that combine to generate receptors for 
fibronectin, collagen, laminin and other ECM molecules. The susceptibility of individual 
integrins to upregulation by TGF p varies depending on the cell type (Heino et al., 1989). 
The ability of TGF p to alter cell adhesion receptors influences the ability of cells to 
interact both with other cells and the ECM, key elements in wound healing.
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1.3.6 TGF p and abnormal wound healing
TGF P stored at high levels in platelets or expressed in monocytes can be physiologically 
delivered to sites of inflammation and wound healing. A localised excess of TGF P 
activity in tissues can lead to unbalanced ECM deposition and result in fibrotic disease. 
TGF p has been shown to be intrinsically involved in the formation of scar tissue and the 
processes of wound healing throughout the body (Ignotz et al., 1986; Khaw et al., 1994a; 
Khaw et al., 1994b; Postlethwaite et al., 1987; Roberts et al., 1985; Shah et al., 1995).
The initial involvement of TGF p came from important observations of fetal wound 
healing. Human fetal skin heals via scarless regeneration and this is thought to result from 
the low levels of TGF p that are present in the foetus (Longaker et al., 1990; Sullivan et 
al., 1995; Whitby et al., 1991).
TGF pi and 2 are heavily implicated as potent stimulators of dermal scarring, the organ 
on which early wound healing research has focused (Gruschwitz et al., 1990; Levine et 
al., 1993; Roberts et al., 1986; Shah et al., 1995). In addition, cutaneous scarring is also 
markedly reduced by the application of antibodies to TGF pi and p2 (Shah et al., 1994). 
Increased TGF p i and P2 protein expression in keloids relative to normal human dermal 
fibroblasts further supports the roles of TGF pi and p2 as fibrosis inducing cytokines 
(Lee et al., 1999). Studies of reproductive hormones and wound healing have also 
indicated that induction of dermal fibroblast TGF pi secretion in females, may be the 
mechanism by which oestrogen accelerates wound healing (Ashcroft et al., 1997).
The actions of the third isoform TGF P3 in dermal scarring are less well established, with 
some evidence indicating that it may inhibit scarring in vivo (Cox, 1995; Shah et al., 
1995).
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TGF p has a central role in the normal scarring response in number of other organ 
systems and is particularly abundant in bone lung, kidney and placental tissue (Critchlow 
et al., 1995). In many diseases excessive TGF p contributes to pathological scarring that 
can compromise normal organ function. Cicatricial diseases such as systemic sclerosis 
and rheumatoid arthritis, which are characterised by inflammation and fibrotic destruction 
result from aberrant growth factor expression (Gruschwitz et al., 1990; Mussener et al., 
1997). In the kidney TGF P promotes renal cell hypertrophy and stimulates extracellular 
matrix accumulation, the two hallmarks of diabetic renal disease (Chen et al., 2003). 
Pulmonary and hepatic scarring diseases are also associated with increased TGF p 
activity (Bartram et al., 2004; Sanderson et al., 1995; Sime PJ, 2001)
Growth factors including TGF P play a critical role in the pathogenesis of cardiovascular 
disease such as atherosclerosis and myocardial remodelling (McCaffrey, 2000). TGF p 
stimulates fibronectin production by vascular intimal smooth muscle cells, which 
contributes to atherosclerotic plaque formation (Kaiura et al., 2000).
1.3.7 TGF p production in the eye
TGF p has been detected in the ocular tissues of the anterior and posterior segment, the 
aqueous and vitreous humour and tear fluid (Kokawa et al., 1996; Lutty et al., 1993, 
Jampel et al., 1990; Pasquale et al., 1993). Of the three human isoforms TGF P2 is 
thought to be the most predominant ocular isoform (Connor et al., 1989; Jampel et al., 
1990b).
Anterior segment: Immunohistochemical techniques localise TGF pi to the superficial 
conjunctival epithelial cells, TGF p2 to the conjunctival stroma, ciliary processes and the 
ciliary body, and TGF P3 to white blood cells within the anterior segment (Pasquale et al.,
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1993). Latent TGF p2 appears to be produced locally by cells found within the iris and 
ciliary body (Knisely et al., 1991). Latent TGF P2 is also produced by trabecular cells and 
evidence suggests that it displays an autocrine and/or paracrine action in the trabecular 
meshwork system. This enables trabecular cells to respond and contribute to the presence 
of TGF P2 in their microenvironment as well as in aqueous humour (Tripathi et al., 
1994a).
The concentration of active TGF p2 in the aqueous of normals is estimated to be 0.73- 
10.98 x 10'11 M compared to a concentration of 12-16 x 10'11 M in the serum. 22-66% of 
the aqueous TGF p2 is estimated to be in the active form. Total TGF p2 concentration in 
the aqueous decreases with age, shows slight changes with axial length and is elevated in 
patients with complicated diabetes who have undergone panretinal photocoagulation for 
diabetic retinopathy (Nakamura et al., 2004). All three isoforms and TBR-I and II 
receptors have been identified in the cornea (Hayashi et al., 1989; Nishida et al., 1995; 
Zieske et al., 2001). TGF p i, P2 and TGF P3 mRNA transcripts are expressed in corneal 
epithelial cells, whilst stromal keratocyte samples express TGF pi and P2 mRNA but not 
TGF p3 mRNA. Endothelial cells expressed all three transcripts (Nishida et al., 1995). 
TGF p i is implicated as the key molecule responsible for abnormal corneal wound 
healing. High basal levels of this isoform can be detected pre injury, in contrast, levels of 
TGF P2 and TGF P3 mRNAs were very low in normal corneas, but increase significantly 
after injury (Chen et al., 2000).
In quiescent lens epithelial cells (LECs) the expression pattern of TGF P shows regional 
heterogeneity. Anterior LECs exhibit TGF p immunoreactivity, while equatorial LECs 
are positive for TGF p i and P2. Quiescent LECs express TBR-II. Proliferating LECs
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express proteins of each TGF P isoform and each TGF P receptor. TGF Ps were also 
localized in the ECM on lens capsules undergoing repair (Saika et al., 1997).
Posterior Segment All isoforms have been detected in the posterior segment with TGF 
pl and p2 confined to the rod outer segments, P3 the inner segments and p2 
predominantly in the RPE (Anderson et al., 1995)
Overall in the rat eye TGF P2 and p3 were found to be approximately 10 times more 
potent than TGF p i. All three isoforms were expressed in the eye in spatially distinct but 
overlapping patterns. TGF pi and TGF p2 and their mRNA were detected in most ocular 
tissues, including the lens. Although TGF p3 was immunolocalized in lens epithelium and 
fibers and in other ocular tissues, its mRNA was detected only in the retina and choroid 
(Gordon-Thomson et al., 1998). The cornea, ciliary body, iris, lens, retinal cells, RPE and 
vascular cells all express the receptors for TGF P superfamily at protein level. (Obata et 
al., 1999)
1.3.8 TGF P and ocular scarring
TGF P is a potent stimulator of scarring in the eye has also been implicated in the 
pathogenesis of cataract, posterior capsule opacification (PCO: secondary cataract), 
glaucoma, comeal and retinal disease.
The comeal stromal keratocyte, plays a pivotal role in comeal scarring. TGF P is reported 
to stimulate ECM production by keratocytes and TGF P isoforms and their receptors are 
up regulated following comeal injury (Chen et al., 2000; Faktorovich et al., 1999; Kaji et 
al., 2001; Sakamoto et al., 2000). Studies demonstrate that injury-induced activation and 
transformation of keratocytes to myofibroblasts results in the deposition of new matrix,
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wounds contraction and the development of "haze", which reduces visual acuity. 
Transformation of keratocytes to myofibroblasts is induced in culture by TGF p and 
blocked in vivo by antibodies to TGF p (Jester et al., 1999).
Down-regulation of the TGF P signalling system has been employed as a strategy to 
prevent scarring in the cornea (Jester et al., 1997; Moller-pedersen et al., 1998; Myers et 
al., 1997; Thom et al., 1997). In addition, Tseng et al have applied amniotic membrane 
tissue to suppress TGF p i and P2 protein expression and subsequent myofibroblast 
differentiation by corneal fibroblasts in the management of ocular surface disease.
In the rodent lens TGF P can induce morphological and molecular changes similar to 
those associated with cataract formation (Hales et al., 1995; Hales et al., 2000). Human 
studies have also highlighted the importance of TGF p in cataract formation and in the 
development of PCO (Lee et al., 2000; Nishi et al., 1995).
In the posterior segment high levels TGF p2 in vitreous aspirates have been found to 
correlate with the degree of intraocular fibrosis and proliferative vitreoretinopathy (PVR) 
(Connor et al., 1989; Kon et al., 1999). RPE cells are believed to play an important role in 
the formation and contraction of epiretinal membranes in PVR and anti TGF p antibodies 
have be shown to inhibit RPE-mediated contraction (Carrington et al., 2000). Conversely 
its use as a scarring agent has been advocated and studies have suggest exogenous TGF 
p2 application as a potential treatment for macular holes and retinal tears. (Glaser et al., 
1992; Smiddy et al., 1989)
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1.3.9 TGF p and glaucoma
TGF P activity is involved in both the pathogenesis and the treatment of glaucoma. 
Increased outflow resistance with subsequent elevation of the IOP is an important 
aetiological factor in POAG, and may be secondary to increased deposition of ECM 
within the trabecular meshwork. Jampel first highlighted the presence of TGF P in the 
aqueous humour (Jampel et al., 1990b) and Tripathi identified that the aqueous of 
glaucomatous eyes contains elevated levels of TGF p2 (1.8 x 1CT11 POAG vs. 0.71 x 1011 
Normals) (Tripathi et al., 1994b). These observations have lead to the hypothesis that 
elevated levels of aqueous TGF p2 may drive the increase in ECM deposition in the 
trabecular meshwork. In support of this TGF p has been shown to modify the alternative 
splicing pattern of fibronectin pre-mRNA and enhance the synthesis and secretion of this 
extracellular matrix molecule by trabecular cells in a dose-dependent fashion (Li et al., 
2000). Moreover the up-regulation of fibronectin mRNA by trabecular cells exposed to 
growth factors present in secondary aqueous humour, augmented by the down-regulation 
of MMP 3 mRNA, contributes to the accumulation of fibronectin in trabecular cells 
(Tripathi et al., 2004).
Raised pressure induces compression, stretching and remodelling of optic nerve head 
which results in direct mechanical axonal damage, compromised blood flow and reduced 
delivery of nutrients. Fuchshofer et al have demonstrated that TGF P2 is capable of 
inducing the expression of ECM and basement membrane components in cultured ONH 
astrocytes via CTGF and upregulated TSP-1, a protein naturally involved in the activation 
of latent TGF p. This has lead to the hypothesis that TGF P2 could be a factor in the 
initiation of the modification of ECM in the glaucomatous ONH. In addition, TSP-1
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induction may be a mechanism by which TGF p amplifies its own activation (Fuchshofer 
et al., 2005).
With its widespread involvement in the wound healing processes through out the body, 
TGF P has also been implicated in subconjunctival scarring and the failure of glaucoma 
filtration surgery.
1.3.10 TGF p and conjunctival wound healing after glaucoma surgery
Aqueous flow bathes the wound and provides a unique and changeable environment 
which influences post-operative healing. Latent TGF-P2 is produced by tissues within the 
eye (ciliary body and trabecular meshwork) prior to activation by plasmin and 
thrombospondin released from blood components after breakdown of the blood aqueous 
barrier (Grainger et al., 1995; Knisely et al., 1991; Schultz-Cherry et al., 1995; Tripathi et 
al., 1994a). After glaucoma surgery elevated levels of activated TGF p2 at the wound site 
are therefore likely to be related to aqueous concentration, the flow of aqueous and 
breakdown of the blood aqueous barrier. TGF P is also derived locally from degranulating 
platelets and inflammatory cells at the wound site. In addition, TGF p also displays the 
ability to auto induce its own production thereby initiating a perpetuating cascade of 
activation (Kelley et al., 1993; Li et al., 1999). In general most of the TGF P2 is thought 
to originate from inside the eye and whilst TGF P1 is produced locally by conjunctival 
inflammatory cells.
1.3.10.1 Expression of TGF p in conjunctival scarring Reichel et al 
demonstrated that TGF p i, p2 and p3 are all expressed in a mouse model of conjunctival 
scarring (Reichel et al., 1998). TGF p2 protein was the predominant isoform, being 
detected in the basement membrane of conjunctival epithelium, conjunctival stroma,
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sclera and comeal stroma. TGF (32 activity in the wounded area was apparent on day 2 
and reached a peak on day 7. In situ hybridization highlighted a temporal pattern of TGF 
(3 mRNA expression with TGF (32 mRNA, the most predominant type, peaking at day 1 
and localizing to granulocytes. TGF (31 and p3 displayed maximal expression on day 2 in 
lymphocytes and mononuclear cells, with some evident on day 1 in platelets. Only small 
amounts of TGF (33 mRNA were detected.
TGF pi and TGF P2 together with their binding protein LTBP-1 have been immuno- 
localised in failed filtering blebs from patients with POAG and pseudoexfoliation 
glaucoma. In normal conjunctival specimens, only TGF p2 was present in the 
conjunctival and subconjunctival stromal fibroblasts, whereas TGF p i was confined to 
the basal cells of the conjunctival epithelium. In both POAG and PEX glaucoma, TGF p 
levels were increased in the subepithelial extracellular matrix of the filtering blebs and co 
localized with LTBP-1 in the stroma. TGF P immunoreactivity was also increased and 
localized to epithelial cells and stromal fibroblasts and not to the extracellular matrix. 
These findings provide further evidence for the role of TGF p in the pathogenesis of the 
conjunctival wound healing response after glaucoma filtration surgery (Kottler et al., 
2003).
1.3.10.2 Effect of TGF p on human Tenon’s fibroblast activity in vitro TGF P is
the most potent growth factor in the aqueous at stimulating in vitro subconjunctival 
fibroblast activity. EGF, P FGF, TGF pi IGF1 all stimulate migration, proliferation and 
collagen production by human Tenon’s fibroblasts. TGF p i, however, stimulates 
migration and proliferation at much lower concentrations than all the other growth factors 
and induces greater collagen synthesis than EGF and P FGF (Khaw et al., 1994a) (Denk 
et al., 2003).
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All 3 TGF p isoforms appear to behave in a similar manner in vitro. They each stimulate 
human Tenon’s fibroblast-mediated collagen contraction, proliferation and migration with 
a characteristic concentration dependent biphasic response, with peak activities at 10'9M 
(TGF p i), 10'12M (TGF P2), and 10"9M (TGF P3) demonstrating a stimulatory effect on 
conjunctival scarring (Cordeiro et al., 2000b). This is contrary to Shah et al and others 
who have showed that TGF pi and P2 promoted scarring in rodent wound healing, 
whereas TGF p3 inhibited it (Shah et al., 1994; Shah et al., 1995). These somewhat 
contrasting results may well be attributable to differences between species, wound healing 
models and the anatomical site studied.
The implications of different peaks of TGF p induced fibroblast functions can be 
explained physiologically. Following wounding fibroblasts migrate to the area and 
proliferate. TGF p is initially released from inflammatory cells and platelets at the wound 
site. At early low concentrations TGF P may stimulate proliferation and act as a week 
chemoattractant 1 0 13-1 0 12M. With time the proliferating fibroblasts secrete growth 
factors and the concentration of TGF p increases. At concentrations of 10"9M TGF P 
activity is adapted to stimulate collagen deposition and matrix contraction. The role of 
TGF p during conjunctival scarring appears to be dependent on its concentration at the 
wound site.
1.3.10.3 Effect of TGF P on conjunctival scarring in vivo TGF P is a potent 
modifier of subconjunctival healing response in vivo. Exogenous application of all three 
TGF P isoforms following conjunctival wounding in the mouse can initiate an 
exaggerated scarring response compared to controls. TGF p treated eyes displayed an 
earlier peak in inflammatory cell activity and increased collagen type III production 
(Cordeiro et al., 1999b).
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TGF (32 also has the ability to modify the effects of the anti proliferative agent Mitomycin 
C, which demonstrates profound pro scarring activity (Cordeiro et al., 1999b; Khaw et al., 
1994b). When drainage blebs are injected with TGF (31 a healing response is generated 
which begins to reverse the effects of mitomycin C. Thick scar formation develops 
around the bleb which begins to opacify and shrink.
Wimmer et al demonstrated that aqueous TGF (32 levels can become elevated after argon 
laser treatment to the drainage angle in certain subgroups. Patients in which aqueous TGF 
(32 levels increased had a higher risk of surgical failure after subsequent trabeculectomy 
than individuals in which the TGF (32 level remained normal (Wimmer et al., 2003). The 
technique of microarray has been employed to analyse the changes in gene expression 
during the failure of filtering blebs in a rat model. TGF (3 appears to be one of a number 
of genes upregulated in the conjunctiva (Esson et al., 2004).
1.4 MODULATION OF WOUND HEALING AFTER GFS
1.4.1 General
The processes regulating the wound healing response are both numerous and complex. 
Strategies to modify scarring can be directed to any stage of the pathway and these 
principles can also be applied to other surgical procedures (Figure 16). Although some 
anti-scarring therapies have been in clinical use for some years, an increased 
understanding of the cellular and molecular biological mechanisms involved in wound 
healing has lead to advances in their use and to the development of potentially new
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Figure 16 Modulation of the wound healing response
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The molecular and cellular events leading to subconjunctival scarring and potential areas of wound 
modulation after glaucoma filtration surgery. A-D represent the wounding, inflammatory, 
proliferative and remodelling phases of wound healing.
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modulating agents. Ocular agents may also have more widespread application in the 
prevention of scarring at other sites throughout the body.
The principle is to evaluate the patients’ risk factors for scarring and adjust the treatment 
accordingly. The wound healing response should be inhibited to a level which lowers IOP 
to a predetermined target value without introducing complications due to inadequate 
healing (Figure 17).
Many agents are currently and potentially available for modulation of the scarring 
response and these will be described in further detail (Figure 16)
1.4.1 Inhibition of pre-operative tissue and cellular activation
Broadway et al highlighted the relationship between long-term topical treatment, pre­
operative fibroblast activation and surgical failure (Broadway et al., 1994a; Broadway et 
al., 1994b). Patients on topical treatments prior to surgery exhibited higher rates of failure 
compared to patients without drops. Removal of the pre-operative topical treatment 
increased the rate of surgical success (Broadway et al., 1996). The state of cellular 
activation may also affect the response to anti-scarring agents. Activated cells are still 
able to stimulate scarring in neighbouring cells via soluble mediators after treatment with 
anti-proliferative agents. These findings suggest that the degree of cellular activation prior 
to surgery is extremely important in determining the post-operative scarring response. 
Where possible, medical treatment known to cause inflammation, is stopped prior to 
surgery.
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Figure 17 Aims when modulating the conjunctival wound healing response
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Maintenance of IOP in the low teens delays glaucomatous progression. The use of 
novel and existing modulating agents combined with improved surgical techniques 
will ideally enable wound healing to be controlled and low target pressures to be 
achieved in the long term.
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1.4.2 Steroid and Anti-inflammatory agents
Persistent inflammation is associated with enhanced conjunctival scarring. Anterior 
chamber flare has been shown to be elevated for a prolonged period following 
phacoemulsification compared to trabeculectomy (Siriwardena et al., 2000). It is also 
accepted that cataract surgery can reduce co-existing bleb function. These observations 
highlight the role of the inflammatory response in accelerated wound healing. Treatment 
with steroids and anti-inflammatory agents inhibit inflammatory cell chemotaxis, 
angiogenesis, fibroblast proliferation and matrix synthesis, thereby depressing the local 
inflammatory response (Wahl, 1989). The beneficial effect of post-operative topical 
corticosteroid treatment on IOP reduction is well established (Roth et al., 1991; Starita et 
al., 1985) and topical ocular steroids are routinely following most ocular surgical 
procedures. The use of oral steroids in unselected patients does not confer any additional 
benefit over topical application after trabeculectomy.
Non-steroidal anti-inflammatory drugs (NSAIDS) suppress the inflammatory response 
by blocking conversion of arachidonic acid to endoperoxidases via inhibition of 
cycloxygenase. They also inhibit platelet function and aggregation. Platelets, thrombin 
and the products of arachidonic acid metabolism are important stimulators of the 
inflammatory response and hence the wound healing pathway. The beneficial effect of 
NSAID’s as anti-inflammatory agents following glaucoma surgery however, remains 
unclear (Kent et al., 1998; Migdal et al., 1983). Topical Cyclosporin may also have 
potential anti-inflammatory role.
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation (Shaunak et 
al., 2004). Dendrimers are hyperbranched macromolecules that can be chemically 
synthesized to have precise structural characteristics. Polyamidoamine dendrimers of 
D(+)-glucosamine and D(+)-glucosamine 6-sulfate demonstrate immuno-modulatory and
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antiangiogenic properties respectively. Dendrimer glucosamine inhibits synthesis of pro- 
inflammatory chemokines (MIP-1 alpha, MIP-1 beta, IL-8) and cytokines (TNF-alpha, 
IL-1 beta, IL-6) from human dendritic cells and macrophages but allows upregulation of 
the costimulatory molecules CD25, CD80, CD83 and CD86. Dendrimer glucosamine 6- 
sulfate blocks fibroblast growth factor-2 mediated endothelial cell proliferation and 
neoangiogenesis in human Matrigel and placental angiogenesis assays. A combination of 
the two dendrimers hyas been shown to increase the long-term success of glaucoma 
surgery from 30% to 80% in the rabbit model. Engineered macromolecules such as the 
dendrimers described here can be tailored to have defined immuno-modulatory and 
antiangiogenic properties, and may represent a novel synergistic approach to prevent scar 
tissue formation.
1.4.3 Fibrinolytic agents
Fibrin formation can be prevented by heparin. A combined injection of heparin and 5- 
fluorouracil has been shown to reduce the development of proliferative vitreoretinopathy 
in high risk patients (Asaria et al., 2001). Once a clot has formed fibrinolysis can be 
achieved by local administration of tissue plasminogen activator (TPA). Snyder et al 
developed a quantitative reproducible model for intraocular fibrin deposition and 
demonstrated the efficacy of human TPA in promoting intraocular fibrinolysis (Snyder et 
al., 1987). However, the risk of further haemorrhage and the release of pro-scarring 
breakdown products limit any potential clinical application.
1.4.5 Anti-proliferative agents
The introduction of the anti-proliferative agents 5-fluorouracil (5-FU) and mitomycin C 
(MMC) represents one of the major advances in glaucoma surgery over the last decade
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and these agents are in widespread use. A recent survey performed in university based 
hospitals in the USA showed that mitomycin C is now used in over 50% of primary 
trabeculectomies (Chen et al., 1997). An anti-proliferative can be defined as any agent 
that interferes with cellular division and processing and the mechanisms of action of the 
anti-proliferative agents used after glaucoma surgery are summarised in Figure 18. 5FU 
mediates its effect by inhibition of DNA synthesis and its actions ultimately result in cell 
death. The ribosylphosphate form of 5FU may also be incorporated in to mRNA leading 
to abnormal ribosymes, altered mRNA translation and abnormal protein synthesis (Falck 
et al., 1992). MMC is an antibiotic with anti-proliferative activities derived from the soil 
fungus Streptomyces caespitosus. It can be classified as a cell cycle non specific 
alkylating agent which x links DNA during all phases of the cell cycle and thereby 
inhibits DNA replication, mitosis and protein synthesis.
1.4.5.1 Effect of anti-proliferative agents on Tenon’s capsule fibroblast activity
The anti-proliferative agents are effective inhibitors of fibroblast function and thereby act 
to reduce post-operative subconjunctival scarring.
In vitro experiments have identified that short exposures of ocular fibroblasts (5 minutes) 
to 5FU and MMC can induce long-term fibroblast growth arrest (Khaw et al., 1992c). 
Given the appropriate concentration and agent effective inhibition of proliferation can be 
achieved for periods up to 36 days without significant cell death (Khaw et al., 1992c). 
Long term suppression occurs with both 5-FU and MMC. The inhibitory action of 5FU 
on thymidylate synthetase should be readily reversible, however the secondary 
interactions of the drug with RNA synthesis may help to explain its longer term actions. 
Suppression of proliferation with single short exposures of 5FU and MMC is also able to 
inhibit other aspects of fibroblast function such as the ability of fibroblasts
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Figure 18 Mechanism of action of the anti-proliferative agents
5-Fluorouracil
1° action
2° action
MMC
1° action 
2° action
Inhibition of thymidylate synthetase prevents DNA 
synthesis and cell proliferation.
Incorporation into the RNA abnormal ribosyme 
formation, altered mRNA translation and abnormal 
protein synthesis.
Alkylating agent which X links the DNA 
Free radicals are generated which cause non-specific 
damage to DNA, RNA and protein synthesis.
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to contract the ECM. Occleston et al demonstrated that ocular fibroblast mediated 
collagen gel contraction is inhibited by short exposure to both 5-FU and MMC and at 
high doses MMC induced cytotoxicity (Occleston et al., 1994).
Long term suppression of ocular fibroblast proliferation has also been demonstrated in 
vivo using an experimental model of glaucoma surgery. The treatment appears to be focal 
(only fibroblasts in the treated area are affected) and titratable in terms of length of action 
(Doyle et al., 1993a; Khaw et al., 1993b, Khaw et al., 1992b).
Fibroblasts are derived from the local conjunctival population of fibrocytes. To reinitiate 
the scarring process these cells must either recover from the focal treatment or new 
untreated fibroblasts must migrate into the area. At the molecular level, it has been shown 
that suppressed growth arrested fibroblasts are still able to perform several crucial aspects 
of wound healing, including the expression of growth factors and receptors, migration and 
ECM production (Occleston et al., 1997). Despite entering growth arrest, fibroblasts still 
maintain the ability to respond to stimulatory factors in the local environment and can 
influence the behaviour of other cells by soluble mediators (Figure 19)(Daniels et al., 
1999). This may help to explain why some operations still fail due to subconjunctival 
scarring despite the use of anti-proliferative agents.
At clinical concentrations MMC causes cell death and permanent inhibition of fibroblast 
function, however there is only temporary inhibition with late recovery after single 
application of 5-FU (Khaw et al., 1993a; Khaw et al., 1993c; Khaw et al., 1992b). This 
has important implications in terms of the clinical application and drug selection for each 
individual patient. In summary, application of 5-FU induces suppression of cellular 
activity for a number of weeks and this is adequate to modify a normal or exaggerated
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Figure 19 Action of anti-proliferative agents on Tenon’s capsule fibroblasts
Untreated fibroblasts
Secrete cytokines
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At clinical concentrations MMC causes cell death and permanent inhibition 
of fibroblast function, however there is only temporary inhibition with late 
recovery after single application of 5-FU. This has important implications in 
terms of the clinical application and drug selection for each individual 
patient
MMC
0.2 or 0.4 mg/ml
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healing response. However persistent healing will only be suppressed by application of 
mitomycin C (Figure 20).
Application of B irradiation has similar anti-proliferative effects as anti-metabolites, p 
irradiation delivered from a solid state probe can be focally applied to the bleb 
immediately following surgery. Rapid attenuation of the p particles makes it ideal for 
treatment of superficial tissues. Miller and Rice reported that peropertive treatment with 
750 cGy b radiation significantly enhanced bleb survival and improved IOP control 
following trabeculectomy in congenital glaucoma (Miller et al., 1991). Clinical 
experience of this treatment suggests that the blebs which form after treatment are 
generally diffuse rather than cystic. A single application of p irradiation leads to long 
term inhibition of fibroblast proliferation inducing a state of growth arrest (Khaw et al., 
1991, Constable et al., 1998). Its use is advocated for patients with an intermediate risk of 
scarring after filtration surgery (Khaw et al., 2001).
1.4.5.1 Evolution of anti-proliferative adjunctive therapy Experimental work 
performed by Blumenkranz first established that 5-FU inhibited the proliferation of 
fibroblasts in vitro and in an experimental model of epiretinal scarring (Blumenkranz et 
al., 1984; Blumenkranz et al., 1982). This stimulated the landmark studies of the 
fluorouracil filtering surgery study group (FFSS) which pioneered the use of 5-FU in 
glaucoma surgery (Group, 1989; Group, 1996). In this study patients who had previously 
failed filtration or cataract surgery were randomized to receive a post-operative course of 
21 subconjunctival injections of 5-FU (twice a day for one week and once a week for the 
second week) or no treatment. The trial was stopped early due to the dramatic 
improvement in surgical success. (73% treated vs. 50% untreated). However corneal
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Figure 20 Healing profiles after GFS
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Postulated effect of a single application of 5-FU (1) and MMC (2). 5FU causes 
temporary suppression which is adequate for normal and an exaggerated response 
but not for higher risk patients with a persistent healing response who cross the 
exessive healing line and fail surgery. MMC is able to supress the persistent response 
but pushes the normal response below the inadequate healing line potentially 
resulting in hypotony and its related complications. Adapted from Khaw et al (Khaw 
P.T. et al, 1994b)
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epitheliopathy was reported in 50% of patients. Extensive investigation followed looking 
at the effects of 5-FU and other anti- proliferative agents on ocular fibroblasts in culture 
in an attempt to find the optimal agent (Blumenkranz et al., 1987; Gillies et al., 1993; Lee 
et al., 1990a; Lee et al., 1990b; Lee et al., 1991; Schmidt et al., 1982; Senderoff, 1990) 
and a delivery system that did not require multiple injections (Jampel et al., 1990a; Kay et 
al., 1986; Lee et al., 1987; Sachdev et al., 1990; Skuta et al., 1987; Winter et al., 1987). 
Single applications of intra-operative MMC were first introduced by Chen who had been 
using this regimen unnoticed for more than a decade (Chen, 1983; Chen et al., 1990). 
However, this technique did not gain acceptance until sufficient evidence was generated 
to prove that short term application of these agents could adequately suppress long term 
fibroblast proliferation (Khaw et al., 1993a; Khaw et al., 1993b; Khaw et al., 1993c; 
Khaw et al., 1992b; Khaw et al., 1992c; Khaw et al., 1992d, Doyle et al, 1993).
There have been numerous clinical studies demonstrating the efficacy of 5-FU in 
augmenting the success of glaucoma surgery (Araie et al., 1992; Goldenfeld et al., 1994; 
Heuer et al., 1986; Mora et al., 1996; Ophir et al., 1992; Rothman et al., 2000; Ruderman 
et al., 1987; Sidoti et al., 1998; Towler et al., 2000; Tsai et al., 1995). The cumulative data 
supports a significant benefit in terms of bleb survival and IOP lowering in treated eyes 
compared to controls. As mentioned the landmark study was performed by the 
fluorouracil surgery study group. Overall, however, there have been few randomised 
prospective clinical trials evaluating 5-FU versus no 5-FU. Total dose and mode of 
administration (injection or sponge) as not been standardised across them, study sizes 
have been small and considerable variability is demonstrated in patient selection (high 
risk versus low risk of scarring). The multicentre MRC 5-FU study pioneered by 
Moorfields Eye Hospital should help to finally answer questions about the optimum use 
of 5-FU.
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The prolonged potent effects of MMC make it suitable as a single-use adjunct in GFS 
especially in those eyes at high risk of failure. Since 1983 when Chen first used MMC in 
the treatment of severe refractory glaucoma, numerous studies have investigated the anti­
proliferative effects of MMC. Again, most have been retrospective, uncontrolled, non 
randomised and of relatively short duration. Moreover, the method and duration of 
application, ocular pathology and patient details have varied significantly. However, 
despite this MMC has been shown to significantly augment the success of GFS in high 
risk eyes compared to controls (Cheung et al., 1997; Cohen et al., 1996; Perkins et al., 
1998). Several important studies have compared intra-operative 5-FU with MMC and 
revealed that in high risk patients a single application of MMC provides better long-term 
pressure control than 5-FU (Katz et al., 1995; Kitazawa et al., 1991; Lamping et al., 
1995).
1.4.5.3 Selection of anti-proliferative agent
Intraoperative antimetabolites A number of factors seem to increase the risk of 
scarring and failure following glaucoma filtration surgery which are summarised in 
Figure 21. One treatment regimen is not adequate for all patients. A titratable regimen has 
evolved at Moorfields Eye Hospital called the More Flow (Moorfields/Florida) based on 
laboratory and clinical data (Khaw et al., 1992c). Both intaoperative MMC and 5-FU are 
delivered by placement of a drug impregnated cellulose sponge in between the episcleral 
surface and the undersurface of the conjunctiva for a predetermined time.
Post operative Despite these intra-operative applications bleb failure can occur later in 
the post-operative period. Injections of 5-FU are used post-operatively on their own or in 
combination with intraoperative 5-FU or MMC if the pressure is rising and the healing 
response is still marked (Mastropasqua et al., 1998, Gallenga et al., 1997; Ophir et al., 
2000; Shin et al., 1993; Smith et al., 1992, Ophir et al., 1992). Drainage of fluid can
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Figure 21 Risk factors for subconjunctival scarring and failure of
glaucoma filtration surgery
Risk Group Risk Factors Anti-scarring regimen
• Topical medications ( Pilocarpine) 
Low risk • Youth <40 years
• Elderly Afro-carribeans
• No risk factors
Intermediate
risk
High risk
• Cataract surgery (No conjunctival incision)
• Previous conjunctival surgery ( Squint)
• Several low risk factors
• Combined glaucoma and cataract extraction
• Topical medications (Adrenaline/preservatives)
• Neovascular glaucoma
• Chronic uveitis
• Failed 5-FU trabeculectomy or tube
• Chronic conjunctival inflammation
• Multiple risk factors
• Aphakic glaucoma
None*
5-FU 50mg/ml for 5 
minutes*
b irradiation 750 cGy*
5-FU 50mg/ml for 5 
minutes*
b irradiation 1000 cGy* 
MMC 0.2mg/ml for 3 
minutes*
MMC 0.5 mg/mL for 3 
minutes*
* Post-operative 5-FU injections can be given in addition to intra-operative anti-metabolites 
Anti-metabolite regimen currently in use at Moorfields. (Continuously evolving regimen)
become localised with time due to circumferential healing which results in bleb 
encystment. Subconjunctival injection of 5-FU with physical disruption of the scar tissue 
provides a useful tool to remodel encysted blebs (Allen et al., 1998).
The technique of injection is important. In the FFSS regimen 5mg of 5-FU was given in a 
volume of 0.5mg/ml at 180 degrees from the filtration site (Group, 1989). Weinreb 
subsequently used a higher concentration (5mg in 0.1ml) delivered much closer to the 
bleb to demonstrate improved efficacy (Weinreb, 1987). It is logical that delivery to the 
surgical area should be most effective. However, it is vital that 5-FU does not enter the 
eye because apart form its anti-metabolite action, commercial 5-FU has a pH of 
approximately 9. Current clinical practice varies according to the preference of the 
surgeon with most in this country favouring a superior injection site. Injections are 
administered and titrated as necessary based on bleb appearance.
1.4.5.4 Complications associated with anti-proliferative use Introduction of anti­
scarring agents MMC and 5-FU has improved results of GFS however their use can be 
associated with severe and potentially blinding complications (Figure 22).
Corneal toxicity is the most common complication following application of 5-FU. It 
decreases the mitotic rate of actively replicating corneal epithelial cells, which can 
manifest as punctate epitheliopathy, frank epithelial defects or striate melanokeratits. 
Whilst these complications may resolve without a long term loss of visual acuity, they 
can be associated with severe discomfort and the development of secondary pathology 
such as corneal ulceration, melt or even perforation. Concurrent use of topical 
corticosteroids can potentiate the toxicity. Comeal epitheliopathy was common in the 
early studies with 5-FU when total doses approached lOOmg (Group, 1996).
Application of both 5-FU and MMC leads to the development of thin avascular blebs, 
which are associated with enhanced transconjunctival filtration as a result of lowered
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Figure 22 Complications associated with antimetabolite use
Antimetabolites can be associated with severe and potentially blinding side effects 
such infection of the eye shown in A and B, and low pressure or hypotony and its 
associated complications (C).
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resistance to flow through the bleb. Whilst this reduces the intraocular pressure it 
increases the risk of bleb leaks, that can facilitate the passage of bacteria and lead to the 
potentially blinding complication of endophthalmitis (Soltau et al., 2000, Parrish et al., 
1996, Greenfield et al., 1998, Belyea et al., 1997, Kangas et al, 1997).
Low outflow resistance in the bleb can also lead to overfiltration and the development of 
hypotony and subsequent choriodal effusions and maculopathy (Jampel et al., 1992). 
Stamper reported a series of 6 patients treated with post-operative 5-FU that developed 
hypotony with maculopathy and demonstrated that young myopic individuals were more 
prone to maculopathy with visual loss (Stamper et al., 1992).
As a result of its biological potency, with prolonged cytological toxicity after 
administration, the risk and severity of complications is more severe when using MMC. 
Indeed blebs treated with MMC are 3 times more likely to result in focal bleb leaks 
(Greenfield et al., 1998).
The biological activity of the anti proliferative agents can represent a double edged 
sword. Whilst the tissue changes enhance transconjunctival flow they can potentiate the 
risk of blinding complications. To take full advantages of these agents they have to be 
used appropriately and in combination with adaptations in surgical technique to optimise 
safety.
1.4.5.6 Advances in anti-proliferative use Strategies to minimise the incidence of 
complications associated with anti-proliferative use in glaucoma surgery include 
optimising the choice of agent, method of application and surgical technique. 
Anti-metabolite regimen: The selection of the single-application anti-scarring agent and 
concentration is titrated against patient risk factors. Figure 21 summarises the constantly 
evolving regimen used by our unit, which is based laboratory and clinical experience. 
Exposure time and concentration: Most surgeons now use between 0.2 and 0.5 mg/ml
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of MMC, 50mg/ml for intra-operative 5-FU and 5mg (0.1 ml of 50mg/ml) for 
subconjunctival 5-FU. The time of exposure varies amongst centres. We have shown that 
tissue uptake rises sharply and peaks at 3 minutes. Therefore applications of 3 minutes 
have the same efficacy as 5 minute exposure but reducing it below 3 minutes can result in 
suboptimal cellular absorption. Changing the concentration of the agent leads to more 
reproducible titratable effects than variations in exposure time.
Area of treatment: Experimental work suggested that peripheral growth arrested cells 
located around the area of anti-proliferative treatment could still form a dense ring of scar 
tissue (‘ring of steel’), which gives rise to encapsulated cystic blebs. In vivo studies have 
confirmed that increasing the area of anti-proliferative treatment can reduce the incidence 
of cystic bleb formation. Clinical practice has been changed to adopt this technique which 
has led to a dramatic fall in the incidence of bleb related complications such as blebitis 
and endophthalmitis (15% to 0%) (Wells et al., 2003).
Surgical technique: After anti-metabolite use, scleral flap resistance determines the early 
IOP. The introduction of larger scleral flaps, smaller sclerostomies, and multiple tight 
adjustable and releasable sutures helps to avoid post-operative hypotony and provides a 
means of exquisitely controlling early post-operative IOP.
Post-operative injections: The original regimen of 21 injections has been modified and 
most Ophthalmologists give less than 10 with longer intervals between injections. 
Injections of 5-FU can be used in conjunction with intra-operative anti-metabolites if the 
healing response is still marked and the pressure is rising. Technique is also important. 
Injections are now given closer to the bleb (avoiding intraocular entry as the pH of 5-FU 
is 9), via a long subconjunctival needle track with the use of small bore needles to 
improve efficacy and reduce comeal side effects.
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Despite high dose anti-metabolites and modifications in their application patients still fail 
surgery. Development of alternative more physiological anti-scarring agents is needed.
1.4.6 Agents affecting Growth factors
The scarring process is under the control of a number of growth factor proteins as 
discussed in section 1.2 and illustrated in Figure 10. Consequently, these growth factors 
and the receptors through which their effects are mediated, present themselves as 
potential targets for therapeutic intervention. A number of approaches can be employed to 
antagonise growth factors activity (Figure 23). These include the use of antibodies 
directed against the growth factor protein or growth factor receptor protein, antisense 
oligonucleotides and ribozomes. As previous mentioned of all the growth factors involved 
in the wound healing cascade, TGF p has been shown to be one of the most potent 
stimulators of scarring in the eye and is involved in the pathogenesis of cataract, 
proliferative vitreoretinopathy and conjunctival scarring (Connor et al., 1989; Hales et al., 
1995). TGF p2, the most predominant of the three mammalian isoforms in the eye, is the 
most potent growth factor in the aqueous at stimulating conjunctival fibroblast function 
and elevated levels of this isoform are found in the aqueous of glaucomatous eyes 
compared to normals (Khaw et al., 1994b; Pasquale et al., 1993; Tripathi et al., 1994b). 
Shah et al convincingly demonstrated that neutralising antibody to TGF p i and 2 can 
reduce cutaneous scarring in adult rats. A reduction was seen in the monocyte and 
macrophage profile, neovascularisation, fibronectin, collagen HI and collagen I deposition 
in the early stages of wound healing compared to control wounds. To be effective, the 
neutralising antibody to TGF P needed to be administered at the time of wounding or
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Figure 23 Strategies to modify growth factor activity
Antibodies to the TGF p protein Antibodies to the TGF p receptor
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TGF P activity can be inhibited in several ways. Fully human monoclonal 
antibodies can be directed against TGF p or the TGF p receptor molecule to 
decrease activity. Alternatively inhibition at the level of gene expression may be 
possible using antisense oligonucleotides or ribozymes, which act at on the 
messenger RNA and prevent protein synthesis of TGF p itself or the receptor.
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soon thereafter. The antiscarring effects of this neutralising antibody to TGF (3 were dose 
dependent (Shah et al., 1992; Shah et al., 1994; Shah et al., 1995).
These findings suggest that neutralising the effects of TGF (3 isoforms may reduce 
conjunctival scarring following glaucoma filtration surgery.
1.4.6.1 Human monoclonal neutralising antibodies Monoclonal antibodies (mAB), 
which can be defined as the product of a single clone of B lymphocytes, are 
monospecific, homogeneous and are therefore effective tools in the development of 
therapies and diagnostics. The hybridoma technique used to generate mAB was first 
described in 1975 by Kohler and Milsten (Kohler et al., 1975). Splenic cells from 
immunised animals are fused with cells of a cultured myeloma cell line to form a 
hybridoma that is capable of producing a single antibody. The specificity and affinity of 
the antibody are a function of original mouse monoclonal. However, murine mAbs are 
recognised as foreign by the patient and can induce human anti-mouse antibody immune 
response (HAMA), which limits their therapeutic potential. Attempts to reduce HAMA 
have led to the development of chimeric antibodies in which the variable region of a 
murine antibody is combined with the constant region of a human antibody 
(approximately 70% human). More recently the construction of humanised engineered 
antibodies, achieved by grafting the murine antigen binding or hypervariable region on to 
a human antibody, can result in a protein sequence that is 95% human (Figure 24)
The production of fully human monoclonal antibodies has been a major advance in this 
area. Such antibodies can be engineered by the use of transgenic mice or by phage display 
technology. Transgenic mice are genetically modified so they express human antibody 
genes. Endogenous mouse IgG genes are inactivated in embryonic stem cells to block B
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Figure 24 Engineering of therapeutic monoclonal antibodies
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cell production followed by subsequent introduction of unrearranged human IgG gene 
segments. Following immunisation with an antigen these animals produce fully human 
antibodies (Jakobovits, 1995). The technique, which is still developing, has the advantage 
that a whole antibody is generated but the specificity and affinity of the mAb remain a 
function of immune response of transgenic mouse.
Display of antibody fragments (Fabs or scFvs) on the surface of a filamentous phage was 
first described in 1990 and the first human antibodies were generated soon after 
(McCafferty et al., 1990; Winter et al., 1994). The technique of phage display consists of 
three steps: firstly human antibody light and heavy chains are identified from a large 
human antibody library; secondly, the human genes coding for these chains are 
incorporated into a bacterial virus (phage); finally when the phage infects a bacterium 
(Escherichia.coli) the bacterium makes the antibody protein which it displays on its 
surface. A phage antibody is, therefore, a bacterial virus engineered to display antibody 
proteins that will bind specifically to a target molecule or antigen with which it comes in 
to contact. Specific clones binding to the antigen can then be amplified and used to 
produce the antibody fragment so that a fully human recombinant mAb is produced 
(Figure 25). Apart from the completely human nature of the antibody the advantages of 
this technique include the speed of isolation, the ability to generate high affinity mAbs 
(subnanomolar) and the potential selection of complex antigens (Griffiths et al., 1994; 
Vaughan et al., 1996).
Using the technique of phage display Cambridge Antibody Technology have designed a 
mAb that is specific to the active form of TGF (32 (CAT-152) suitable for the treatment of 
fibrotic diseases. CAT-152 is IgG4 antibody with a high affinity for TGF (32 (dissociation 
constant of 0.89nM).
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Figure 25 Structure and generation of antibodies using the technique of
phage display
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Human antibody light and heavy chains are identified from a large human antibody 
library. The DNA encoding these genes are then incorporated into a bacterial virus 
(A). When the phage infects a bacterium (E.coli), the bacterium makes the antibody 
protein which it displays on its surface (B). Specific clones binding to an target 
antigen can then be amplified and the whole antibody produced by recombinant 
methods (C).
100
It has 9% cross reactivity with TGF p 3 and no displays not detectable binding with TGF 
P 1 (Thompson et al., 1999).
1.4.6.2 Effect of human anti TGF p 2 antibody (CAT-152) on Tenon’s capsule 
fibroblast activity CAT-152 has been shown to significantly inhibit the conjunctival 
fibroblast functions of proliferation, migration and collagen gel contraction at IC50 
concentrations of < l.OnM (Proliferation p<0.05 IC50 0.885nM, Migration p<0.05 IC50 
0.627nM and contraction p<0.05 IC 50 0.12 0.818nM) (Cordeiro et al., 1999a).
1.4.6.3 Effect of human anti TGF P2 antibody CAT-152 on glaucoma filtration 
surgery The safety and efficacy of CAT-152 in vivo was initially investigated in a rabbit 
model of aggressive conjunctival scarring after glaucoma surgery. Tolerance was 
assessed in 11 New Zealand white (NZW) rabbits which were randomly assigned to 
receive 7 subconjunctival injections of either 100 jliI of CAT-152 (1.0 mg/ml), null 
antibody (1.0 mg/ml) or PBS. The injections were administered on days 0 ( 2  injections
1.5 hours apart) 1,2,3, and 7 and the animals were observed for 30 days .The clinical 
parameters of conjunctival vascularity, anterior chamber activity and intraocular pressure 
acted as indicators of local toxicity. Injections were well tolerated and no intraocular 
inflammation was seen at any time. The same subconjunctival injection regimen was used 
to investigate the efficacy of CAT-152 on the outcome of filtration surgery. 72 NZW 
rabbit underwent modified glaucoma surgery and were randomly assigned to one of four 
treatments that consisted of l.Omg/ml CAT-152, 0.1 mg/ml CAT-152, Null antibody 
(l.Omg/ml) or PBS. Animals were observed until sacrifice on days 3,8,14 and 30. The 
ocular tissue was processed for histology. CAT-152 significantly prolonged bleb survival, 
the primary outcome variable, compared to control (p= 0.0291), reduced subconjunctival 
scarring (p= 0.001) and improved bleb morphology (Bleb Height p=0.029 Area p=0.059).
101
No significant difference was seen between the two doses of CAT-152 (Figure26) 
(Cordeiro et al., 1999a).
The first clinical trial of CAT-152 was designed to asses the safety and tolerance of CAT- 
152 in patients undergoing primary trabeculectomy (Randomised prospective placebo 
controlled phase I/IIa trial). 24 patients were treated with CAT-152 (lOOmg, n=16) or 
placebo (n=8). Four subconjunctival injections were given immediately before and after 
surgery, at one day and one week postoperatively. Assessment consisted of full 
ophthalmic examination with recordings of LogMAR visual acuities performed at 
baseline and at set intervals after surgery. No statistical differences in the incidence of 
complications were seen between the groups after 12 months of follow up and no serious 
adverse events related to the study drug occurred. There was a trend towards lower IOP 
and less intervention in those treated with CAT-152. CAT-152 antibody blebs were 
diffuse, non avascular and non cystic (Siriwardena et al., 2002).
Follow-up was extended to investigate whether these observations were maintained over 
a longer period of time. Twenty-one patients completed 3 year follow-up with 
assessments being conducted at approximately six month intervals. A total of 11 patients 
were defined to be treatment failures by virtue of receiving injection(s) of 5-FU or re­
starting topical IOP lowering medications. Six of eight patients in the placebo group 
(75%) were treatment failures as compared to 5/16 (31.3%) of patients who had been 
treated with CAT-152 (p=0.082). Survival analysis of the time to treatment failure 
showed CAT-152 to be superior to placebo at the 10% level (p=0.072). Mean IOP was 
consistently lower in the CAT-152 treated patients, with a mean IOP at 36 months of 13.2 
mmHg. Bleb appearance in both treatment groups was most frequently reported as 
diffuse, with normal vascularity. Adverse events were infrequent with no longer term 
adverse consequences of CAT-152 being observed.
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Figure 26 Effect of peri-operative CAT-152 on GFS
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A course of 6 subconjunctival injections of CAT-152 or placebo were 
administered on day 0,1,2,3,4 up to seven days after surgery. This kaplan meier 
survival curve shows that CAT-152 significantly improved bleb survival 
compared to control. In addition, CAT-152 reduced subconjunctival scarring and 
was safe and well tolerated (Cordeiro et al., 1999a).
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The positive results observed at one year were consistently maintained throughout the 3 
year post-surgery follow-up (Khaw et al., 2003).
In the second clinical trial the safety and tolerability of CAT-152 was investigated after 
phacotrabeculectomy. 56 patients were recruited and randomised to receive CAT-152 or 
placebo. No serious adverse effects occurred. The treatment regimen was the same as for 
the trabeculectomy study with 4 subconjunctival injections being given in total. CAT-152 
was associated with less adverse event and less side effects than placebo. The mean IOP 
was 14.5 mmHg after CAT-152 compared to 16.6 in the placebo. More patients achieved 
target IOP after CAT-152 (Broadway et al., 2002).
Two large international confirmatory studies are in progress.
1.4.6.2 Agents against growth factor receptors The antiparasitic drug, suramin (a 
heparin analogue) specifically inhibits growth factor activity ( PDGF, p FGF, TGF p, 
EGF, IGF-I, IGF-II) (Campochiaro et al., 1994; Chamberlain et al., 1995; Zumkeller et 
al., 1995). Suramin competitively binds with the growth factor receptors and thereby 
displaces the growth factor molecule from the target cells. Meitz et al have shown that 
suramin delays the conjunctival wound healing response in a mouse model. Changes were 
observed in the expression and time course of growth factors in the forming scar tissue 
with TGF p i and TGF P 2 levels persisting longer than in the controls. In addition, 
Suramin specifically decreased the production of collagen types I and in by ocular 
fibroblasts in tissue cultures at concentrations that did not affect cell viability (Mietz et 
al., 1998b).
Furthermore, this group have demonstrated that combined intra-operative and early post­
operative application of Suramin significantly delays wound closure after trabeculectomy 
in the rabbit. At concentrations of 200 mg/ml and 333 mg/ml Suramin increased the mean 
failure time to 9 and 14 days, respectively, with a p value of 0.001, representing an
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evident delay in failure over untreated controls (Mean failure 4.7 days) and MMC treated 
animals (Mean failure 8.2 days). Histopathological evaluation showed lower degrees of 
cellularity, fibrosis, collagen III deposition, and CD3 density in the suramin- and 
mitomycin C-treated eyes compared to control eyes at all time points (p < 0.05) (Mietz et 
al., 1998a).
In this first clinical study using suramin to inhibit fibrosis following trabeculectomy for 
complicated cases of glaucoma, the use of suramin was associated with fewer cases of 
severe hypotony, choroidal detachment, and severe visual loss as compared to mitomycin, 
while the success rates seemed to be similar (Akman et al., 2003). This method of growth 
factor inhibition may represent a new approach to the surgical treatment of glaucoma, 
although its application may be limited by the non specific effect on all local growth 
factor receptors rather that targeting a specific molecule.
1.4.6.3 Modification of gene expression Other methods of neutralizing growth factors 
include blocking gene expression of the growth factor or the receptor.
Antisense oligonucleotides (OGN) are synthetic molecules that bind to specific 
intracellular messenger RNA strands. They consist of short DNA/RNA sequences around 
20 nucleotides in length, which are designed to be complementary to the mRNA sequence 
that code for the production of specific proteins. By binding to the mRNA molecules 
antisense OGN block the synthesis of the target protein. The possible mechanisms by 
which this occurs include the modulation of protein translation by disruption of ribozome 
assembly, RNase mediated cleavage of targeted mRNA and pre-translational modification 
of splicing (Dean et al., 1996).
Antisense OGN represent a promising therapeutic strategy that has been successfully 
applied to oncology, inflammatory and viral infective disease. The potential advantage of 
oligonucleotides as inhibitors of protein expression is the specificity that may be
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achieved, as the approach allows the highly selective targeting of particular nuclei acid 
sequences (Tamm et al., 2001). Antisense technology was first proposed in 1978, but 
adjustments in their structures and increased understanding of the technology has lead to 
improvements in pharmacokinetics and pharmacokinetics (Stephenson et al., 1978). 
Certain criteria need to be met for an antisense OGN to demonstrate optimum biological 
activity and the search for molecules to reach these requirements had lead to 
modifications in the nucleobase, sugar and the phosphate backbone of conventional DNA 
(Altmann et al., 1996, Dean et al., 1997). Firstly, the antisense molecule must be 
sufficiently resistant to endogenous cellular nucleases to avoid rapid cleavage and 
breakdown. Incorporation of a sulphur atom for an equatorial oxygen in the phosphate 
backbone (creating a phosphorothioate backbone) acts to increase resistance to these 
nucleases and thereby improves OGN stability. Secondly, antisense OGN must have 
sufficient affinity for the target mRNA to bind with a high degree of specificity and 
fidelity. Modification of the bases, for example, use of 5-methyl C for C in the 
synthesised oligonucletide, can increase specificity without interfering with the method of 
action and is often employed in antisense design. Finally, the antisense molecule must be 
taken up effectively into the cell and historically this has proved problematic. Combined 
administration with cationic liposomes such as lipofectin can enhance OGN uptake 
(Marcusson et al., 1998).
ISIS pharmaceuticals (Carlsbad, CA, USA) have designed a number of phosphorothioate 
OGN that target the mouse TGF (31 sequence and rabbit TGF (31, (32 and TGF (3 receptor 
(typell TBR II) sequences (Table 3)
The effect of ISIS TGF (3 1 antisense OGN has been investigated in a mouse model of 
conjunctival scarring. Following subconjunctival injection the antisense OGN was 
localised to the treatment area for 7 days, significantly inhibited the scarring response,
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Table 3 Design and selection of TGF P antisense oligonucleotides
RNA target ISIS number Sequence
Rabbit TGF p i 105204 GTC ACC ATT AGC ACGGGGG
Rabbit TGF P2 123285 CCGTGACCAGATGCAGGAT
Rabbit TBR II 123787 GGCCAGGGAGCTGCCCAGCT
Universal control 29848 Mix of A,G,C,T
Sequences of selected OGN targeting rabbit TGF p i, 02 and TBR II
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reduced the numbers of inflammatory cells in the wound site, and appeared to decrease 
the expression of conjunctival TGF pi and P2 (Cordeiro et al., 2000a; Cordeiro et al., 
2003).
Ribozymes are RNA molecules that have the ability to enzymatically cleave specific 
bonds within another RNA molecule (Bartel et al., 1993; Wilson et al., 1995). 
Transcription and translation of a selected protein can be inhibited if the RNA sequence 
encoding it is cleaved by ribozyme activity. Ribozymes can be designed to target any 
message, for example RNA encoding growth factors can provide a targeted approach to 
the inhibition of wound healing. In addition, they display a number of advantages over 
antisense OGN in their potential as therapeutic agents. Firstly, they form a more stable 
intracellular enzyme/substrate within cell that is relatively resistant to intracellular 
nucleases. Secondly ribozyme activity is not as concentration or time dependent, multiple 
copies of specific mRNA strands can be cleaved rapidly at a catalytic rate, and each 
individual molecule is able to re attach and destroy other messages of the same sequence 
many times.
The use of ribozymes as RNA enzyme directed gene therapies in the management of 
ocular disease is in its infancy but early studies have shown potential. Ribozymes have 
been designed that selectively decreased the expression of the insulin like growth factor 
(IGF-1R) which is associated with abnormal retinal neovascularization. These ribozymes 
were tested in angiogenesis models and were effective at reducing the expression and 
function of the IGF-1R in vitro and in vivo. They not only provide an effective method 
for studying the process of angiogenesis but may also ultimately be effective as gene 
therapy tools for the reduction of pathologic retinal angiogenesis (Shaw et al., 2003). 
Blalock et al investigated the effect of hammerhead ribozymes targeting connective tissue 
growth factor (CTGF) mRNA on TGF P mediated cell proliferation in cultured human
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fibroblasts. TGF P induced cell proliferation was reduced 90% in fibroblasts stably 
transfected with the ribozyme, CHR 859, compared to control cell groups. This study 
supports the concept that CTGF mediates TGF p induced cell proliferation, and implies 
that regulating CTGF expression with ribozymes may be effective in reducing ocular 
scarring (Blalock et al., 2004).
Ribozymes represent an exciting new mode of specific, focal, titratable treatment.
1.4.7 MMP inhibition: Modulation of cellular migration, wound contraction, 
matrix synthesis and remodelling
As mentioned in section 1.2.4 matrix metalloproteinases (MMPs) are a group of 
ubiquitous proteolytic enzymes which degrade the extracellular matrix and play a critical 
role in the evolution of scar tissue. Dysregulated MMP activity has been implicated in 
diseases associated with uncontrolled proteolysis of connective tissue matrices such as 
arthritis and tissue ulceration (Vaalamo et al., 1996). In the eye MMP’s are thought to be 
involved in conjunctival (Di Girolamo et al., 2000), comeal (Daniels et al., 2003b; Mohan 
et al., 2002; Pflugfelder et al., 2005), lens epithelial cell (Wong et al., 2004) and retinal 
scarring (Noda et al., 2003; Sheridan et al., 2001; Sivak et al., 2002).
Matrix metalloproteinase gene expression is upregulated in failed filtering blebs in rat 
(Esson et al., 2004) and rabbit models of glaucoma surgery (Liu et al., 2004) and 
elevated levels of MMP’s are present in the aqueous humour in individuals with 
glaucoma (Ho et al., 2005).
The use of synthetic MMP inhibitors has been shown to reduce tissue destruction. Recent 
work in our laboratory has shown that the broad spectrum MMP inhibitor, Domastat, can 
inhibit ocular fibrobroblast mediated collagen contraction, migration and collagen 
production at concentrations not associated with cellular toxicity (Daniels et al., 2003a).
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In vivo Domastat can prolong bleb survival, reduce conjunctival scarring and was safe 
and well tolerated (Wong et al., 2003). More recently we have shown that Domastat can 
maintain long term bleb survival and appears comparable to MMC but without the side 
effect profile (Wong et al., 2005). Conversely, conjunctival gene transfer of MMP 3 prior 
to glaucoma surgery appears to prolong bleb survival (Mamiya et al., 2004).
1.4.8 Apoptosis and termination of healing
Wound healing is terminated by apoptosis, although little is know about the physiological 
signals initiating fibroblast apoptosis. MMC and high dose 5-FU can induce conjunctival 
fibroblast apoptosis (Crowston et al., 1998). Conversely, Human Tenon's fibroblasts 
produce interferon beta which prevents T cell apoptosis. These fibroblast/T cell 
interactions contribute to the persistence of fibroblasts at the wound site and the failure of 
the immune system to deactivate, which can lead to chronic inflammation and the failure 
of glaucoma surgery (Chang et al., 2001). Proapoptotic peptides induce death in targeted 
cells by means of a homing motif and these peptides exhibit anti-proliferative activity in 
mice. The induction and regulation of apoptotic mechanism offer another potential way to 
regulate wound healing.
1.5 JUSTIFICATION AND AIMS
The conjunctival wound healing response remains the major barrier to achieving long 
term intraocular pressure control after glaucoma filtration surgery. Current anti-scarring 
agents improve the outcome of surgery but act by causing widespread cell death and can 
be associated with potentially blinding complications. In addition some individuals still
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fail surgery. A more physiological and targeted approach to wound healing control and 
scarring prevention is required.
Of all the growth factors, TGF p has been shown to play a pivotal role in wound healing 
throughout the body, and has been implicated as a potent stimulant of the scarring process 
in the eye, where TGF-p2 the second human isoform, is most commonly implicated.
Modulation of TGF P has been highlighted as a possible mechanism by which ocular 
scarring may be reduced. Initial preclinical studies have identified that neutralisation of 
TGF p2 reduces conjunctival fibroblast function in vitro and reduces subconjunctival 
fibrosis in a model of aggressive scarring in vivo.
The main aim of this study was to continue to establish the role of TGF p modulation as a 
potential anti-scarring strategy in glaucoma surgery. In particular to:
1. Delineate the expression of the TGF P isoforms in the rabbit eye and identify the 
changes associated with glaucoma surgery and TGF p modulation.
2. Investigate the effect of the human anti-TGF p2 monoclonal antibody (CAT-152) on 
the outcome of glaucoma surgery using in vitro and in vivo models of conjunctival 
scarring and move CAT-152 in to the clinical arena.
3. Investigate the role of antisense oligonucleotides directed against TGF P on the 
conjunctival scarring in vivo.
4. Finally to compare these novel agents with the current gold standard anti-scarring 
agents to benchmark their future clinical application and benefit.
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CHAPTER 2 MATERIALS AND METHODS
2.1 CELL CULTURE TECHNIQUES
The in vitro experiments in this project were based on the cellular activity of human 
Tenon’s fibroblasts, which are the key cell type involved in the subconjunctival scarring 
response.
2.1.1 Human Tenon’s capsule fibroblast explant.
Human Tenon’s fibroblasts were propagated from multiple 0.5 cm explants of human 
tissue (Khaw et al., 1992d). Cadaver eyes were obtained from Moorfields Hospital Eye 
Bank 1 to 5 days after death. Informed consent and institutional human experimental 
committee approval were granted and the Tenets of the Declaration of Helsinki were 
adhered to. Tenon’s capsular tissue was identified and carefully dissected from the globe. 
Up to four 0.5cm3 explants were placed in a 25cm3 flask (BD Biosciences, Oxford, UK) 
and the tissue was left to adhere to the plastic flask for two hours. 5mls of standard 
culture medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) containing 
10% Fetal Calf Serum, 2mM L-glutamine, 100 IU/ml Penicillin and lOOjig/ml 
Streptomycin was carefully added to each flask (All Gibco, Invitrogen Corporation, 
Scotland, UK). Primary explants were incubated at 37°C in humidified 5% Carbon 
Dioxide (CO2) in air and fed once a week with new culture medium. All of the procedures 
were performed in a laminar flow hood, using aseptic technique, and all the solutions 
were warmed to 37°C in a water bath prior to use.
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2.1.2 Culture and maintenance of fibroblasts.
Human Tenon’s fibroblasts were usually observed within two weeks of primary culture 
and viewed under a phase contrast inverted microscope (Olympus CK4, Japan) at lOx 
magnification. Epithelial cell growth was occasionally observed in addition, however 
these cells were unable to survive in the conditions and detached from the flask. The cells 
reached confluence on average after 4 weeks of culture. At this point the monolayers 
were passaged in a 1:3 ratio. The culture medium was removed from each flask and the 
monolayer was washed twice with 5mls of Phosphate Buffered Saline solution (PBS, 
Gibco: Invitrogen Corporation, Scotland, UK). The cells were detached using a solution 
of Trypsin (1 in 10 dilution with PBS, Gibco: Invitrogen Corporation, Scotland, UK) of 
sufficient volume to cover the base of the flask, which was then incubated at 37°C for 
approximately 2 minutes. The cells were then observed by phase contrast microscopy and 
once they had become mobile and adopted a round phenotype, trypsinisation was stopped 
by adding an equal volume of DMEM culture medium. Explant tissue was removed and 
the cell suspension was transferred to a Universal container (Sterilin, Staffs, UK) and 
centrifuged at 1600 rpm for 5 minutes. The resultant cell pellet was resuspended in 12mls 
culture medium and this volume was placed in a 75cm flask (1:3 expansion), which was 
labelled with the cell type, passage number, date of passage, and donor number (cell line). 
Flasks were kept in a humidified 5% CO2 incubator at 37°C and the cells were fed with 
culture media every 3 days.
Fibroblasts between passage 2 and 6 were used for the following experiments. Cells 
between these time points have been shown to behave in a similar way with respect to cell 
proliferation and growth curve characteristics, despite originating from different explant 
tissue (Khaw, 1994). Experiments were performed on primary cells from at least two
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donors to ensure that the trends were reproducible. When monolayers reached over 80% 
confluence they were passaged using the method described in a 1: 3 ratio.
2.1.3 Storage and recovery of liquid nitrogen frozen cells
Low passage fibroblasts were stored in liquid nitrogen for future use. Confluent 
monolayers were trypsinised using the method previously described. A sterile solution of 
10% Dimethyl Sulphoxide (DMSO, Sigma, Dorset, UK) in standard culture media was 
prepared and placed at 4°C for 15 minutes. The resultant cell pellet was resuspended in 
this solution which was added dropwise with continuous mixing. 1ml of cell suspension 
was placed in each cryovial at a cell density of 1 x 106 cells per ml. The cells were cooled 
to -70 °C over a period of 24 hours in propan-2-ol before being transferred into liquid 
nitrogen (- 160 °C liquid phase).
The cells were retrieved using the following method. The cells were rapid thawed by 
immersing the bottom of the cryovial in hot running water (60 °C). The cell suspension 
was transferred into a universal container, 5-10ml of culture media was added dropwise 
with continual mixing and the suspension was centrifuged at 1500rpm for 5 minutes to 
obtain a cell pellet. The pellet was resuspended in 10 mis of culture media and 
centrifuged again at 1500rpm for 5 minutes. The process was repeated until the cells had 
been pelleted 3 times. This was to ensure complete removal of DMSO from the cell 
suspension. The final cell suspension was seeded into appropriately sized tissue culture 
flasks and the cells were maintained in 5% humidified CO2 in air at 37°C and fed every 3 
days with renewed culture media.
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2.1.4 Haemocytometry
The fibroblasts in each flask were counted prior to each of the following experiments in 
order to seed a specific cell density. A Neubauer haematocytomer (Assislent, Germany) 
was used to obtain a qualitative and quantitative cell count. Confluent tissue culture flask 
monolayers were trypsinised to obtain a cell pellet. This was resuspended thoroughly in 
lml of culture media and 50|il of this was removed and mixed to 50(il of trypan blue 
solution (Sigma, Dorset, UK). This solution was transferred to the haematocytometry 
chamber slide via capillary action. The number of live cells in each chamber A and B 
(Chamber = grid of 5x5 squares) was counted using a light microscope and an average 
from both chambers was calculated. Each chamber represents the number of cells in 
0.1 jxl. To obtain the number of cells per ml the average cell count is multiplied by 10000. 
After allowance for the dilution factor of the original cell suspension, a value for the cell 
count in the original sample can be made. This method is accurate for cell counts of 
between 30-300 cells per chamber. Fibroblasts from the original cell suspension were 
therefore diluted according prior to the mixing with trypan blue to account for this.
2.2 FIBROBLAST MONOLAYERS
2.2.1 Monolayer assays
Monolayer experiments were performed on either 6 well, 24 well or 96 well plates (BD 
biosciences, Oxford, UK). Cells were seeded at a specific density calculated from pilot 
studies. Experiments were performed with a minimum of three wells per concentration of 
treatment (triplicates) and were repeated at least 4 times on primary cells, from at least 
two different donors.
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2.2.2 Stimulation of cells with TGF p
The recombinant TGF (32 used in the following experiments was a generous gift from 
Cambridge Antibody Technology (Batch number: TG 815). A stock solution of 1.7mg/ml 
in 12 mM Hydrochloric Acid (HCL) 20% ethanol, pH 2.5 was provided. Single use 20 pi 
aliquots of a 20 pg /ml solution made up in 4 mM HC1 / 1 mg /ml Bovine Serum Albumin 
(BSA, Sigma, Dorset, UK) were prepared and stored -70 °C prior to use.
A range of TGF [32 concentrations were selected to investigate the effect of this growth 
factor on fibroblast functions; 0, O.OlpM, O.lpM, lpM, 3pM, lOpM, 30pM lOOpM, 
300pM and lOOOpM which corresponds to 0, 10'14, 10'13,10'12, 3x1 O'12, 10'11, 3xl0'u ,10' 
10, 3xl0 '10 and 10'9 M and 0.00025, 0.0025, 0.025, 0.075, 0.25, 0.75, 2.5 , 7.5 and 25 
ng/ml. These concentrations were selected not only because they covered a large scale to 
encompass possible biphasic concentration effects of TGF-(3, but also on evidence from 
previous experiments (Cordeiro et al., 2000b). All dilutions were made using serum free 
cell culture medium with 1% BSA.
2.2.3 Inhibition of TGF [3 activity with Anti-TGFp2 antibody (CAT-152)
This recombinant antibody was supplied by Cambridge Antibody Technology (CAT, 
Cambridge, UK). It is an engineered human monoclonal IgG4 antibody, which is 
formulated in PBS at pH 7.2, and was stored at a stock concentration of 1 mg/ml at -70 
°C. Working dilutions of the antibody were made in serum free culture medium with 1% 
BSA prior to use. A range of concentrations were selected to investigate the effects of the 
antibody on fibroblast function; 0.0 InM, 0.1 nM, InM, 3nm, lOnM, 30nm, lOOnM, luM 
which corresponds to 10n M, 10‘loM, 10'9M, 3xlO'9M, 10'8M, 3xl0'8 M, 10‘7 M, 10'6 M 
or 0.0015 pg/ml, 0.0015 pg/ml, 0.15 pg/ml, 0.45 pg/ml, 1.5 pg/ml, 4.5 pg/ml, 15 pg/ml
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and 150 jig/ml. The control solution CAT-152 was a null lgG4 antibody, CAT-001 
(Cambridge Antibody Technology) used at the same concentrations as the test antibody.
2.2.4 Imaging of Fibroblast Monolayers
Phase contrast microscopy was used to observe the morphology of the cells at set time 
points throughout the experiments. Images were captured by the use of digital camera 
with a microscope attachment and stored as JPEG files (Nikon Coolpix 950, Tokyo, 
Japan)
2.3 EXTRACELLULAR MATRIX PRODUCTION BY HUMAN TENON’S 
FIBROBLASTS
2.3.1 Acid soluble collagen production (Matrix associated)
2.3.1.1 Effect of TGF (32 on collagen production by human Tenon’s fibroblasts This 
was determined by means of the Sircol Assay (Biocolor, UK) which is a quantitative dye 
binding method designed for in vitro analysis of collagen production (Blease et al., 2002; 
Huang et al., 2002) (Figure 27). Cells were seeded into 6 well plates at a cell density of 7 
x 105 cells per well and allowed to settle overnight. After 12 hours exposure to serum free 
conditions (DMEM with 1% BSA, 2mM L-glutamine, 100 IU/ml Penicillin and 100jng/ml 
Streptomycin) the cells were washed and stimulated with increasing concentrations of 
TGF (32 ( 0 pM, O.OlpM, O.lpM, lpM,10pM, 30pM, lOOpM, 300pM and lOOOpM). After 
48 hours the conditioned media was removed and stored. The cell layer and extracellular 
matrix was treated with 0.5% acetic acid to release the acid soluble collagen. A sircol dye 
was mixed to the cell lysate, spun at 13000 RPM for 15 minutes. The pellet was
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Figure 27 The molecular structure of sircol dye
OH
H C O  N
R
Mode of Action of the Sircol dye 
with soluble collagens:
The Sircol dye reagent contains sirius 
red. The colour commission name is 
Direct Red 80
Mechanism by which the dye reacts 
with collagen:
Sirius red is an anionic dye with 
sulphonic acid side chain groups. 
These groups react with the side chain 
groups of the basic amino acids 
present in collagen
The specific affinity of the dye for the 
collagen, under the assay conditions is 
due to the elongated dye molecules 
becoming aligned in parallel with the 
long rigid structure of native collagens 
that have intact triple helix 
organisation.
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resuspended in 1ml of 0.5M NaOH and the absorbance was read @ 540 nm. Collagen 
standards were provided to obtain a standard reference curve.
2.3.1.2 Effect of CAT-152 on TGF (32 mediated collagen production by human 
Tenon’s fibroblasts After the initial experiments had been completed a dose response 
relationship was generated for TGF-[32 and collagen production. The sircol assay was 
repeated using a single concentration of TGF (32 (EC 90: lOOpM) to stimulate the cells in 
the presence of increasing concentrations of anti-TGF p2 antibody 0.0InM, O.lnM, InM, 
3nm, lOnM, 30nm, lOOnM, luM and Null antibody.
2.3.2 Type 1 collagen production
Metra CICP (Collagen I C-terminal propeptide) sandwich enzyme linked immuno assay 
was performed to determine the amount of collagen in the culture supemantant from 
fibroblast monolayers (Metra CICP EIA kit; Quidel, San Diego, USA). This assay 
measures the release of collagen propeptides, cleaved from C-terminal of the type 1 
collagen molecule prior to the incorporation of collagen into the growing collagen fibril. 
The release of these peptides thereby provides a stoichiometric representation of the 
production of newly formed collagen.
2.3.2.1 Effect of TGF p2 on type 1 collagen production by human Tenon’s 
fibroblasts Conditioned media was collected from the cells cultured for the sircol 
assay after 48 hours of stimulation with increasing concentrations of TGF p2 (2.3.1.1). 
Briefly, the media was diluted 1 in 64 with assay buffer and then lOOpl was added to the 
wells of a 96 well elisa plate precoated with a monoclonal anti-CICP antibody and 
incubated at room temperature (RT, 18-25 °C) for 2 hours. In the sircol assay each 
concentration of TGF (32 was tested in triplicate providing 3 samples of conditioned
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media for the CICP assay. Duplicate aliquots of each of these 3 samples were added to 
the elisa plate (6 samples per TGF 02 concentration analysed). Collagen standards were 
provided to generate the standard curve. The strips were manually everted and each well 
was washed 3 times with wash buffer. lOOjul Rabbit anti-CICP antiserum was then added 
to each well and incubated for 45 minutes at RT after which the cells were washed again. 
A goat anti-rabbit alkaline phosphatase conjugate was incubated for 45 minutes, followed 
by a pNitrophenyl Phosphate substrate to quantify the CICP in the media for 30 minutes. 
The reaction was stopped with 50pl IN NaOH per well and the optical density was read 
at a wavelength of 405nm. The assay is summarised in Figure 28.
2.3.2.2 Effect of CAT-152 on TGF (32 mediated type 1 collagen production by human 
Tenon’s fibroblasts Conditioned media was generated in two ways. In the first set of 
experiments it was collected from the cells in the sircol assay after 48 hours of 
stimulation with a single concentration of TGF (32 (EC 90: lOOpM) in the presence of 
increasing concentrations of anti-TGF (32 antibody (O.OlnM, O.lnM, InM, 3nM, lOnM, 
30nM, lOOnM, luM and Null antibody). In the second set of experiments cells were 
seeded into 24 well plates at a density of 1 x 105 cells per well and allowed to settle 
overnight. After 12 hours exposure to serum free conditions the cells were washed and 
stimulated with a single concentration of TGF 02 (lOOpM) in the presence of increasing 
concentrations of anti-TGF 02 antibody (O.OlnM, O.lnM, InM, 3nM, lOnM, 30nM, 
lOOnM, luM and Null antibody). After 48 hours the condition media was removed and 
analysed. The reason for change in the methodology was primarily to reduce the number 
of cells need for the assay as explant tissue was unavailable due to temporary closure of 
Moorfields Eye Bank. In addition, the CICP method provides a more accurate and 
specific quantification of type 1 collagen production.
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Figure 28 Assay of C terminal propeptide of collagen type 1
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conjugated to alkaline 
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Binding of Antigen- cicp
Monoclonal anti-cicp antibody 
coated on the plate
The CICP assay is a sandwich enzyme immunoassay in a mictrotitre plate format 
utilising a monoclonal anti-cicp antibody coated on the plate, a rabbit anti-cicp 
antiserum, a goat anti-rabbit alkaline phosphate conjugate and a pNPP substrate 
to quantify the CICP in the medium.CICP standards were used to generate a 
standard curve.
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2.4 CYTOSKELETON AND CELL MORPHOLOGY
2.4.1 Quantification of alpha smooth muscle actin (a  SMA) expression by ELISA
An elisa technique was used to quantify a  SMA production in cultured human Tenon’s 
fibroblasts (Richter et al., 2001). Low passage cells were seeded in 96 well plates at a cell 
density of 7 x 10 and allowed to settle for 8 hours. After 16 hours exposure to serum free 
conditions (culture media with 1% BSA) the cell were treated with increasing 
concentrations of TGF (32 (OpM, O.lpM, lpM, 3pM, lOpM, 30pM lOOpM and lOOOpM). 
After 72 hours the elisa was performed. Briefly, the supernatant was removed and the 
cells were carefully washed three times with PBS. The cells were fixed with methanol for 
15 minutes at -20 °C and then left to air dry for 20 minutes at RT. lOOjal of antibody 
buffer [PBS containing 1% BSA, 1% Ovalbumin and 0.1% Tween-20 (Sigma, Dorset, 
UK)] to each well and incubated at RT for 30 minutes to block non specific binding sites. 
After removal of the antibody buffer by blotting the plate the cells were incubated in 100 
pi primary anti a  SMA antibody (1:2000 dilution in antibody buffer, Clone 1A4; Sigma, 
Dorset, UK) for 2 hours. The plate was washed three times with 250 pi PBS prior to the 
addition of 100 pl/well of horseradish peroxidase conjugated anti-mouse secondary 
antibody (IgG; Dako A/S, Demark). After 1 hour and further washing, TMB one step 
solution (Promega, Madison, USA) was added 100 pi/ well. The colour reaction was 
stopped after 15 minutes with 100 pi 1M HCL and the optical density was read at 450nm 
with a 630nm reference filter.
2.4.1.1 Effect of CAT-152 on alpha smooth muscle actin expression After the 
initial experiments had been completed a dose response relationship was generated for 
TGF-(32 and a  SMA expression. The elisa was repeated using a single concentration of
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TGF (32 (EC 90: 30pM) to stimulate the cells in the presence of increasing concentrations 
of anti-TGF (32 antibody O.OlnM, O.lnM, InM, 3nm, lOnM, 30nm, lOOnM, luM and 
Null antibody.
2.4.2 Immunocytochemical staining of the actin cytoskeleton: a  SMA 
Immunocytochemistry. The presence of a  SMA in the cells was demonstrated by 
fluorescent immunocytochemistry. Low passage fibroblasts were seeded at a density of 1 
x 105 on glass cover slips in 6 well plates and left to settle for 8 hours. The wells were 
washed carefully 3 times with PBS and subjected to serum free conditions for 16 hours. 
The cells were then treated with OpM, 10 pM or lOOpM TGF (32 or a combination of 
OpM, 10 pM or lOOpM TGF (32 with lOOnM or 300nM CAT-152. After 72 hours the cells 
were washed in PBS, fixed with 4% Paraformaldehyde (Sigma, Dorset, UK) for 30 
minutes and left to air dry. The coverslips were removed from the base of the 6 well plate 
and transferred with forceps to a microscope slide. Briefly the slides were permeablised in 
1% Triton x-100 in TBS (Sigma, Dorset, UK) for 15 minutes and blocked with Fetal Calf 
Serum (1:10 dilution in TBS) for 30 minutes. The primary antibody mouse anti-human a  
SMA FITC conjugate (1:250 dilution in 1:10 FCS; Sigma, Dorset, UK) was incubated for 
3 hours. The slides were counterstained with Diamidino-2- phenylole dilactate (DAPI; 
Sigma, Dorset, UK) for 1 minute, washed in TBS and air dried. Coverslips were mounted 
with fluorescent mounting medium. The cells were imaged by confocal microscopy.
2.4.3 Data analysis
Collagen production in response to TGF (32 is presented as the amount of collagen per ml 
of cell lysate for the Sircol assay, or the amount of CICP per ml of culture medium. The
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EC50 values for TGF(32 or IC50 values for CAT-152 (geometric mean with 95% 
confidence intervals) were determined using four-parameter logistic curve fitting (Prism 
2, GraphPad Software, San Diego, USA). When a four parameter fit failed, a three or two 
parameter fit was performed by holding the curve top and/or bottom values constant. All 
data are tabulated in Appendices. ANOVA and Dunnett’s test was used to identify 
significant changes between treatment groups (Instat, GraphPad Software, San Diego, 
USA). The level of significance applied to the statistical analysis was P<0.05.
2.5 RABBIT MODEL OF GLAUCOMA FILTRATION SURGERY
A number of animal models have been developed in order to study wound healing after 
glaucoma filtration surgery. The rabbit model is most widely accepted and exhibits an 
extremely aggressive scarring response compared to human tissue (Miller et al., 1989; 
Miller et al., 1985; Prince, 1964; Tahery et al., 1989). Histological analysis has shown 
that scarring after glaucoma surgery occurs at the level of the sclera, conjunctiva and 
within the subconjunctival Tenon’s capsule (Doyle et al., 1993a; Khaw et al., 1992a; 
Khaw et al., 1992b; Miller et al., 1989). Our group has developed a model of rabbit 
filtration surgery in which a microtube is inserted into the eye, to maintain a permanent 
sclera fistula (Cordeiro et al., 1997). This eliminates the effects of scleral wound healing 
and localises the healing response to the conjunctival tissues (Figure 29). The model has 
been shown to be consistent, reproducible and to date if efficacy is shown in this model 
then the treatment has always been shown to be effective in humans (Cordeiro et al., 
1999a; Siriwardena et al., 2002). We therefore adopted this model for the purposes of this 
project, to investigate the effects of novel anti-scarring agents. It is important to note that 
this is a model of conjunctival scarring rather than elevated pressure and glaucoma.
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Figure 29 Model of subconjunctival scarring after experimental
glaucoma surgery
Drainage of fluid
Anterior Chamber
Aggressive Scarring Lens
Tube
Rabbit model of filtration surgery in which a tube is inserted into the anterior 
chamber to create a permanent fistula draining fluid into the subconjunctival 
space. The IOP of the rabbit is normal pre-operatively and it therefore acts as a 
model of subconjunctival scarring rather one a model of glaucoma. Healing is 
very exaggerated and a week in this model represents approximately four weeks 
in humans.
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2.5.1 Study design
All experiments were performed as randomised controlled masked observer studies using 
New Zealand White Rabbits, aged between 12-14 weeks and weighing 1.5-2.0 kg, in 
accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research. All animals were housed in the Biological Resources Unit at the Institute of 
Ophthalmology and were allowed an acclimatisation period of at least 7 days. Surgery 
was performed in two batches on successive days. Randomisation was performed by a 
masked individual using the programme available on www.randomisation.com. taking 
into account the 3 treatment groups and two batches of surgery. Three copies of the 
randomised treatments were placed in sealed envelopes and stored.
2.5.2 Surgical technique
Glaucoma filtration surgery was performed on the left eye of all rabbits under general 
anaesthesia [Intramuscular muscular Ketamine (50mg/kg; Fort Dodge Animal Health Ltd, 
UK) and Xylazine (lOmg/kg; Bayer PLC, Suffolk)] as summarised in figure 30. A partial 
thickness 8-0 silk comeal traction suture (Ethicon; Johnson and Johnson, UK) was placed 
at 12 O’clock to gain exposure to the superior conjunctiva. A fomix based conjunctival 
flap was raised and blunt dissection of subconjunctival space was performed to a distance 
of 15mm behind the limbus. An MVR blade (Vistech; Warwickshire, UK) was used to 
fashion a partial thickness scleral tunnel starting 4mm behind the limbus and continuing 
until the blade was just visible in the anterior cornea stroma. A 22 G/25mm Venflon 
intravenous cannula (BD Biosciences, Oxford, UK) was then passed through the scleral 
tunnel until the cannula needle was visible in the clear cornea. The cannula needle entered 
the anterior chamber, the cannula was advanced to the mid pupillary area, and the needle 
was withdrawn. Finally the cannula was trimmed and bevelled at its scleral end so that it
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Figure 30 Model of Rabbit Glaucoma Filtration Surgery
The nyctitating membrane was removed to provide access to the anterior 
segment (A). A partial thickness 8-0 silk corneal traction suture was placed at 
12 O’clock (B) after which a fomix based conjunctival flap was raised and 
blunt dissection of subconjunctival space was performed (C,D). An MVR 
blade was used to fashion a partial thickness scleral tunnel starting 4mm 
behind the limbus and continuing until the blade was just visible in the anterior 
cornea stroma (E). A 22 G/25mm Venflon intravenous cannula was then 
passed through the scleral tunnel until the cannula needle was visible in the 
clear cornea (F).
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Figure 32 (Cont) Model of Rabbit Glaucoma Filtration Surgery
The cannula was trimmed and bevelled at its scleral end so that it protruded 
1mm from the insertion point and a 10-0 nylon suture on a B/V 100-4 needle 
was used to fix the tube to the scleral surface (G,H). The conjunctival incision 
was closed with two interrupted sutures and a central mattress-type 10-0 nylon 
suture to give a water-tight closure (I,J,K). One drop of Atropine Sulphate 1% 
and Betnesol N ointment was instilled at the end of surgery (L).
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protruded 1mm from the insertion point and a 10-0 nylon suture on a B/V 100-4 needle 
(Ethicon, Johnson and Johnson, UK) was used to fix the tube to the scleral surface. The 
conjunctival incision was closed with two interrupted sutures and a central mattress-type 
10-0 nylon suture on a B/V 100-4 needle to give a water-tight closure. One drop of 
Atropine Sulphate 1% (Martindale Pharmaceuticals, Romford, UK) and Betnesol N 
ointment was instilled at the end of surgery.
2.5.3 Clinical assessment of the rabbit model
Baseline observations were performed prior to glaucoma filtration surgery. The 
contralateral unoperated eye acted as a control. Measurement of IOP in both eyes was 
made using the Mentor Tonopen (Mentor, Norwall, MA, USA) after topical instillation of 
0.5% Proxymetacaine HCL eye drops (Chauvin Pharmaceuticals, Romford, Essex) 1 drop 
per eye, with a mean reading of three recordings being documented per time point. The 
conjunctival appearance and the drainage area were observed. All animals were examined 
by a masked observer at set times after surgery. Assessment of both eyes was made daily 
from day 0 to day 4 and there after at regular periods, at least twice weekly, until 
sacrifice. Bleb characteristics including length, width and height were measured using 
calipers, and IOP were recorded. Previous experience with this surgical model has 
identified a small area of avascularity (<3mm) that appears in the nasal conjunctiva. This 
is a transient clinical observation and appears to develop independently of any treatment 
given. The incidence of avascularity was noted (normal vascularisation, 0; avascular 
region, 1). The drainage bleb vascularity characteristics were assessed independently 
from this area and were graded by dividing the conjunctival areas into quadrants 
(superior, nasal and temporal) and scoring the appearance (0, avascular; +1 normal 
vascularity; +2 hyperaemic; +3 very hyperaemic). Slit lamp examination was performed
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to identify both anterior chamber activity (0 quiet; 1 cells; 2 fibrin; 3 hypopyon) and 
anterior chamber depth which was recorded as either deep (+2), shallow (+1), or flat (0). 
An assessment of the presence and duration of comeal epitheliopathy was made after 
topical installation of 0.5% Proxymetacaine 0.25% Fluorescein (Chavin Pharmaceticals, 
Romford, Essex) into the left eye and was graded according to the area of the cornea 
affected (0 = nil, 1 = < 25%, 2 = < 50%, 3 = < 75%, 4 = < 90%, 5 = up to 100% ). To 
minimise discomfort in the case of worsening comeal epitheliopathy, defined as 
deterioration or an increasing comeal epithelial defect as recorded on two consecutive 
examinations, affected animals would stop receiving subconjunctival injections until the 
defect healed. The conjunctival was observed for the presence of a chemotic response 
(localised swelling and injection) which was graded as mild, moderate or severe (grade 
l=mild, grade 2=moderate and grade 3=severe).
Any other clinical findings were noted including the presence of blood in the anterior 
chamber (hyphaema), lid swelling or subconjunctival haemorrage. All observations were 
recorded on an observation data sheet.
2.5.4 Photography and image storage
Images of the operative wound site were taken weekly after surgery. At the start of the 
study a 35mm fundus camera was used (Genesis, Kowa Company Ltd, Japan). This 
method was superseeded by use of a digital camera in terms of image quality, acquisition 
and storage (Nikon Coolpix 950, Tokyo, Japan). Digital images were stored as JPEG 
files.
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2.5.5 Technique of drug administration
In the following experiments anti-scarring agents or control vehicle were administered by 
subconjunctival injection at set time points on the day of surgery or in the post-operative 
period. The subconjunctival injections were administered under topical anaesthesia 
(Proxymetacaine hydrochloride 0.5% eye drops, 1 drop per eye), using a 30 G needle 
(Myjector lOOu; Terumo, Japan). lOOjil of agent was injected 5mm behind the limbus at 
the nasal margin of the superior rectus muscle, such that a visible bleb was formed on the 
supranasal quadrant of each eye (Figure 31). This volume was selected to be the 
maximum deliverable by the subconjunctival route in this model. Subconjunctival 5-FU 
was administered 180 degrees from the site of surgery. The rationale for this injection site 
selection was in keeping with the method used in the original studies of subconjunctival 
5-fiuorouracil in glaucoma filtration surgery and widespread clinical practice (Group, 
1989; Group, 1996). 5-FU has a pH of 9 and the risk of intraocular penetration must be 
reduced to a minimum. No other agents were administered at the time of injection. All 
injections were given in a masked fashion to ensure that the operator (ALM) was unaware 
of the treatment being given. When 5-FU was given the injections were given by an 
independent clinician as the different injection sites for each treatment precluded 
masking.
Treatment was either given at the time of surgery or in the post-operative period. Intra 
operative CAT-152 and control vehicles was given as two subconjunctival injections The 
first dose was administered 0.5 hour prior to surgery and the second dose was given 
immediately post-operatively. Inter-operative 5-FU was the only treatment administered 
by a different technique. It was given by application of a sponge soaked in 5-FU which 
was positioned under the conjunctival flap for 5 minutes. This is the accepted route of 
administration of inter-operative 5-FU in clinical practice. Extreme care was taken to
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Figure 31 Technique of subconjunctival injection in the rabbit
The subconjunctival injections were administered under topical anaesthesia 
using a 30 G needle. lOOpl of agent was injected 5mm behind the limbus at 
the nasal margin of the superior rectus muscle, such that a visible bleb was 
formed.
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avoid exposure of the free conjunctival edge to the anti-metabolite. All post-operative 
treatments were given by subconjunctival injection. (Table 4)
CAT-152 was prepared as a sterile colourless solution at a concentration of 1 mg/ml, 
which was stored at 4 °C. Previous studies by our group had determined that lOOjig was 
the optimum dose per treatment, so lOOpl of drug was administered with each 
subconjunctival injection (Cordeiro et al., 1999a). 100ml of lmg/ml CAT 001 was given 
as the control antibody.
2.5.6 Blood Sampling
Pre dosing venous blood was sampled from the ear vein of each rabbit 3 days before the 
start of the study. A small area of the ear was shaved and the topical local anaesthetic 
Ametop (Smith and Nephew Healthcare Ltd, Hull, UK) was applied to the area, which 
was warmed by application of a hot sponge to dilate the vessels. 4 mis of blood was 
collected using a 25 gauge butterfly cannula (BD Biosciences, Oxford, UK) attached to a 
5 ml syringe. The blood was transferred to a clotted sample blood bottle with serum filter 
(BD Biosciences, Oxford, UK) and centrifuged at 4000 rpm for 20 minutes to separate the 
serum from the cellular components. The serum was placed in a labelled eppendorf (BD 
Biosciences, Oxford, UK) and stored at -70 °C. 2mls of blood was also sampled from 
each animal once a week until day 45. A terminal sample of blood (30mls) was collected 
by cardiac puncture under general anaesthesia just prior to sacrifice of the animal on day 
70.
2.5.7 Measurement of CAT-152 or CAT-001 in rabbit serum
Detection of CAT-152 and CAT-001 concentrations in the rabbit serum were based on an 
anti-Fc capture ELISA developed at CAT (SOP number 06/07/044). Briefly, 96-well
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Table 4 Drug administration in the rabbit model of glaucoma surgery
Drug Dose Intra­
operative
treatment
Post-operative
treatment
Site of 
injection
CAT -152 1 mg/ml 
lOOjig
2 x 100 pi 
subconjunctival 
injections (First 
dose 30 mins 
before surgery, 
second dose 
immediately 
after)
100 pi
subconjunctival
injection
Superior
5FU 50mg/ml 
5 mg
Pre soaked 
sponge 
positioned 
under the 
conjunctival 
flap for 5 mins
100 pi
subconjunctival
injection
Inferior
PBS 100 |il 2 x 100 pi
subconjunctival
injections
100 pi
subconjunctival
injection
Superior or 
inferior
CAT-001
Null
antibody
1 mg/ml 
lOOpg
2 x 100 pi
subconjunctival
injections
100 pi
subconjunctival
injection
Superior
Antisense
Oligonucle
otides
TGFpl
TGFp2
TBRII
Misense
25mg/ml
50mg/ml
lmg/ml
25|ig
50|ig
lOOng
2 x 100 jlxI
subconjunctival
injections
Superior
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maxisorb plates (Nunc) were coated (100 pi per well) with goat anti-human Fc (1:400 in 
Dulbecco’s PBS Sigma [D-PBS]) and incubated at +4°C overnight. Thereafter, the plates 
were washed three times with PBS/T (PBS + 0.1% Tween 20) and non-specific sites 
blocked for one hour at +25°C with 150 pi of M-PBS (PBS + 2% [w/v] Marvel dried 
skimmed milk). Eleven point CAT-152 or CAT-001 standard curves in M-PBS ( 1 : 2  
serial dilution; top concentration 2 pg/ml) and rabbit serum samples ( 1 : 4  start dilution or 
1 : 2 serial dilution, respectively) were incubated on the plates at +25°C for one hour. 
CAT-152 or CAT-001 were detected by incubating the plate with a detection antibody 
(sheep anti-human ^-HRP conjugate; diluted 1 : 2,500 in M-PBS) and after washing 3,3’, 
5,5’-tertra methylbenzidine (TMB) substrate (Sigma) was added and the absorbance 
measured at 450 nm.
2.5.8 Measurement of Anti-CAT-152 and Anti-CAT-001 in rabbit serum
Rabbit anti-CAT-152 and anti-CAT-001 were measured using a procedure based on CAT 
SOP number 06/07. Maxisorb plates (Nunc) were coated (100 pi per well) with 0.1 pg/ml 
in D-PBS, of either CAT-152 or CAT-001 and incubated at +4°C overnight. Plates were 
washed with PBS/T and blocked with M-PBS for one hour at +25°C. Rabbit anti-human 
IgG standards (eleven point curve, 1:3 serial dilution; top concentration 200 pg/ml) and 
rabbit serum samples (1:500 start dilution, 1: 3 serial dilution) were incubated at +25°C 
for one hour. Anti-CAT-152 or Anti-CAT-001 were detected by incubating the plate with 
a detection antibody (goat anti-rabbit Ig-HRP; dilution, 1: 5000 with M-PBS) and after 
washing TMB substrate was added and the absorbance measured at 450 nm.
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2.5.9 Tissue collection
All animals were sacrificed at 30 days using a lethal injection of pentobarbitone 
intravenously under a general anaesthetic. Both eyes were enucleated. The upper lid was 
left intact, attached to the globe in order to preserve the architecture of the superior fomix 
and conjunctival tissues around the drainage site. All of the eyes were fixed in 10% 
buffered formal saline for 24 hours and then stored in 70% alcohol. The site of the 
conjunctival injections in the left eye was marked post-mortem, but pre-exenteration with 
10-0 nylon suture. Tissue was stored until the efficacy data had been analysed when a 
decision was made to process it.
2.5.10 Data analysis
Bleb survival was taken as the primary efficacy end point in the analysis of a treatment on 
subconjunctival scarring in rabbit filtration surgery. Bleb failure was defined as the 
appearance of a flat, vascularised and scarred bleb in the presence of a deep anterior 
chamber. Kaplan Meier and log rank statistics were used to compare treatment groups in 
bleb and intraocular pressure failure (defined as the return of the intraocular pressure in 
the surgical eye to baseline level). Bleb area and height, anterior chamber depth and 
activity, and conjunctival vascularity per quadrant were all analysed using repeated 
measures procedure and the generalised linear model (SPSS, SPSS Inc. Chicago, USA). 
This allowed comparison of treatment groups over the whole study period, using between 
subject tests. Duration comeal epitheliopathy and avascularity were analysed using 
Kruskal-Wallis test and Dunn’s test. Finally intraocular pressure was analysed using the 
multivariate analysis of variance, with Bonferroni’s modification to compare differences 
between treatments and the effects of time and treatment. The level of significance 
applied to the statistical analysis was P<0.05.
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2.6 TEMPORAL AND SPATIAL EXPRESSION OF TGF P AND ECM 
MOLECULES IN SUBCONJUNCTIVAL RABBIT TISSUE AFTER GLAUCOMA 
FILTRATION SURGERY
Three isoforms of TGF p are expressed in the eye. Previous studies have identified that 
TGF p2 is the most predominant ocular isoform (Pasquale et al., 1993; Tripathi et al., 
1994a; Tripathi et al., 1994b). We set out to investigate which intraocular and extraocular 
tissues express TGF p RNA and protein in unoperated eyes and in eyes in which 
glaucoma filtration surgery has been performed. Only once the temporal and spatial 
expression of the TGF p isoforms has been fully identified will it be possible to fully 
delineate how modulation of this growth factor can reduce conjunctival scarring in vivo.
2.6.1 Experimental details
The model of glaucoma filtration surgery described in section was adopted and the 
experimental protocol is summarised in Table 5.
2.6.2 Tissue retrieval
Tissue samples from the Conjunctiva (tube drainage area), Sclera, Cornea, Iris, Ciliary 
body, Lens and Vitreous Humour, from right and left eyes, were collected under general 
anaesthesia on days 1, 3, 8 and 14 after surgery (Day 0). The tissue was then divided in 
half. One part was placed in an eppendorf containing a solution of RNA later (lOul 
reagent per 1 mg tissue; Qiagen, UK). The thickness of the tissue did not exceed 5mm to 
allow the solution to fully penetrate the tissue and prevent RNA degradation. The samples 
were stored at 4° C prior to processing. The other half of the tissue was placed in a
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Table 5 Expression of TGF (3 in ocular tissue after rabbit glaucoma surgery: Experimental details
Study No of NZW 
rabbits
Treatment groups Treatment regimen 
Day of surgery = 0
Day of 
Sacrifice
Tissue collection
8 CAT-152 n=4 
No treatment n=4
Inter-operative 
treatment only (Pre­
operative and 
immediate post­
operative doses only)
1 Samples of 
conjunctiva, sclera, 
cornea, iris, ciliary 
body, lens, and aqueous 
humour were collected 
from the operated (i.e. 
left) eyes at each time 
point. Unoperated right 
eyes were sampled on 
day 1 (8 eyes in total) 
to provide control 
tissues for evaluation of 
TGF[3 levels
8 CAT-152 n=4 
No treatment n=4
Inter and post-operative 
treatment Days 0,1,2
3
8 CAT-152 n=4 
No treatment n=4
Inter and post-operative 
treatment Days 
0,1,2,3,4,7
8
8 CAT-152 n=4 
No treatment n=4
Inter and post-operative 
treatment Days 
0,1,2,3,4,7,9,11
14
cryotube and snap frozen in liquid nitrogen. The cryotubes were stored at -70 °C before 
processing. 0.1ml of aqueous humour was also sampled and snap frozen. Injections due to 
be given on the day of sacrifice were omitted (i.e. animals sacrificed on day 1 had two 
doses of treatment before the tissue was retrieved.) After the tissues had been sampled the 
animals were sacrificed using lethal injection of pentobarbitone (Rhone Merieux, Essex, 
UK)
2.6.3 Tissue analysis: mRNA Detection: Quantitative Competitive Reverse 
Transcriptase Polymerase Chain Reaction (QCRT-PCR / TaqMan)
2.6.3.1 Primer And Probe Design
For mRNA quantification, TaqMan primers and probes were designed to the target genes 
TGFp 1 and TGFp2. All primers and probes were designed using Primer Express software 
(Applied Biosystems, California, USA). Probes were designed to span two exons to 
ensure assay specificity for cDNA rather than any contaminating genomic DNA. BLAST 
N searches were performed against the nr (non redundant set of Genbank, EMBL, DDBJ 
and PDB) database sequences to confirm the gene specificity of the selected primer and 
probe nucleotide sequences. The sequences of the primers and probes used are shown in 
Table 6.
2.6.3.2 RNA extraction from tissue samples
Control tissue samples for each ocular structure were pooled and homogenised together 
before total RNA extraction. Left eye samples from both untreated and CAT-152 treated 
groups were homogenised and extracted individually. Total RNA was extracted from 
each sample with RNAeasy 96 using a Biorobot 8000 (Qiagen, UK).
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Table 6 Primers and probes used for quantitative PCR
Primers
Gene Sequence in 5’-3’ direction
TGFpi (forward) CG G G CT C AAC AT CT AC AC AGTT C
TGF(M (reverse) GT CCTTGCGG AAGT CAAT GT ACA
TGF|32 (forward) CT ACAAG AT AG ACATGCCGT CCT ACT
TGFP2 (reverse) CAT CAAAT CGG ACAATT CT G AAGT
18S ribosomal RNA (forward) CGGCTACCACATCCAAGGA
18S ribosomal RNA (reverse) CAATTACAGGGCCTCGAAAGAG
Probes
Gene Sequence in 5’-3’ direction 5’
reporter
3’ quencher
TGFB1 ACCAACT ACTGCTT C AGCT CCAC AG A GAAGAACT FAM TAMRA
TGFB2 CCCCT CCG AAAAT GCCAT CCCA FAM TAMRA
18S
ribosomal
RNA
C AG C AG G CG CG C AAATT ACCC A TET TAMRA
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2.6.3.3 cDNA synthesis Reverse transcription of RNA was performed in a final 
volume of 30|liL in the presence of lx RT-PCR buffer (Applied Biosystems) containing 
50mM KC1, lOmM Tris-HCl (pH 8.3), 5.5mM MgCl2 , 500jiM each deoxynucleotide 
triphosphate, 2.5jiM random hexamer primer, 12 units of RNase inhibitor and 37.5 units 
MultiScribe RT (Applied Biosystems). Samples were incubated at 25°C for lOmin then 
48°C for 30min before inactivation of reverse transcriptase by heating at 95°C for 5min.
2.6.3.4 PCR Amplification Real-time semi-quantitative TaqMan PCR and data analysis 
was performed using the ABI Prism 7700 Sequence Detection System (Applied 
Biosystems). For each PCR reaction, 2pL cDNA was added to 23pL of master mix 
containing: 5 mM MgCl2, 200pM dATP, dCTP, and dGTP, 400pM dUTP, 300nM each 
primer and 1.25 units of AmpliTaq Gold DNA polymerase (Applied Biosystems) in 
TaqMan buffer. Each reaction contained lOOnM specific TaqMan probe carrying the 
reporter dye FAM (6-carboxy-fluorescein) at the 5’ end and the quencher TAMRA (6- 
carboxy-tetramethyl-rhodamine) at the 3’ end. Thermocycler conditions were as follows: 
95°C for lOmin, 40 cycles at 95°C for 15s and 60°C for lmin. Experiments were 
performed in duplicate for each data point and included a no-template control. RNA input 
was normalised to 18S ribosomal RNA as a housekeeping gene control. Amplification of 
18S ribosomal RNA was performed with the TaqMan ribosomal RNA control reagents kit 
(Applied Biosystems).
The readout of the PCR amplification reaction is the parameter Ct, defined as the 
fractional cycle number at which the increase in fluorescence crosses a threshold above 
baseline. The threshold is set as ten times the standard deviation of the baseline signal 
before amplification is detectable. The methodology used in this study does not provide 
an absolute quantification of RNA levels in each sample, but rather a measure of relative
141
mRNA expression in a given sample group. An explanation of the way that relative 
mRNA expression is calculated is outlined in Figure 32.
2.6.4 Tissue analysis: Protein detection
2.6.4.1 TGF P2 content of aqueous humour samples Total (i.e. latent and active) and 
active TGF P2 concentration was measured in each aqueous humour sample using a 
human TGF p2 ELISA kit (Quantikine; R&D Systems). The Quantikine kit enables 
quantitative analysis of total TGF P2 after conversion of latent TGF p2 to the active form 
by acidification. Assays were carried out according to the manufacturer’s instructions 
except that 20jiL 1M HC1 was used for sample acidification, 20pL 1.2N NaOH/0.5M 
HEPES was used for subsequent sample neutralisation, followed by addition of 640pL of 
the supplied calibrator diluent (RD51). A sample dilution of 1:10 in calibrator diluent 
was used for measurement of active TGF p2 and a dilution of 1:7.8 (including all reagents 
used for activation) was used for measurement of total TGF p2.
2.6.4.1 TGF P2 content of conjunctival samples
Total TGF p2 content of conjunctival bleb tissue was determined using pooled samples 
from each group for a given time point. Pooled tissue was cut up in 0.3mL ice-cold PBS 
before centrifugation at 9300 ref (lOmin, 4°C). The supernatant was removed for 
measurement of active TGF p2 concentration using a human TGF p2 ELISA kit 
(Quantikine; R&D Systems) according to the manufacturer’s instructions. Samples were 
assayed at a dilution of 1:10 in the supplied calibrator diluent (RD51).
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Figure 32 Quantification of gene expression Comparative Ct Method
The Ct value is defined as the PCR cycle at which a given sample passes through a 
predetermined fluorescence threshold.
Delta Ct (ACt) is a measure of the relative expression of one target to another, as 
illustrated in the example below:
target A/target B= 2-DCt
If the difference in Ct (ACt) between mRNA species A and B = 5 cycles (i.e it took 5 
more cycles to see amplification of A) then there is: 2 5=l/32 as much A as B. In 
order to control for sample input, the relative amount of a chosen target is normalised 
to an endogenous control using the formula
2-AACt
For the this calculation to be valid, the efficiency of the target amplification and the 
efficiency of the reference amplification must be approximately equal. For amplicons 
designed and optimized according to Applied Biosystems guidelines (amplicon size 
<150 bp), the efficiency is close to one.
Example calculation
The table below shows the average Ct results for the human brain, kidney, liver and 
lung samples and how these Cts are manipulated to determine ACt, AACt, and the 
relative amount of c-myc mRNA.
Relative Quantitation Using the Comparative Ct Method
Tissue c-myc
Average
Ct
GAPDH
Average
Ct
DCt
c-myc - 
GAPDH
DDCt
ACt -ACt 
Brain
c-myc 
Rel to 
Brain
2-AACt
Brain 30.49 23.63 6.86 0.00 1.0
Kidney 27.03 22.66 4.37 -2.50 5.6
Liver 26. 24.60 1.65 -5.21 37.0
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2.6.5 Data analysis
Statistical comparison between sample groups was performed as outlined below. In all 
cases a probability (P) value of <0.05 was considered significant.
In order to calculate relative mRNA expression levels in each tissue following 
experimental GFS, data were normalised to the level of mRNA detected in control tissues 
obtained from unoperated eyes. Therefore, the relative level of gene expression in control 
tissue was 1 in all cases. Changes in mRNA expression after GFS were analysed by 
comparing mean relative mRNA expression in no-treatment group tissues to mean control 
mRNA expression (i.e. 1) using ANOVA followed by Bonferroni’s post-hoc test. The 
same statistical test was also applied for comparison of the relative mRNA expression 
between CAT-152 treated and no-treatment groups at each time point.
The effect of experimental GFS on TGF p protein expression was analysed by comparing 
mean protein values in no-treatment group tissues to mean control protein values using 
ANOVA followed by Bonferroni’s post-hoc test. Comparison of mean protein values 
between CAT-152 treated and untreated groups at each time point was performed by 
ANOVA followed by Bonferroni’s test.
2.7 MODULATION OF THE WOUND HEALING RESPONSE IN VIVO: 
NEUTRALISATION OF TGF P WITH AN ANTI-TGF p2 ANTIBODY (CAT-152) 
IN THE RABBIT MODEL OF GLAUCOMA SURGERY
Four experiments were performed in this project to investigate the potential role of this 
novel anti-TGF p2 antibody in glaucoma surgery. Experiments were designed to
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specifically address issues that related to the application and development of the antibody 
for clinical use and the methodology used in these studies is summarised in Table 7.
2.7.1 Investigation of the effect of intra-operative application of CAT-152 on 
experimental glaucoma surgery (Intra-operative study)
Treatment at the time of surgery would be the optimum method of drug delivery of a new 
anti-scarring agent in terms of ease of application and surgeon acceptance. We therefore 
performed a randomised masked observer study to investigate the efficacy of intra­
operative application of CAT-152 in experimental glaucoma surgery.
2.7.2 Comparison of prolonged post-operative application of CAT-152 with 5- 
Fluorouracil after experimental glaucoma filtration surgery (Prolonged post­
operative study)
Current anti-scarring agents are used in the post-operative period to maintain long-term 
bleb function. Using the same model of glaucoma filtration surgery, this present study 
was designed to determine:
(a) if post-operative application alone of CAT-152 could improve bleb survival and
(b) to compare the effectiveness of CAT-152 to one of the gold standard post-operative 
anti-scarring agent 5-FU.
2.7.3 Investigation of the long term effects of combining intra-operative and 
prolonged post-operative CAT-152 treatment on experimental glaucoma surgery 
(Maximum dosing study)
The ongoing healing response remains the major barrier to a maintaining long-term bleb 
function. In this study we used the model of glaucoma surgery to investigate:
145
(a) How long blebs can survive when treated with a combined intra-operative and 
extended long-term post-operative regimen and
(b) Compared CAT-152 with the anti-scarring agent 5-FU.
By combining the previously tested intra-operative and post-operative treatments, we 
anticipated that we may be able to determine the optimal dosing of CAT-152 required to 
prevent long-term failure of experimental glaucoma surgery.
2.7.4. Investigation of the effects of a combined course of intra-operative and 
prolonged treatment with the CAT-152 on the immune response in the rabbit 
(Chemosis Study)
The DNA encoding rabbit TGF (32 shares over 96% homology with human TGF P2 with 
conserved alignment of the nine cysteine residues as shown in figure 13 (Cordeiro et al., 
2003). Therefore treatment of the rabbit with a human antibody anti-TGF P2 antibody, 
CAT-152, should still show efficacy in neutralising TGF P2, as we have shown in 
previous studies (Cordeiro et al., 1999a). However, we were suspicious that prolonged 
dosing with a human antibody may induce a systemic immune response in the rabbit. In 
order to investigate this further we repeated the experiment described in 2.7.3 using 
combined intra-operative and prolonged post-operative course of treatment. Blood 
samples were collected for to look for the presence of antibody (CAT-152) and anti­
product (anti-CAT-152) antibodies.
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Table 7 Neutralisation of TGF p with an anti TGF p2 antibody in the rabbit glaucoma surgery: Experimental details
Study No of NZW 
rabbits
Treatment groups Treatment regimen 
Day of surgery = 0
Day of 
Sacrifice
Histology Blood
sampling
Intra -
operative
study
30 CAT-152 n=10 (Batch 
150427)
PBS n=10
No treatment n=10
Intra-operative 
treatment only
2x subconjunctival 
injections
30 No No
Prolonged
post­
operative
study
48
24 Efficacy
CAT-152 n=8 (Batch 
150427)
5FU n=8
NT n=8
Post-operative treatment
Days 2,3,4,7,9,11 and 
14
30 No No
24 Histology CAT-152 n=8 
5FU n=8 
NT n=8
As above
10 n=12 
21 n=12
Yes No
Maximum 
dose study
27 CAT-152 n=9 (Batch 
8086)
5FU n=9
PBS n=9
Inter and post-operative 
treatment Days 
2,3,4,7,9,11, 14,21,24, 
28, 31, 35, 38 and 42 
(PBS 5 inferior 
injection, 4 superior 
injection)
45 No No
Chemosis
Study
18 CAT-152 n=6 (Batch 
P020821)
Null n=6
PBS n=6
As for maximum dose 
study
70 No Yes
2.8 MODULATION OF THE WOUND HEALING RESPONSE IN VIVO: 
INHIBITION OF TGF P WITH ANTISENSE OLIGONUCLEOTIDES IN THE 
RABBIT MODEL OF GLAUCOMA SURGERY
2.8.1 Assessment of tolerance to TGF P antisense oligonucleotides in the rabbit eye.
The aim of this experiment was to determine whether the selected doses of antisense 
oligonucleotide to TGF p, administered by the subconjunctival route, were tolerated and 
safe to administer in vivo, using the rabbit model.
2.8.2 Assessment of efficacy of TGF P antisense oligonucleotides after experimental 
glaucoma surgery.
The aim of this experiment was to determine whether single application of antisense 
oligonucleotides to either: TGF pi, TGF p2, TBR II were able to reduce conjunctival 
scarring in vivo following experimental glaucoma filtration surgery. The methodology is 
summarised in Table 8.
2.9 HISTOLOGICAL ANALYSIS OF THE RABBIT MODEL
2.9.1 Histological preparation
All of the eyes were fixed in 10% buffered formal saline for 24 hours, stored in 70% 
alcohol. A ballot of tissue was removed from each globe to access the area of interest 
(Figure 33) and the specimens were then transferred to processing cassettes and subjected 
to conventional overnight processing including dehydration, clearing and infiltration
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Table 8 Inhibition of TGF p with antisense oligonucleotides in rabbit glaucoma surgery: Experimental details
Study No of NZW 
rabbits
Treatment groups Treatment regimen 
Day of surgery = 0
Day of 
Sacrifice
Histology Blood
sampling
Intra -  
operative 
tolerance 
study
9 25|Xg TGF-pi OGN 
50jig TGF-pl OGN 
lOOpg TGF-p 1 OGN
2x subconjunctival 
injections only: no 
surgery performed
30 No No
Intra -  
operative 
efficacy 
study
60
48 Efficacy
lOOjLig of TGFpi, 
TGFP2, TGFp Type 
II Receptor, misense 
OGN or lOOpl PBS
2x subconjunctival 
injections only
As above
15 n=18 
30 n=30
Yes No
12 Histology
21 n=12 Yes No
Figure 33 Preparation of rabbit eye prior for histological sectioning
Drainage Bleb Tube
Conjunctiva
Iris
Rabbit Eye Section of tissue removed from globe 
prior to embedding
5 pm sections
Wax embedded tissue block 
from which 5pm sections of the 
operative wound site were cut
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steps. They were removed from the cassettes, and carefully orientated in moulds prior to 
embedding in paraffin wax. Sequential 5pm sections of the operative wound site were 
prepared and mounted on superfrost charged slides (Merck Eurolab, Leicester, UK). 
Sections were viewed using light microscopy and images were captured using a digital 
camera with microscope attachment. Images were stored as JPEG files. Confocal 
microscopy was also performed to image fluorescent immunohistochemical sections.
2.9.2 Cellular analysis
Sections were stained with hematoxylin and eosin (H and E) to demonstrate cellular 
nuclei for assessment of total cellularity. For more specific cellular identification a  
smooth muscle actin immunohistochemistry was performed to identify the presence of 
myofibroblast transformed fibroblasts. Briefly, sections were dewaxed through xylene, 
70%, 90% and 100% Methylated Spirit, washed in 70% alcohol and then placed in 
endogenous peroxidase blocking solution for 20 minutes. Tris buffered saline (TBS: 
150mM sodium chloride, lOmM Tris-HCl, pH 7.6) was prepared and used to wash the 
slides prior to blocking non specific binding sites with normal rabbit serum for 20 
minutes (NRS, 1:10 dilution in TBS; DAKO A/S Denmark). The sections were incubated 
in the primary antibody, Mouse anti-human a  SMA (1:150 dilution in 1:100 NRS, 
IgG2A, Clone 1A4 DAKO, A/S, Denmark) for 1 hour, washed in TBS and then incubated 
in the secondary antibody, biotinylated rabbit anti-mouse (1:300 in TBS, DAKO) for 45 
minutes. A streptavidin AB complex / horseradish peroxidase kit was used (DAKO A/S, 
Demark) and finally a solution of 3,3- Diaminobenzadine (DAB, Sigma, Dorset, UK) was 
placed on the slides for 10 minutes. Nuclei were stained in Meyer’s haemotoxylin for 30 
seconds, and the slides were dehydrated through alcohol and mounted. Positive control
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was in built in the iris and ciliary body of the eye. For negative control slides a mouse 
anti- human negative control primary antibody was used (IgG2a, DAKO A/S, Demark), a  
SMA fluorescent labelled antibody staining was also performed using the method 
described in section 2.4.2.
Proliferating cell nuclear antigen (PCNA) immunohistochemistry was used as a marker of 
recent cell division. Before incubation with the antibodies, citrate buffer was added to the 
sections, which were then placed under microwave power for 2 x 5 minutes, for antigen 
retrieval purposes. Mouse anti-rat proliferating cell nuclear antigen (1:8000 in 1:100 
NRS, IgG2a, DAKO A/S, Denmark) was used as the primary antibody. A section of 
tonsillar tissue was used as a positive control. The primary antibody stage was omitted on 
tonsillar sections to act as a negative control.
2.9.3 Extracellular matrix demonstration
Extracellular matrix collagen deposition was identified using several stains; Picrosirius 
red for total collagen and Gamori’s trichrome for scar formation, collagen density and 
orientation (Juinquera et al., 1978; Lillie et al., 1980; Shah et al., 1994). Aldehyde fuschin 
staining was performed to identify members of the elastic fibre family of connective 
tissues. Oxytalan fibres, a member of this family, are characteristic of the early stages of 
elastogenesis indicating early local extracellular matrix production and deposition. 
Oxytalan fibres were demonstrated by oxidised aldehyde fuschin staining (Jefferies et al., 
1995; Montes, 1996).
2.9.4 Histological grading system
2.9.4.1 Light microscopy The parameters of cellularity and extracellualr matrix 
deposition were graded by two masked observers using a modified scoring system based
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on that described by Shah (Shah et al., 1994). Each parameter was graded on a scale: 0 to 
4; 0 = same as control eye; 1 = l%-25% of control; 2 = 26%-50% of control; 3= 51%- 
75% of control; 4 = >75% of control. We identified visual reference standards for each 
grade and incorporated these into the system. All operated eyes were compared to 
contralateral non surgical eyes. Mean scores of histological parameters for each treatment 
group per time point were calculated and this semi quantitative data was analysed using 
analysis of variance statistics (SPSS).
2.9.4.2 Confocal microscopy Quantification of the fluorescent a  SMA staining in 
the histological tissue sections was performed using a binary image analysis system, 
originally described by Wormstone et al (Wormstone et al., 2002). Confocal images slices 
were converted from colour into binary format with black pixels representing the FITC 
fluorescent label, using Adobe Photoshop software (Adobe systems software, Middlesex, 
UK). A threshold for intensity of pixel detection was selected and applied to all images 
(central point of the intensity range of all the images in data set). All images were the 
same dimensions (i.e. total number of pixels per image was constant) and were stored as 
TIFF files. The images were analysed using Scion Image (Scioncorp, Maryland, USA) 
and the total number of black pixels was recorded for each image. The central image slice 
from each confocal stack and two further slices, one 2 slices above and one 2 slices 
below, were analysed per section of rabbit tissue. (Image stack n=10, central slice =5, 
slices 3 and 7 also analysed). 3 tissue sections per treatment group were included. Finally, 
the pixel data was analysed using analysis of variance statistics (SPSS) to compare the 
effect of treatment on a  SMA expression.
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2.9.5 Electron Microscopy
We also compared the electron micrograph characteristics of 2 rabbit eyes treated with 
CAT-152 and 2 untreated eyes. The methodology from experiment 2.7.2 was repeated in 
terms of surgical technique and post-operative injection regimen. Animals were sacrificed 
on day 10 and the operative wound site was processed for both scanning and transmission 
electron microscopy. This time point was selected to provide maximum information on 
the comparative bleb appearances between treated and untreated animals prior to the 
onset of bleb failure.
Tissue preparation for Electron Microscopy
Rabbit eyes were immersion fixed in 3%glutaraldehyde and 1% to pH 7.4 with 0.07M 
sodium cacod-HylateCl. After 1 -12h, cells were washed three times with PBS, and 
dissected to remove the anterior segment and lens from the posterior segment. Specimens 
were then osmicated for 2h with a 1% aqueous solution of osmium tetroxide and 
dehydrated through ascending alcohols (50 - 100%, 10 min per step).
2.9.5.1 Transmission EM After 3 changes of 10% ethanol specimens for TEM 
examination were passed through propylene oxide (2 x 20 minutes). Specimens were then 
osmicated for 2h with a 1% and left overnight in a 50:50 mixture of popylene oxide and 
araldite. Following a single change to fresh araldite (5h with rotation) specimens were 
embedded and cured overnight at 60’C. Semithin and ultrathin sections were cut using a 
Leica ultracut S microtome fitted with the appropriate type of diamond knife. Following 
sequential contrasting with 1% uranyl acetate and lead citrate thin sections were viewed 
and photographed using a JEOL 1010 TEM operating at 80kV.
2.9.5.2 Scanning EM Specimens for SEM examination were critical point the third 
change of absolute alcohol, mounted on stubs and sputter coated dried after with gold 
prior to examination in a JEOL 6100 SEM operating at 15kV.
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CHAPTER 3 RESULTS
3.1 EFFECT OF TGF-p ON CELLULAR EVENTS OF WOUND HEALING
3.1.1 ECM production in Human Tenon’s Fibroblasts
3.1.1.1 Effect of TGF £2 on acid soluble collagen production by human Tenon’s 
fibroblasts Stimulation with TGF p2 resulted in a dose dependent increase in soluble 
collagen production as shown in Figure 34. At a concentration of lOOOpM TGF p2 
increased collagen production by 148 % over serum free (basal) levels. The concentration 
at which TGF p2 displayed 50% of maximal stimulation (Effective Concentration 50, EC 
50 was 41.7 (95% Cl 14.6-118.9) pM. From these results a concentration of 100 pM TGF 
P2 (EC 90) was selected to investigate the effect of CAT-152 on TGF P2 stimulated 
soluble collagen production by human Tenon’s fibroblasts. At a concentration of lOOpM 
and above, TGF p2 stimulation significantly increased collagen production over basal 
levels (p<0.05).
3.1.1.2 Effect of TGF p2 on Type 1 Collagen production by human Tenon’s 
fibroblasts Collagen type 1 C terminal peptide (CICP) released into the conditioned 
media from fibroblast monolayers during the soluble collagen assay (3.1.1.1) was 
quantified by ELISA. The results are displayed in Figure 35. A dose dependent increase 
in Type 1 collagen production was demonstrated in response to TGF P2 stimulation, 
which correlated closely to the effect of TGF p2 on soluble collagen production. Maximal 
stimulation was seen at a concentration of lOOOpM TGF p2, which resulted in a 265.5% 
increase over basal levels. The EC 50 was calculated to be 12.3 (95% Cl 1.3-121.4) pM. 
Analysis of variance statistics revealed that the effect of TGF p2 was significant (p<
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0.0045; multiple comparisons: p< 0.05 lOOpM and 300pM TGF (32, p< 0.001 lOOOpM 
TGF (32).
3.1.2 Cytoskeleton and cell morphology
3.1.2.1 Effect of TGF (32 on a  smooth muscle actin expression by human Tenon’s 
fibroblasts To investigate the effect of TGF (32 on myofibroblast differentiation, an 
ELISA procedure was used to quantify a  SMA expression by human Tenon’s fibroblasts. 
Figure 36 shows that a proportional increase in a  SMA expression was seen in the 
presence of TGF P2 (p< 0.001). Maximal stimulation was seen at a concentration of 
lOOOpM TGF P2, which increased a  SMA production by 200.8 % over serum free 
conditions. EC 50 was calculated to be 7.3 (95% Cl 3.1-17.3) .The data was also analysed 
according to cell passage number at the time of seeding, where low passage experiments 
used cells at p < 4, and higher passage experiments used cells at p > 4. Figure 37 
illustrates that cells at higher passage have increased expression of a  SMA under serum 
free conditions. TGF P2 still upregulates a  SMA production, however this additional 
effect of is not as pronounced. On the basis of these results low passage cells were 
stimulated with 30pM (EC 90) TGF p2 when investigating the effect of CAT-152 on 
myofibroblast differentiation.
3.1.2.2 Effect of TGF P2 on cell morphology and a  smooth muscle actin stress fibre 
formation in human Tenon’s fibroblasts The morphology of TGF p2 treated cells was 
observed by phase contrast microscopy at t = 0 and t = 72 hours. The cells appeared 
larger, less spindle shaped and adopted a contractile phenotype with intracellular stress 
fibres. These changes appeared to be related to the concentration of TGF (32 as shown in
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Figure 38. Induction of a  SMA and the assembly into stress fibres following TGF P2 
treatment was confirmed using confocal immunofluorescence microscopy (Figure 39).
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Figure 34 Effect of TGF p2 on acid soluble collagen production by human
Tenon’s fibroblasts.
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Mean soluble collagen production with respect to stimulation by TGF p2 at 
different concentrations at 48 hours. TGF p2 resulted in a dose dependent 
increase in soluble collagen deposition. Peak activity was seen at a 
concentration of 1000 pM TGF P2 with an associated 148 % increase in 
collagen production. * Significantly different to serum free conditions 
p<0.05. (Error bars represent standard error of the mean, n=7)
*
158
Figure 35 Effect of TGF (32 on collagen 1 production by human Tenon’s
fibroblasts.
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Mean type 1 collagen production with respect to stimulation by TGF p2 at 
different concentrations at 48 hours. TGF p2 resulted in a dose dependent 
increase in soluble collagen deposition. Peak activity was seen at a 
concentration of 1000 pM TGF p2 with an associated 265% increase over 
basal levels. Significantly different to serum free conditions * p<0.05, ** 
p<0.01 (Error bars represent standard error of the mean, n=4)
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Figure 36 Effect of TGF [32 on a smooth muscle actin expression by
human Tenon’s fibroblasts.
3n
B
GO
G<DT3
GhO
2 -
1-
o-
1 -
Basal -13 -12 -11 -10
Log TGF (32 Concentration (M)
-9
The a  SMA content of cells was measured using an ELISA technique. TGF 
[32 induced a dose dependent upregulation of a  SMA, which was significant 
over basal levels at concentrations of 30pM, lOOpM and lOOpM. **P< 0.001. 
Data are means +/- standard error of 5 experiments.
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Figure 37 Effect of cell passage number on a  smooth muscle actin
production in human Tenon’s fibroblasts
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Basal a  SMA expression was increased in cells of higher passage. TGF p2 still 
resulted in an increase in a  SMA production, however this was less marked than in 
low passage cells. Maximal stimulation was seen at lOOOpM and this was associated 
with a 374.9% and 190% increase over basal levels with low passage and higher 
passage cells, respectively.
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Figure 38 Effect of TGF (32 on cell morphology
oIIH T = 72 Serum
T = 72 Basal T = 72 0.1pm TGF 02
T = 72 1pm TGF 02 T = 72 10 pm TGF 02
T = 72 30 pm TGF 02 T = 72 100pm TGF 02
At concentrations of lOpM and above stimulation with TGF (32 was associated with 
intracellular fibre formation. Cells became less spindle shaped and there appeared to 
be a greater degree of cell/cell overlap
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Figure 39 Effect of TGF P2 on a smooth muscle actin stress fibre formation in
human Tenon’s fibroblasts.
Confocal images of human Tenon’s fibroblasts after stimulation with lOpM TGFp2 
(A and B) or 100 pM TGF P2 (C-E). F represents untreated control. A SMA is 
labelled with FITC (green) and the nuclei labelled with DAPI (blue). Images A-D 
and F are taken at a magnification of x 40. Images C-E are at x 60. TGF p2 induces 
the formation of intracellular aSMA stress fibres.
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3.2 EFFECT OF CAT-152 ON TGF P MEDIATED CELLULAR EVENTS OF 
WOUND HEALING
3.2.1 ECM production in human Tenon’s fibroblasts
3.2.1.1 Effect of CAT-152 on TGF-P2 mediated acid soluble collagen production
The sircol assay for acid soluble collagen production was used to investigate the effect of 
CAT-152 on human Tenon’s fibroblasts. The results are shown in Figure 40. CAT-152 
resulted in a dose dependent inhibition of soluble collagen production. Complete 
inhibition of the TGF p2 response was achieved at concentrations of lOnM, 30nM and 
lOOnM. However, because of the high seeding density for this assay and difficulty 
obtaining primary tissue from Moorfields Eye Bank it was only performed once. In 
addition the type I collagen ELISA was judged to be a more specific and accurate method 
of determining collagen production.
3.2.2.1 Effect of CAT-152 on TGF-p2 mediated Type 1 Collagen production The
effect of CAT-152 on type 1 collagen production was determined using two methods. In 
the first experiment the conditioned media that had been generated from the sircol assay
3.2.1.1 was analysed (Figure 40). CAT-152 resulted in a dose dependent inhibition of 
soluble collagen production with complete inhibition of the TGF p2 response being 
achieved at concentrations of lOnM, 30nM and lOOnM. Null antibody (CAT-001) had no 
effect on collagen production.
In the second set of experiments an independent CICP assay was performed, in which 
cells were seeded into 24 well plates at a density of 1 x 105 cells per well. Stimulation 
with 30 pM TGF (32 resulted in a mean increase in collagen production of 34 % over 
basal levels, which was lower than had been detected when the type I collagen had been
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analysed from the conditioned media from the sircol assay (3.1.1.2). Application of CAT- 
152 achieved full inhibition of this TGF-p2 induced response. At concentrations of 10 nM 
and above CAT-152 reduced collagen production to below serum free levels and 
significantly inhibited the TGF P2 response compared to control antibody (p<0.05) 
(Figure 41). The concentration of CAT-152 to produce 50% inhibition of the TGF p2 
response (Inhibitory Concentration 50, IC 50) was calculated to be 1.31 (Cl 95% 0.36- 
4.86) nM.
3.2.2 Cytoskeleton and cell morphology
3.2.2.1 Effect of CAT-152 on TGF P2 mediated a  smooth muscle actin expression by 
human Tenon’s fibroblasts The increased expression of aSMA in response to TGFP2 
(30pM) was inhibited by CAT-152. This inhibition was related to the concentration of 
CAT-152 and attained statistical significance (Figure 42). CAT-152 30nM fully inhibited 
the response to TGFP2 and CAT-152 had an IC50 of 1.54 (0.56-4.25) nM. CAT-001 
(lOOnM) did not significantly affect the response to TGFP2.
3.2.2.2 Effect of CAT-152 on cell morphology and a  smooth muscle actin stress fibre 
formation in human Tenon’s fibroblasts The morphology of TGF P2 stimulated cells 
after treatment with CAT-152 was observed by phase contrast microscopy at t = 0 and t = 
72 hours. CAT-152 appeared to prevent the cells from adopting the morphological 
changes seen with isolated TGF P2 stimulation. At concentrations of lOnm and above the 
cells remained spindle shaped and minimal intracellular fibre formation was detected 
(Figure 43). Confocal immunofluorescence microscopy confirmed that CAT-152 
prevented the assembly of a  SMA into stress fibres (Figure 44).
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Figure 40 Effect of CAT-152 on acid soluble collagen production in human
Tenon’s fibroblasts
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The effect of CAT-152 on TGF-|32 stimulated soluble collagen production was 
investigated using the sircol assay (Chart A, n=l). At concentrations of lOnM, 
30nM and lOOnM CAT-152 reduced collagen production to basal levels. The 
data in chart B represents the type 1 collagen production from the supernatant of 
the same experiment (n=l). A similar effect of CAT-152 was shown. Null 
antibody (CAT-001) did not reduce collagen production. Error bars represent the 
standard error of the triplicate samples per time point in N=1 experiment.
Figure 41 Effect of CAT-152 on Type 1 Collagen production by human Tenon’s
fibroblasts.
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The effect of CAT-152 on Type 1 collagen production was assessed using the C 
terminal peptide ELISA. 30pM TGF (32 generated a 34% increase in collagen 
production that was completely inhibited by CAT-152. * significant reduction in 
TGF (32 response p<0.05 (Mean and Standard error plotted, n=4)
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Figure 42 Effect of CAT-152 on a  smooth muscle actin expression
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30 pM TGF p2 induced a mean increase of 75% over basal levels. CAT-152 
application resulted in a dose dependent inhibition of a  SMA production. 
The concentration of CAT-152 to produce 50% inhibition of the TGF p2 
response (Inhibitory Concentration 50, IC 50) was calculated to be 2.079 nM 
+/- 0.776 nM. At a concentration of 30nM and lOOnm CAT-152 
significantly inhibited the TGF p2 response compared to control antibody 
(p<0.05).
Figure 43 Effect of CAT-152 on the cell morphology of TGF P2
stimulated human Tenon’s fibroblasts
T = 0 T = 72 Basal
T = 72 30 pM TGF p2 T = 72 Null antibody
T = 72 0.01nm CAT-152 T = 72 0.1 nm CAT-152
T = 72 InM CAT-152 T = 72 lOnM CAT-152
T = 72 30nM CAT-152 T = 72 lOOnM CAT-152
CAT-152 appeared to prevent the cells from adopting the morphological changes 
seen with isolated TGF p2 stimulation. At concentrations of lOnm and above the 
cells remained spindle shaped and minimal intacellular fibre formation was 
detected.
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Figure 44 Effect of CAT-152 on a  SMA stress fibre formation in human Tenon’s
fibroblasts.
Confocal images of low passage human Tenon’s fibroblasts stimulated with 
TGF-p2 labelled with FITC to demonstrate the presence of a  SMA (green). The 
cells in B,D and F have also been treated with 15mg/ml (lOOnM) CAT-152. 
Neutralisation of TGF-p2 prevents the assembly of a  SMA stress fibres. 
Magnification: Images A-D x 40, E and F x 60.
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3.3 TEMPORAL AND SPATIAL EXPRESSION OF TGF P AND
EXTRACELLULAR MOLECULES IN OCULAR RABBIT TISSUE
AFTER GLAUCOMA FILTRATION SURGERY
3.3.1 mRNA expression in control eye tissue
The relative expression of mRNA encoding TGFpi and TGFP2, collagen I, collagen III 
and a  SMA was determined in tissues sampled from control (right) eyes that had not 
undergone experimental GFS. Data for each gene of interest were normalised relative to 
the expression level observed for the conjunctiva. Variation in TGF p i mRNA expression 
across the tissues analysed was small, with greatest expression observed in the iris (rank 
order of expression; iris > ciliary body > conjunctiva > cornea > sclera). In contrast, the 
ciliary body appeared to express considerably greater levels of TGF p2 mRNA than all 
other tissues (rank order of expression; ciliary body »  iris > cornea > conjunctiva > 
sclera) (Figure 45).
Expression of collagen Types I and III was greatest in the conjunctiva. Small variation in 
Collagen I was demonstrated between tissues. Negligible levels of Collagen I and III were 
detected in the lens, a  SMA was expressed most highly in the iris and ciliary body 
(approx 700-fold and 100-fold higher than conjunctiva respectively). Sclera showed 
similar a  SMA levels to the conjunctiva while lower levels of a  SMA mRNA were 
detected in the cornea and lens (Figure 46).
3.3.2 TGF P mRNA expression following experimental GFS
Relative expression of TGF p i and TGF p2 mRNA was determined in tissues taken from 
CAT-152 treated, or untreated, rabbits that had undergone experimental GFS. For each
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gene, data were normalised to the level of mRNA detected in control tissues obtained 
from unoperated eyes.
Conjunctival TGF (31 mRNA in samples from untreated animals was significantly 
increased at day 3 post-GFS (P<0.05 c.f. unoperated control conjunctiva). Although TGF 
(31 mRNA expression appeared to remain elevated at day 8 this was not significant 
(P>0.05) when compared with control tissues. Similarly, whilst there was a trend for a 
small increase in TGF (32 mRNA expression in conjunctiva at day 3 post-GFS, this was 
not statistically significant (P>0.05) (Figure 47).
As observed in conjunctival tissue, scleral TGF pi mRNA expression was also 
significantly increased at day 3 post-GFS in samples from untreated animals (P<0.001 c.f. 
unoperated control sclera). There was no significant change in scleral TGF p2 mRNA 
expression at any other time point (all P>0.05 cf unoperated control sclera).
TGF pi mRNA expression in the cornea was unchanged at all time points studied (all 
P>0.05). However, TGF P2 mRNA levels were significantly raised in corneal samples 
from untreated eyes at day 14 post-GFS (P<0.05 c.f. unoperated control cornea), but not 
at any other time point (Figure 47).
Expression of TGF P1 mRNA in post-GFS iris tissue was unchanged at most time points 
compared with control iris expression levels. However, a small but significant increase 
(i.e. 1.6-fold over control iris; P<0.05) in TGF pi mRNA expression in samples from 
untreated animals was observed at day 1 post-GFS (Figure 47). At day 3 post-GFS, there 
was a small but significant (PcO.Ol) increase in TGF p2 mRNA expression in iris 
samples taken from untreated animals. Furthermore, at day 3 post-GFS CAT-152 TGF p2 
mRNA expression levels were significantly lower than those observed in the untreated 
group. Thus, TGF P2 mRNA expression in the untreated and CAT-152 treated samples
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was 1.83±0.26 -fold and 1.25±0.24 -fold that seen in control samples, respectively (both 
n=4; P<0.05) (Figure 47).
Ciliary body samples from untreated animals displayed significantly raised TGF (31 
mRNA levels at day 3 post-GFS, compared to control samples (P<0.001). TGF (31 mRNA 
levels in samples taken at the same time point from CAT-152 treated animals were 
significantly lower. Thus, TGF pi mRNA expression in untreated and CAT-152 treated 
samples at day 3 post-GFS was 1.87±0.05 -fold and 1.34±0.23 -fold that seen in control 
samples, respectively (both n=4; P<0.05). There was a small but significant increase in 
TGF (32 mRNA expression relative to control ciliary body samples in the untreated group 
samples at days 3 and 14 post-GFS (PcO.OOl and P<0.05, respectively) (Figure 47). 
Finally mRNA of collagen types I and III and a  SMA was negligible in the lens both 
before and after experimental glaucoma surgery therefore accurate data on changes in 
expression could not be obtained.
Overall, the expression of TGF p i and p2 in most of the tissues appears to follow the 
same temporal pattern. Levels rise to a peak on day 3 following surgery and then follow a 
step wise reduction back towards pre operative levels by day 14. This is clearly 
demonstrated in the conjunctiva (Figure 47).
3.3.3 ECM molecule mRNA expression following experimental GFS
Strong up regulation of a  SMA was seen in conjunctiva following glaucoma surgery, 
over 100-fold increase compared to controls. Lower level of mRNA induction was also 
seen for collagen type in, collagen type I. However, on day 3 conjunctival collagen I 
mRNA expression was significantly increased compared to the control unoperated eyes 
(p<0.05). Increased levels of mRNA of a  SMA and collagen III were seen in sclera
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following glaucoma surgery, over 30-fold higher for a  SMA (Day 3, p< 0.001) and over 
10-fold for collagen in compared to controls (Day 3 p<0.01; day 8 p<0.05). No up 
regulation was seen in mRNA levels of collagen I. In the cornea strong up regulation of 
a  SMA and collagen in was seen up to a maximum of around 100-fold increase on day 
14. At this time point expression of collagen I (p<0.01) and collagen HI (p<0.001) 
reached significance over controls. Weak up regulation of collagen type III mRNA was 
seen in the iris following glaucoma surgery. A 2-fold increase was seen compared to 
controls and this was significant on days 3, 8 and 14 (p<0.01). No evidence of up 
regulation was seen for collagen type I or a  SMA. In the ciliary body samples GFS 
resulted in a 3-fold increase in collagen type III mRNA on day 3 (p<0.001) and day 14 
(p<0.01). No evidence of up regulation was seen for collagen type I. A small but 
significant increase in a  SMA expression was detected on day 1 (Figure 48).
As for TGF (3, mRNA expression of collagen types I and III and a  SMA was negligible in 
the lens both before and after experimental glaucoma surgery, therefore, accurate data on 
changes in expression could not be obtained.
Again, a temporal expression pattern was demonstrated across the tissues. This was most 
clearly demonstrated in the conjunctiva, where collagen I, III and a  SMA expression 
peaked on day 3 and then followed a stepwise reduction by day 14 (Figure 48).
Treatment with CAT-152 significantly reduced comeal collagen III mRNA expression on 
day 3 (p<0.01). However, it does not appear to have had any other significant effects on 
the mRNA level of any of the genes tested in the other ocular tissues (Figure 48).
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3.3.4 TGF p2 protein expression in aqueous humour
TGF P2 protein levels were determined in samples of aqueous humour taken from 
unoperated rabbit eyes at day 1 post-GFS (control), and from operated eyes at days 1,3, 
8, and 14 post-GFS. Separate determinations were made for levels of active TGF (32 and 
total TGF (32 (i.e. active plus latent) in the samples.
Total TGF (32 protein content of control rabbit aqueous humour samples in this study was 
2363.9±289.4 pg/mL (n=6). There were significantly greater levels of total TGF p2 
protein in samples taken from untreated animals at day 1 post-GFS (i.e. 4344.0±341.1 
pg/mL, n=4; PcO.Ol c.f. control) (Figure 49). Total TGF P2 levels were highest on day 1 
and gradually returned to control levels by day 14, demonstrating a similar temporal 
pattern to mRNA expression. CAT-152 treatment was associated with a reduction in TGF 
p2 aqueous protein on days 1, 3 and 8, however, this did not reach significance. The level 
of active TGFp2 protein in control samples of rabbit aqueous humour in this study was 
1623.9±183.8 pg/mL (n=6). Active TGFp2 protein levels were significantly lower in 
aqueous humour samples taken from untreated animals at days 1, 3 and 14 post-GFS (i.e. 
P<0.01, P<0.05 and PcO.Ol, respectively) (Figure 49). Statistical comparison of the day 8 
post-GFS measurement could not be made because only a single sample was available for 
analysis. Treatment with CAT-152 reduced TGF p2 aqueous levels compared to untreated 
controls on days 1, 3 and 8. However, pair wise comparison of results between treatment 
groups did not highlight any significant effect of CAT-152 treatment.
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3.3.5 Total TGF |32 protein expression in conjunctival bleb tissue after GFS
Conjunctival tissue samples were pooled for each treatment / sampling time point and 
assayed for total TGF (32 protein content only. Thus, expression of total TGFP2 protein in 
control conjunctival tissue sampled from seven unoperated right eyes at day 1 post GFS 
was 5.60 pg/mg tissue. Statistical comparison of post-surgical TGF p2 expression in bleb 
tissues was not possible because data was obtained from pooled tissues (each containing 
2-3 samples per treatment /time point). However, the results did highlight an apparent 16- 
fold increase in total TGF p2 protein content of conjunctival blebs taken from untreated 
animals (Figure 50).
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Figure 45 Relative expression of TGF p in rabbit ocular tissue
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Data indicate mean relative mRNA expression calculated from 5 separate 
determinations. Each determination was performed using the RNA extracted 
from pooled samples of eight control tissues for each structure, taken from 
unoperated right eyes one day after experimental glaucoma filtration surgery. 
Samples were normalised to the expression in the conjunctiva. TGF p2 
expression was greatest in the iris and ciliary body. Greater variation was seen 
in TGF P2 expression across the sampled tissues
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Figure 46 Relative expression of ECM molecules in rabbit ocular tissue
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In order to evaluate relative expression of each gene within the different tissue 
of the control unoperated eye, samples were first normalised to expression in 
the conjunctiva. Expression of collagen Types I and III was shown to be 
greatest in the conjunctiva. Small variation in Collagen I was demonstrated 
between tissues, a  SMA was expressed most highly in the iris and ciliary 
body.
178
Figure 47 TGF p mRNA expression in ocular tissues after GFS
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For each gene, data were normalised to the level of mRNA detected in control 
tissues obtained from unoperated eyes. Overall TGF pi and p2 expression appeared 
to be increased following surgery. CAT-152 significantly reduced TGF P2 
expression in iris tissue on day 3 and TGF pi expression in the ciliary body on day
3. * p<0.05, **p<0.01, *** p<0.001
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Figure 48 ECM mRNA expression in ocular tissues after GFS
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For each gene, data were normalised to the level of mRNA detected in control tissues 
obtained from unoperated eyes * p<0.05, **p<0.01, *** p<0.001. ASMA represents 
alpha smooth muscle actin expression which acts as a marker of myofibroblast 
transformation.
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Figure 49 TGF p2 protein levels in the aqueous humour following experimental
glaucoma filtration surgery
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Figure 50 TGFP2 protein levels in conjunctival bleb tissue following
experimental glaucoma filtration surgery
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3.4 MODULATION OF THE WOUND HEALING RESPONSE IN VIVO: 
EFFECT OF ANTI TGF 02 ANTIBODY (CAT-152)
3.4.1 Effect of intra-operative CAT-152 on the outcome of Experimental 
Glaucoma Filtration Surgery
3.4.1.1 Bleb survival Using the single dose treatment regime CAT-152 was not found to 
significantly improve surgical outcome in this aggressive model of subconjunctival 
scarring. No significant advantage in bleb survival was shown with CAT-152 compared 
to control treatments as illustrated in the Kaplan-Meier curve in Figure 51. All blebs 
failed by day 21. Median bleb failure was 14 days after treatment with CAT-152, PBS 
and with no treatment (Table 9). These findings were consistent with previous studies 
using this model, in which untreated control animals most commonly fail around day 14.
3.4.1.2 Bleb Morphology All blebs were associated with normal conjunctival 
appearance and morphology (Figure 52). Subconjunctival scarring occurring at the 
filtration site causes flattening and a decrease in surface area of the bleb, important 
indicators of effective filtration surgery therefore include the bleb area and bleb height. 
Analysis of these variables using the repeated measures procedure by the generalized 
linear model did not reveal any statistically significant differences between the three 
groups (Bleb area p= 0.838, bleb height p= 0.598; Figure 51). These findings correspond 
to and are consistent with the absence of any effect of treatment on bleb failure across the 
groups.
3.4.1.3 Intraocular Pressure There was an initial rise in the IOP within the first 24 hours 
in most cases followed by a fall between days 2 to day 4. IOP failure, defined as the 
return of the IOP in the operated eye to the baseline level, was seen in 28 of the 30 rabbits 
by 10 days after the surgery. In the 2 remaining cases, both treated with CAT-152, the
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IOP did not fail; this result however, did not reach statistical significance (p= 0.368). 
Analysis of mean intraocular pressure, in the surgical eyes during the entire study period, 
showed no significant differences between treatment groups over the entire study period 
(p >0.05, Figure 53).
3.4.1.4 Side effects of treatment No drug related side effects were detected. Cytotoxic 
anti-scarring regimes use can result in non perfused, avascular areas in the locally treated 
tissues. These areas of avascularity are associated with thin walled, cystic blebs and the 
attendant risks of leakage and infection. All the rabbit eyes were studied for the presence 
of avascularity. In all the rabbits a small region of avascularity (< 3mm) was noted on the 
nasal side of the bleb, within the first 7 days. This was a transient finding and no 
significant increase in this variable was seen after treatment with CAT-152 compared to 
controls.
3.4.1.5 Tolerance Local reaction to CAT-152 injections was assessed by the degree of 
anterior chamber activity and conjunctival vascularity. No treatment was found to 
adversely influence either of these indicators of the inflammatory response. All treatments 
were safe and well tolerated (Figure 54).
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Figure 51 Effect of intra-operative CAT-152 on bleb survival
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All blebs had failed by day 21 (A). Median bleb survival was 14 days after CAT- 
152, PBS or no treatment. No statistically significant differences were shown 
between the treatment groups for bleb survival (A; p= 0.8570), bleb area (B; p= 
0.838) or bleb height (C; p=0.598).
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Figure 52 Effect of intra-operative CAT-152 treatment on bleb morphology
Bleb morphology on day 10 after surgery. CAT-152 treatment was well 
tolerated and normal conjunctival vascularity was preserved.
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Figure 53 Effect of intra-operative CAT-152 treatment on intraocular
pressure
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IOP failure was defined as return of the IOP to the pre-operative level. In two 
animals both treated with CAT-152, the IOP did not fail during the 30 day period 
( p = 0.368). However, no significant differences were seen in mean IOP at any 
time point ( p< 0.05)
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Table 9 Incidence of bleb failure and the percentage bleb survival in rabbits 
undergoing glaucoma filtration surgery with intra-operative CAT-152
Treatment
0
Days after Surgery 
7 10 14 17 21 30
Survival 
30 days
/ n
CAT-152 0 1 2 5 1 1 0 0 /1 0
% survival 100 90 70 20 10 0 0
PBS 0 0 2 4 4 0 0 0 / 10
% survival 100 100 80 40 0 0 0
No Treatment 0 0 2 5 3 0 0 0 /1 0
% survival 100 100 80 30 0 0 0
Bleb survival: Log rank Statistics and (significance)
Treatment CAT-152 PBS
PBS 0.24(0.6235)
NT 0.05 0.13(0.8198) (0.7162)
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Figure 54 Effect of intra-operative CAT-152 on conjunctival vascularity after
glaucoma filtration surgery
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All treatments were well tolerated. Conjunctival injection was graded according to 
severity (Grade 1= normal vascularity, grade 2= hyperaemic, grade 3= very 
hyperaemic). No significant differences in this variable were detected between 
treatment groups during the 30 day study period (Nasal conjunctival p= 0.453, 
superior conjunctiva p= 0.524, temporal conjunctiva p= 0.07)
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3.4.2 Effect of prolonged post-operative application of CAT-152 on 
subconjunctival scarring after experimental glaucoma filtration surgery: 
Comparison with 5-Fluorouracil.
3.4.2.1 Experimental details Of the 24 rabbits observed for the duration of the 30 
day experimental period, 23 completed the experimental protocol. One animal was 
observed to be developing signs of severe intraocular infection 3 days after surgery. The 
rabbit was sacrificed and an independent observer (to preserve masking) identified that 
the animal was in the control group. Observational analysis was therefore performed on 8 
animals that received CAT-152, 8 animals that received 5-FU and 7 untreated control 
animals.
3.4.2.1 Bleb survival CAT-152 was found to significantly improve glaucoma filtration 
surgery outcome in this animal model of aggressive post-surgical scarring. CAT-152 
significantly prolonged bleb survival compared to the 5-FU group and the untreated 
control group as shown in the Kaplan Meier survival curve in Figure 55 (Log rank 
statistics P = 0.0009). The rate of bleb failure and percentage survival in each treatment 
group is shown in Table 10. Interesting, subgroup analysis of the log rank statistic showed 
CAT-152 significantly improved surgical survival compared to both 5FU and NT, 
however 5FU did not have a significant effect over the NT group (Table 10). All the blebs 
in the control and 5-FU groups had failed by day 22, however 62.5% of the CAT-152 
treatment group had functioning blebs. By day 30 all but one of the operations had failed; 
the only animal with a functioning bleb had received CAT-152. The median (range) 
survival rates were 23.5 (20-30), 20 (16-22) and 16 (14-21) days in the CAT-152, 5-FU 
and control groups, respectively (Figure 56).
190
3.4.2.2 Bleb morphology The presence of a well formed bleb is an important 
indicator of effective filtration. Subconjunctival scarring causes contraction and flattening 
of the bleb. Figure 57 shows the typical appearances of the filtration blebs on days 10, 
21, 30. Treatment with CAT-152 was associated with elevated, diffuse, fleshy looking 
blebs compared to the flat scarred blebs in the other groups. Analysis of both bleb area 
and bleb height using the repeated measures of the generalized linear model, revealed 
significant difference in both these variables after treatment with CAT-152 compared to 
5-FU or no treatment regimens ( Figure 55 P<0.005 Area; PcO.OOl Height: Figure B and 
C).
3.4.2.3 Intraocular Pressure Analysis of IOP survival or mean intraocular 
pressure in the surgical eyes showed no significant differences between treatment groups 
over the entire study period (P>0.05). (Figure 58)
3.4.2.4 Side effects of treatment Corneal epitheliopathy is a recognized adverse 
effect associated with the clinical use of 5-FU and is associated with both ocular 
discomfort and the risk of infection. Given this, a grading system was included in the 
methods to assess the severity of this variable. In this experiment only mild punctuate 
staining of the cornea (superficial punctuate keratitis, grade 1) was detected in all 
treatment groups and this was a transient finding. Observations for corneal epitheliopathy 
were started on day 1 after surgery. During the procedure a superior corneal traction 
suture is used to position the globe. This results in a transient epithelial defect which 
would be present in all animals and heals over 24 hours. The duration of the staining 
however, was significantly longer in the 5-FU treated group (PcO.Ol). The duration of 
staining in the CAT-152 group was similar to that observed in the no treatment control 
group (Table 11, Figure 59).
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One of the features of existing cytotoxic anti-scarring regimes is their production of non 
perfused, avascular areas in locally treated tissues. These areas of avascularity are 
associated with thin walled, cystic blebs and the attendant risks of leakage and infection. 
In all the rabbit eyes a small region of avascularity was noted in the nasal side of the bleb 
(<3mm), within the first 7 days. This was transient finding. The duration of the avascular 
segment tended to be longer in the 5-FU treated animals but this did not reach statistical 
significance (P=0.159). The duration of avascularity in the CAT-152 group was similar to 
that observed in the no treatment control group (Table 11).
3.4.2.5 Tolerance Local reaction to treatment was assessed by the degree of anterior 
chamber inflammation and conjunctival vascularity. No significant difference was found 
between treatment groups for either of these indicators of the inflammatory response 
(GLM: vascularity, superior P=0.402, temporal P=0.434, nasal P=0.668; anterior chamber 
inflammation P=0.430: Figure 60)
3.4.2.6 Anterior Chamber Observations The depth of the anterior chamber was 
assessed as an indirect indicator of drainage. On day 1 after surgery the anterior chamber 
was flat in most of the animals. Over the next 7 days the anterior chamber gradually 
deepened. No significant difference was found between the treatment groups in the time 
taken for the anterior chamber to deepen (P=0.302).
3.4.2.7 Histological effects
The histological grading system was used to identify changes in cellularity (H and E), 
total scar tissue deposition (Picrosirius Red), collagen fibre density and orientation 
(Gamoris Trichrome), elastic fibre deposition (oxidative aldehyde fuschin) and 
myofibroblast transformation (a  SMA expression) between the treatment groups over the 
study period.
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CAT-152 treatment reduced scarring at a microscopic level. The greatest histological 
difference between treatment groups was seen on day 10 (Figure 61). At this time point 
total scar formation, as judged by the staining characteristics of picrosirius red, was 
significantly reduced by CAT-152 treatment (P=0.01, Figures 61 and 62). In addition 
CAT-152 significantly reduced the population of cells expressing a  smooth muscle actin, 
indicating less fibroblast differentiation into the myofibroblast phenotype, a  SMA 
staining was performed by two different methods, using a DAB detection method and 
also with a fluorescent labelled antibody. Both these methods detected similar trends in 
the expression of a  SMA in the post-operative wound site (Figures 63 and 64). No other 
significant differences were found between treatment groups in total cellularity, elastic 
fibre deposition or PCNA at day 10 (Figure 61 and 65).
The number of proliferating and total cell population was maximal in the early stages and 
reduced over time (Figure 66 A, B and F). Collagen fibre deposition peaked at day 10, 
whilst differences in collagen fibre orientation were most apparent by day 21 (Figure 66 
C and D). High levels of elastic fibres were seen at all time points with maximum 
deposition by day 21 (Figure 66 E).
By day 30 subconjunctival scarring at the wound site consisted characteristically of 
densely packed collagen and fibroblasts. In contrast, the only surviving CAT-152 treated 
bleb showed much looser architecture with visible conjunctival bleb formation (Figure 
67). Clinical observation of bleb failure correlated well with the degree of conjunctival 
scarring as shown in Figure 68 with higher levels of scar tissue were found in failed 
blebs.
3.4.2.8 Electron Microscopy We compared electron microscopic (EM) 
characteristics of CAT-152 treated animals and untreated controls. Morphologically
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scanning EM demonstrated looser subconjunctival bleb architecture with CAT-152 
treatment (Figure 69 A, C, E). At a cellular level, transmission EM showed a 
corresponding reduction in inflammatory cell infiltrate and collagen fibril formation 
within the blebs of CAT-152 treated animals (Figure 69 : compare E and F).
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Figure 55 Effect of post operative treatment on bleb survival and bleb morphology
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The effect of CAT-152 (n=8), 5-FU (n=8) or no treatment (n=7) on A) bleb survival, B) bleb 
area and C) bleb height. CAT-152 significantly prolonged bleb survival compared to 5-FU 
and the untreated control group as shown in the Kaplan Meier survival curve (P=0.0009 Log 
rank statistics). CAT-152 treated eyes had significantly larger blebs (area and height, 
P<0.05).
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Table 10 Incidence of bleb failure and the percentage bleb survival in rabbits 
undergoing glaucoma filtration surgery: Effect of CAT-152 and 5-FU 
treatment compared to control.
Treatment Days after Surgery Survival
30 days
0 14 16 18 20 21 22 23 24 28 29 30 / n
CAT-152 0 0 0 0 1 1 1 1 1 1 1 0 1 /8
% survival 100 100 100 100 87.5 75 62.5 50 37.5 25 12.5 12.5
5-FU 0 0 1 2 2 2 1 0 0 0 0 0 0 /8
% survival 100 100 87.5 62.5 37.5 12.5 0 0 0 0 0
No Treatment 0 3 1 1 1 1 0 0 0 0 0 0 0 /7
% survival 100 57.1 42.9 28.6 14.3 0 0 0 0 0 0 0
Bleb survival: Log rank Statistics and (significance)
Treatment CAT-152 NT
NT 10.55
'' V':K:" V 7:: 7-7 7:'’*.777 : - ;7-77:> :
(0.0012)
5FU 8.94 1.28(0.0028) (0.2576)
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Figure 56 The effect of post-operative treatment on Bleb survival
Median Bleb survival
CAT-152 5-FU No Treatment
Mean Bleb survival
No Treatment
Median bleb survival in the CAT-152 treated group was 23 days compared 
to 16 in the untreated group and 20 after 5-FU application. On average CAT- 
152 prolonged mean bleb survival by 5.1 and 7.7 days compared to 
treatment with 5-FU or no treatment, respectively. (* P< 0.05)
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Figure 57 Effect of Post-operative treatment on bleb morphology
Day 14
Day 21
CAT-152
Day 30
Bleb morphology on days 10, 21 and day 30 after glaucoma filtration surgery. 
One representative animal is shown per group. Animals were treated with either 
CAT-152 or 5-FU or received no treatment. Treatment with CAT-152 was 
associated with elevated, diffuse, fleshy looking blebs compared to the flat, 
scarred blebs in the 5-FU and control groups. (Black arrows demarcate the bleb 
border and the white arrow shows the cannula.)
198
Figure 58 Effect of post-operative treatment on intraocular pressure after
glaucoma filtration surgery
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No significant differences in intraocular pressure were found between 
treatment groups in terms of IOP Survival (Return of IOP to pre-operative 
baseline) or mean IOP. (Error bars represent standard error of the mean)
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Figure 59 Side effects associated with post-operative treatment
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In all the rabbit eyes a small region of avascularity was noted in the nasal side 
of the bleb (<3mm), within the first 7 days as shown in image A. This was a 
transient finding. The duration of the avascular segment tended to be longer 
in the 5-FU treated animals but this did not reach statistical significance 
(P=0.159). The black arrows demarcate area of nasal conjunctival 
avascularity
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Table 11 Duration of low grade corneal epitheliopathy or avascularity following 
treatment with CAT-152 or 5-FU compared to the no treatment control 
animals. (Mean ± standard error)
Adverse event
Duration of effect (days)
CAT-152 5FU NT
Corneal Epitheliopathy 1.63 ±0.53 10.71 ± 1.71* 1.57 ±0.48
Avascularity 9.13 ± 1.33 16.88 ±3.2 10.57 ± 2.5
* P < 0.01 comparing CAT-152 or 5-FU treatment groups to the no treatment group 
using Kruskal-Wallis test and Dunn’s test. NT = no treatment group.
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Figure 60 Effect of Post operative treatment on conjunctival vascularity after
glaucoma filtration surgery
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Analysis of the mean grade of vascularity is shown in charts A-C. No 
significant differences were detected between the three treatments in 
terms of conjunctival vascularity. Superior P=0.402, temporal P=0.434, 
nasal P=0.668; Grade 1 Normal, Grade 2 hyperaemic, Grade 3 extensive 
hyperaemia.
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Figure 61 Effect of post-operative treatment on the different elements of the
scarring response after glaucoma filtration surgery
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On day 10 CAT-152 significantly reduced collagen production as graded by 
picrosirius red staining and the expression of a  smooth muscle actin (* p=0.01). At 
other time points trends were demonstrated in which CAT-152 reduced collagen 
deposition (picrosirius red), elastic fibre formation (Oxytalan staining) and collagen 
orientation (Gamoris trichrome) although these did not reach significance.
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Figure 62 Effect of post-operative treatment on subconjunctival scarring on day 10 after glaucoma
filtration surgery
Histological characteristics of filtration blebs on day 10. Hematoxylin and eosin (A-C) and picrosirius red (D-F) stained 
sections are shown of one representative animal per group: CAT-152 treated (A,D), 5-FU treated (B,E) and control group 
(C,F). CAT-152 treatment reduced subconjunctival scarring at the microscopic level. The picrosirius red staining 
demonstrates a reduction in the density of subconjunctival collagen deposition (green and yellow) in CAT-152 treated 
animals. Bar represents 500pm
Figure 63 Effect of post-operative treatment on myofibroblast transformation on day 10 after glaucoma
filtration surgery
Fibroblast differentiation to the myofibroblast phenotype is characterised by the expression and assembly of a smooth 
muscle actin into stress fibres. Immunohistochemical staining of the filtration blebs on day 10 , using a DAB detection 
system, demonstrates a reduction in the number of a  smooth muscle actin expressing cells after CAT-152 treatment (A) 
compared to 5-FU (B) and controls (C). Bar represents 500pm
Figure 64 Quantification of alpha smooth muscle actin expression in 
subconjunctival tissue after glaucoma filtration surgery
Quantification of a  smooth muscle actin expression
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Fluorescent immunohistochemical staining for a  smooth muscle actin was 
perfomed on 3 animals per treatment group (Day 10, N=3, A= CAT-152, 
B= 5FU and C= NT). These images were quantified using a binary image 
analysis system. CAT-152 significantly reduced a  smooth muscle actin 
expression compared to 5-FU and control treatments (p< 0.05). The a  sma 
was labelled with FITC shown in green and the nuclei were counterstained 
with DAPI (blue). A negative control primary antibody was used and an 
internal positive control was located within the ciliary body of the eye. Bar 
represents 50 pm
* ■ _
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Figure 65 Effect of post-operative treatment on the subconjunctival scarring response
Gamoris Trichrome: 
Collagen fibre 
density and 
orientation 
(Collagen green)
Oxidised
Aldehyde Fuschin: 
Elastic fibre 
deposition, early 
scarring response 
(Elastic fibres 
purple)
PCNA Immuno- 
histochemistry 
(Proliferating cells 
brown)
Histological characteristics of filtration blebs on day 10. One representative animal per group: CAT-152 treated 
(A,D, G), 5-FU treated (B,E,H) and control group (C,F,I). No significant differences seen between groups.
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Figure 66 Effect of post-operative treatment on subconjunctival scarring
over the 30 day study period
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A grading system was used to quantify the effect of CAT- 
152 treatment on the extracellular matrix. The data is 
displayed for each histological stain over the 30 day study 
period. CAT-152 significantly reduced collagen deposition 
and a  SMA expression on day 10. * p<0.05
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Figure 67 Subconjunctival architecture on day 30 after glaucoma
filtration surgery
By day 30 only one bleb (CAT-152 treated) was still functioning. In failed blebs 
subconjunctival scarring consisted of dense collagen fibres and fibroblasts (B). In 
constrast the surviving bleb showed much looser architecture and visible evidence 
of bleb formation (A). Bar represents 100mm
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Figure 68 Comparison of subconjunctival scarring indices in failed
versus surviving blebs
Day 10 □ Survived n=ll
□ Failed n=l
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The animals were observed to identify the time of bleb failure. The histology 
grading data has been analysed to compared failed versus surviving blebs for 
each time point.
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Figure 69 Bleb and subconjunctival architecture after experimental
glaucoma surgery
Electron microscopy (EM) was performed on CAT-152 treated animals 
(A,C,E) and untreated controls (B,D,F). Morphologically scanning EM (A-D) 
demonstrates looser subconjunctival bleb architecture with CAT-152 
treatment. At a cellular level, transmission EM shows the associated 
reduction in inflammatory cell infiltrate and collagen fibre deposition in the 
CAT-152 treated animals. Bars A-B 1mm, C-D 100mm E-F 10
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3.4.3 Long term effects of combining intra-operative and prolonged post-operative 
CAT-152 treatment on the outcome of experimental glaucoma surgery.
3.4.3.1 Bleb survival All 27 animals completed the study. The main outcome variable 
was the effect of CAT-152, 5-FU or PBS treatment on bleb survival. CAT-152 
significantly prolonged the bleb survival compared to 5-FU and PBS as shown in the 
Kaplan Meier curve in Figure 70 A (Log rank statistics P < 0.0001). Median bleb survival 
was 41, 27 and 17 days with CAT-152, 5-FU and PBS treatment, respectively (Figure 70 
C). Animals treated with CAT-152 started to fail after day 24. 3 animals failed in week 4, 
3 failed in week 6 and in the remaining 1/3 of the CAT-152 animals surgical success was 
maintained throughout the 45 day experiment (Table 12). 5-FU treatment significantly 
prolonged bleb survival compared to PBS (Figure 70 A and table 13, P=0.0024). All the 
animals in the PBS control group failed by the end of week 3.
In half the control animals the PBS treatment was given by superior subconjunctival 
injection and in the remaining ones it was given by inferior subconjunctival injection. 
This was to identify if the site of injection influences bleb survival in this model. 
Subgroup analysis of the PBS animals by injection site did not demonstrate any 
significant differences in bleb survival (Figure 70 B and table 13; Log rank survival, p= 
0.97350).
3.4.3.2 Bleb Morphology The presence of a diffuse, elevated drainage bleb is an 
indicator of scleral patency and trans-conjunctival drainage. Treatment with CAT-152 
was associated with larger more diffuse areas of drainage compared to 5-FU and PBS. 
Analysis of bleb area and bleb height by the generalized linear model revealed significant 
differences in these variables with CAT-152 treatment (Figure 71 p<0.001). Bleb 
morphology was recorded by digital imaging at regular intervals to enable comparison of 
treatment effect. Figure 72 shows bleb morphology after 14, 21 and 42 days. As
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subconjunctival scar tissue is laid down and the bleb fails the tube becomes more 
prominent as seen in the PBS treated animals. CAT-152 appeared to prevent this 
observation and an elevated bleb appearance was maintained.
3.4.3.3 Intraocular Pressure IOP survival was not shown to be significantly 
different between treatment groups as shown in Figure 73 A (Log rank p=0.385). 
However, a trend for higher mean post-operative pressure was seen in the 5-FU treated 
group (Figure 73 B). Multiple comparisons between groups highlighted significantly 
higher pressures in the 5-FU animals compared to CAT-152 on day 14 (p=0.069), day 28 
(p=0.096) and day 31 p=0.068) and also compared to PBS on day 28 (p=0.075). Mean 
IOP with CAT-152 was similar to control.
3.4.3.4 Side effects of treatment
Conjunctival chemosis Transient chemosis has been noted in this model in the 
immediate post-operative period in some animals and resolves spontaneously over 48 
hours (Early chemosis). Transient chemosis was seen in 4 animals, 1 treated with CAT- 
152, 1 with 5-FU and 2 treated with PBS on day 1 after surgery (Figure 74). However, 
using this prolonged injection regimen 3 CAT-152 treated animals were also noted to 
develop chemosis after 2-3 weeks of treatment on a mean of 2.7 occasions, which 
appeared to be related to the injections and had not been previously associated with this 
model. This was termed late chemosis. The conjunctiva became injected and swollen 
(Figure 74 A). These appearances resolved but residual conjunctival hyperaemia persisted 
(Figure 74 B).
Corneal epitheliopathy Self limiting comeal staining is seen in some animals after the 
surgical procedure and results from placement of the comeal traction suture. Comeal 
epitheliopathy is associated with the clinical use of 5-FU. Combined intra-operative and
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prolonged post-operative application of 5-FU significantly increased the duration of low 
grade epithelial changes with a mean duration of 14.6 days (p< 0.01 using Kruskal-Wallis 
test and Dunn’s test). This compared to a mean duration of 10.7 days seen with isolated 
post-operative use. Treatment with CAT-152 was similar to control (Figure 75).
Corneal oedema and vascularision Additional corneal side effects were observed in 
animals treated with combined intra-operative and combined post-operative 5-FU. The 
duration of comeal oedema and vascularisation was significantly prolonged by 5-FU, 
compared to CAT-152 or control (Kruskal Wallis: vascularity p= 0.02, oedema p= 0.007, 
Dunn’s Test p<0.05). These findings tended to occur together rather then in isolation. 
Similar observations have been previous noted in this model. It is likely that reduced flow 
of aqueous through the bleb leads to back pressure and a build up of fluid in the cornea, 
which presents as comeal cloudiness and oedema. This can be aggravated by co-existing 
epitheliopathy. Chronic comeal changes induce secondary vascularisation (Figure 76) 
Conjunctival avascularity was observed in conjunctival bleb tissue after treatment with 
5-FU. This was more extensive than the changes observed after isolated post-operative 
subconjunctival injections of 5-FU and extended across the superior conjunctival in the 
region where the subconjunctival sponge had been applied intra-operatively (Figure 77 
A). Repeated post-operative injection of 5-FU also resulted in an area of inferior 
conjunctival avascularity at the injection site (Figure 77 B).
3.4.3.5 Tolerance Intensity of conjunctival vascularity and the degree of intraocular 
inflammation indicate if a treatment is well tolerated. Analysis of the mean grade of 
vascularity is shown in Figure 78 A-C. Treatment with CAT-152 increased superior 
conjunctival vascularity. (GLM p=0.003). Using multiple analysis of variance superior 
conjunctival vascularity was significantly increased by CAT-152 on days 21 and 38
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compared to control (Bonferroni correction: Day 21 p=0.052, day 38 p=0.029). These 
time points correspond to the presentation of conjunctival chemosis in 3 CAT-152 treated 
animals. Mean grading of nasal and temporal conjunctival vascularity did not 
significantly differ between the three groups (GLM: nasal vascularity p=0.98, temporal 
vascularity p=0.237)
No significant differences in anterior chamber inflammation were detected between 
treatment groups (GLM: p= 0.179)
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Figure 70 Effect of combined intra and post-operative treatment on
bleb survival after glaucoma filtration surgery
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Treatment with CAT-152 significantly prolonged bleb survival compared to both 
5FU and PBS (Ailog rank statistics P<0.0001). Subgroup analysis of the PBS group 
showed that the site of injection does not influence bleb survival in this model (B).
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Table 12 Incidence of bleb failure and the percentage bleb survival in rabbits undergoing glaucoma filtration surgery: Effect of 
CAT-152 and 5-FU treatment compared to control.
Treatment Days after Surgery
No of 
surviving 
blebs
0 14 15 16 17 21 22 24 25 21 28 30 34 38 41 42 45 / n
CAT-152 
% survival
0
100
0 0  0 0 0 0 0  1 2 0 0 0 1 1 1 0  
100 100 100 100 100 100 100 88.89 66.67 55.56 55.56 55.56 44.44 33.33 33.33 33.33
3/ 9
5-FU
% survival
0 0 0 0 0 1 1 0 1 2 2 1 1 0 0 0 0 0 /9
100 100 100 100 100 88.89 77.78 77.78 66.67 44.44 22.22 11.11 0 0 0 0 0
PBS
% survival
0 1 1 1 2 2 0 2 0 0 0 0 0 0 0 0 0 0 /9
100 88.89 77.78 66.67 44.44 22.22 22.22 0 0 0 0 0 0 0 0 0 0
2
1
7
Table 13 Bleb survival: Log rank Statistics and (significance)
CAT-152 5FU PBS Superior
5FU 7.37(0.0066)
PBS Superior 15.62(0.0001) 9.22(0.0024)
PBS Inferior 16.34(0.0001) 10.72(0.0022)
0
(0.9735)
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Figure 71 Effect of combined intra and post-operative treatment on
bleb morphology after glaucoma filtration surgery
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Bleb morphology is an important indicator of effective filtration. Treatment 
with CAT-152 was associated with larger more diffuse areas of drainage. 
Bleb area and height P<0.001. (Mean and Standard error plotted)
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Figure 72 Effect of combined intra and prolonged post-operative treatment on bleb
morphology
Day 14
Day 21
CAT-152 ' ^  5FTT “
.
Bleb morphology on days 14, 21 and day 42 after glaucoma filtration surgery. 
One representative animal is shown per group. Animals were treated with 
either CAT-152 or 5-FU or received PBS. Treatment with CAT-152 was 
associated with elevated, diffuse, fleshy looking blebs compared to the flat, 
scarred blebs in the 5-FU and control groups. (Black arrows demarcate the bleb 
border and the white arrow shows the cannula.)
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Figure 73 Effect of combined intra and prolonged post-operative
treatment intraocular pressure
(A) IOP survival
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IOP survival was not shown to be significantly different between treatment 
groups (Log rank P=0.385). However, a trend for higher mean post-operative 
pressure was seen in the 5FU treated group. ANOVA (multiple comparisons after 
bonferroni correction): Day 14 p=0.069 (5FUvs CAT-152), day 28 p=0.096 
(5FUvs CAT-152), p=0.075 (PBS vs 5FU) and day 31 p=0.068 (5FUvs CAT- 
152). Mean IOP with CAT-152 was similar to control.
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Figure 74 Effect of combined intra and prolonged post-operative CAT
152 on the conjunctival appearance after glaucoma filtration surgery
Incidence of Chemosis
Early Late Early and late
No of occasions chemosis was seen in affected animals
Transient chemosis has been noted in this model in the immediate post-operative 
period in some animals and resolves spontaneously over 48 hours (Early chemosis) 
However, using this prolonged injection regimen 3 CAT-152 treated animals were 
noted to develop chemosis after 2-3 weeks of treatment on a mean of 2.7 occasions, 
which appeared to be related to the injections and had not been previously associated 
with this model (Late chemosis). The conjunctival became injected and swollen (A). 
These appearances resolved but residual conjunctival hyperaemia persisted (B).
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Figure 75 Effect of combined intra-operative and prolonged post-operative
treatment on the corneal epithelium after glaucoma filtration surgery
Number of animals with grade 1 corneal epitheliopathy
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Corneal epitheliopathy is associated with the clinical use of 5-FU. 
Combined intra-operative and prolonged post-operative application of 5- 
FU significantly increased the duration of low grade epithelial changes 
with a mean duration of 14.6 days (PcO.Ol Kruskal wallis and Dunn’s 
Test). This compared to a mean duration of 10.7 days seen with isolated 
post-operative use. Treatment with CAT-152 was similar to control. Mean 
and standard error plotted.
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Figure76 Additional corneal side effects associated with combined intra 
operative and prolonged post-operative application of 5-FU after GFS
(A) Mean duration of corneal Oedema
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Corneal oedema (A) and vascularisation (B-C) were observed in animals treated 
with combined intra-operative and combined post-operative 5-FU. The duration 
of these findings was significantly prolonged by 5-FU, compared to CAT-152 or 
control, (vascularity p= 0.02, oedema p= 0.007). These findings tended to occur 
together rather then in isolation. Similar observations have been previous noted 
in this model. ( Black arrows demarcate comeal vessels). Mean and standard 
error plotted.
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Figure 77 Effect of combined intra and prolonged post-operative
application of 5-FU on conjunctival avascularity
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Conjunctival avascularity was observed in conjunctival bleb tissue after 
treatment with 5-FU. This was more extensive than the changes observed 
after isolated post-operative subconjunctival injections of 5-FU and 
extended across the superior conjunctival in the region where the 
subconjunctival sponge had been applied intra-operatively (A). Repeated 
post-operative injection of 5-FU also resulted in an area of inferior 
conjunctival avascularity at the injection site (B).
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Figure 78 Effect of combined intraoperative and prolonged post-operative
treatment on conjunctival vascularity
Superior vascularity CAT-152
5FU
PBS2.5
Days after surgery
Nasal vascularity
0.5 -
0  -) 1 1 ( 1 1 1 1 1 1
0 5 10 15 20 25 30 35 40 45
Days after surgery
Temporal vascularity CAT-152
5FU
PBS
0.5
Days after surgery
Analysis of the mean grade of vascularity is shown in charts A-C. Multiple 
comparisons showed significantly increased superior conjunctival vascularity after 
treatment with CAT-152 compared to control (ANOVA Bonferroni correction: Day 
21 p=0.052, day 38 P=0.029).These time points correspond to the presentation of 
conjunctival chemosis in 3 CAT-152 treated animals. Mean grading of nasal and 
temporal conjunctival vascularity did not significantly differ between the three 
groups.
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3.4.4 Effects of a combined course of intra-operative and prolonged treatment with 
the CAT-152 on the immune response in the rabbit 
3.4.4.1 Local conjunctival reaction
This experiment was performed to investigate why conjunctival chemosis had been 
detected with intra-operative and prolonged treatment of CAT-152 (3.4.3). Transient 
early chemosis has been previously noted in this model in the immediate post-operative 
period in some animals and resolves spontaneously over 48 hours with no residual effects. 
This does not appear to be related to the treatment given. In this experiment 7 animals 
developed transient early chemosis, 2 treated with CAT-152, 4 with Null antibody and 1 
treated with PBS (Figure 79A). The clinical finding of late chemosis was again detected 
using this combined treatment regimen. 4 animals showed signs of chemosis later in the 
experiment (Null treatment n=3, CAT-152 n=l), the onset of which was during weeks 3- 
4, after a mean of 10.25 injections had been given (Figure 79 B). Late chemosis increased 
in severity with each episode, reached a maximum intensity after 13 injections and was 
associated with conjunctival hyperaemia (Figure 80). Chemosis appeared to be a response 
to the subconjunctival treatment and when present was always detected in the 24 hours 
after a subconjunctival injection had been given (Figure 79 C). The time course of each 
response to the injection varied, but was maximal after 24 hours and resolved after 48 
hours leaving residual superior conjunctival hyperaemia. Once the reaction had been 
detected in a bleb it occurred with all subsequent injections but to a lesser degree with 
time.
3.4.4.2 Systemic detection of CAT-152 and Null antibody in rabbit serum CAT- 
152 was detected in the serum of all CAT-152 treated rabbits 4 days after initiation of 
subconjunctival dosing and GFS. On day 4 (after 6 injections of CAT-152 lOOpg) the
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serum concentration for CAT-152 was 1095ng/ml (n=6, Table 14). In 4 of 6 rabbits the 
concentration of CAT-152 decreased over time and was not detected at the 70 day time 
point. CAT-152 was detected in the serum of 2 rabbits 70 days after GFS.
Similarly, CAT-001 was detected in the serum of all CAT-001 treated rabbits 4 days after 
initiation of subconjunctival dosing and GFS. On day 4 (after 6 injections of CAT-001 
lOOpg) the serum concentration for CAT-001 was 999ng/ml (n=6, Table 15). In all 
rabbits the concentration of CAT-001 decreased over time and was not detected at the 70 
day time point
3.4.4.3 Detection of rabbit serum antibodies to CAT-152 and CAT-001
Antibodies were raised against CAT-152 and CAT-001 in a subset of the animals treated 
with these human antibodies. Anti-CAT-152 and anti-CAT-001 antibodies were detected 
in the serum of treated rabbits 70 days after GFS (4 of 6, and 5 of 6 rabbits respectively; 
Table 16). All the animals that displayed late chemosis were found to have either anti- 
CAT-152 or anti-CAT-001 antibodies in the serum.
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Figure 79 Effect of combined intra-operative and combined
post-operative treatment on conjunctival chemosis
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Conjunctival chemosis was seen in 7 animals on day 1. This was a transient finding 
and resolved within 24 hours. Chemosis was also detected in week 3-4 after 10 
injections had been given (Null treatment n=3, CAT-152 n=l) (A). Late chemosis 
increased in severity with each episode, reached a maximum intensity in week 4 ( 1 3  
injections) and then persisted (B). Chemosis appeared to be a response to the 
subconjunctival treatment (C)
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Figure 80 Appearance of chemotic blebs on day 25
CAT-152
I
4 animals developed conjunctival chemosis which was at maximum 
severity after 13 injections (Null n=3, CAT-152 n=l)
Table 14 Serum concentration of CAT-152 in CAT-152 treated rabbits
ID Treatment CAT-152 serum concentration ng/ml (days after GFS)
No. Predose 4 11 17 24 32 44 70
5 CAT-152 ND 1260 ND ND 63 112 1014 65
6 CAT-152 ND 872 404 432 922 1571 1895 368
7 CAT-152 ND 1379 753 ND ND ND ND ND
8 CAT-152 ND 1098 535 ND ND ND ND ND
15 CAT-152 ND 1290 43 ND ND ND 31 ND
17 CAT-152 ND 802 97 71 32 80 66 ND
Geometric mean 1095
ND, not detected
Table 15 Serum concentration of CAT-001 in CAT-001 treated rabbits
ID Treatment CAT-001 serum concentration ng/ml (days after GFS)
No. Predose 4 11 17 24 32 44 70
2 CAT-001 ND 1161 ND ND ND ND ND ND
4 CAT-001 ND 813 527 33 16 73 169 ND
9 CAT-001 ND 660 77 ND ND ND ND ND
12 CAT-001 ND 580 >2000 710 332 344 57 ND
14 CAT-001 ND >2000 59 ND ND 18 31 ND
18 CAT-001 ND 1374 140 74 ND ND ND ND
Geometric mean 999
ND, not detected; >2000, above the standard curve maximum concentration 
(2000ng/ml)
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Table 16 Serum concentration of rabbit anti-CAT-152 or anti-CAT-001
antibodies 70 days after GFS.
CAT-152 treatment CAT-001 treatment
Rabbit ID.
Anti- 
CAT-152 
Hg/ml
Serum 
CAT-152 
ng/ml
Late
Chemosis Rabbit ID.
Anti-
CAT-001
ng/ml
Serum
CAT-001
ng/ml
Late
Chemosis
5 302 65 Yes 2 123 ND Yes
6 34 368 No 4 6 ND No
7 25 ND No 9 44 ND No
8 ND ND No 12 ND ND No
15 14 ND No 14 43 ND Yes
17 ND ND No 18 30 ND Yes
Serum level of CAT-152 or CAT-001 and incidence of chemosis are also shown. 
(ND = not detected)
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3.5 MODULATION OF THE WOUND HEALING RESPONSE IN VIVO: 
EFFECT OF ANTISENSE OLIGONUCLEOTIDES TARGETING TGF P
3.5.1 In vivo tolerance to TGF p antisense oligonucleotides in experimental 
glaucoma surgery
To assess tolerability of the TGF p antisense in vivo, we investigated the effects of single 
lOOjil subconjunctival injections of rabbit TGF pi antisense OGN at doses of 25 jig, 
50 jig and 100 jig. All injections were well tolerated in NZW rabbits with no evidence of 
intraocular inflammation being seen in any rabbit at any time in the study, or at any 
concentration of the drug. Conjunctival vascularity remained normal throughout the study 
period in all animals.
3.5.2 Efficacy of TGF p antisense oligonucleotides in experimental glaucoma 
surgery
3.5.2.1 Experimental details One anaesthetic death occurred in the first batch of 
surgery. The animal had received Misense OGN and was in the group of rabbits that 
would have been sacrificed after 15 days.
3.5.2.2 Bleb survival All animals failed surgery by day 23. However, TGF p2 antisense 
OGN significantly prolonged bleb survival in this model of aggressive scarring 
(p=0.0059, Figure 81 A). Mean bleb survival was increased by 5.68 days compared to 
PBS control. Kaplan Meier survival analysis also demonstrated enhanced bleb survival in 
the BRII treated animals but this did not reach significance (p= 0.0729, Table 17). TGF 
pi antisense did not affect the surgical outcome. The incidence of bleb failure is shown in 
Table 18.
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3.5.2.3 Bleb morphology All blebs became flat and scarred during the study period. 
Mean bleb area and bleb height were not significantly increased by any of the treatments 
(Bleb area p= 0.407, bleb height p= 0.405, Figure 81 B and 81 C). Figure 82 shows the 
appearances of successful and failed filtration blebs on day 17 of the study. TGF p2 
antisense was associated with diffuse conjunctival drainage compared to flat scarred blebs 
in the other treatment groups.
3.5.2.4 Anterior chamber depth Anterior chamber (AC) depth reflects the drainage 
of fluid through the microtube into the subconjunctival space. Flat or very shallow 
anterior chambers are seen in the early post-operative period, where the drainage of fluid 
exceeds aqueous production. The anterior chamber deepens with time and is usually of 
equal depth to the control eye by day 14, as the bleb starts to fail and transconjunctival 
drainage is reduced. Bleb failure is, therefore, defined as the presence of a flat scarred 
bleb with a deep anterior chamber. TGF p2 antisense prolonged the duration of a shallow 
AC and this result approached significance (GLM p= 0.065, Duration; Kruskal Wallis p= 
0.065, Figure 83).
2.5.2.5 Intraocular pressure Analysis of mean IOP and IOP survival in the
operated eyes showed no significant difference between treatment groups at any time 
point.
2.5.2.6 Tolerance Although an assessment of tolerability had been made for TGF pi 
antisense OGN in the rabbit, additional oligonucleotides were studied in this efficacy 
experiment, the tolerance of which had not been previously assessed. Therefore, 
conjunctival vascularity and intraocular inflammation were observed throughout the study 
period. No significant differences in these indices were detected between the groups
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(superior p= 0.3, nasal p= 0.739 and temporal vascularity p= 0.201; Figure 84). All 
treatments were safe and well tolerated.
3.5.2.7 Histological effects Ocular tissue from the animals sacrificed on days 15 (n=17) 
and 21 (n=15) was processed and analysed. By day 30 all the blebs had failed. The tissue 
from animals sacrificed on day 30 was not analysed. Previous experience with in this 
model has shown that once all the blebs have failed, only limited information can be 
gained on the effect of treatment on subconjunctival scarring.
The histological grading system was used to identify changes in cellularity (H and E), 
total scar tissue deposition (Picrosirius Red), collagen fibre density and orientation 
(Gamoris Trichrome), elastic fibre deposition (Oxidative Aldehyde Fuschin) and 
myofibroblast transformation (a  SMA expression) between the treatment groups over the 
study period. It must be noted that tissue was analysed from a maximum of 3 animals in 
each group. This must be taken into account when interpreting the data.
TGF (32 antisense OGN treatment reduced collagen deposition and improved fibre 
orientation as judged by Gamoris Trichrome staining (p=0.036, Figure 85 and 86). In 
addition TGF (32 antisense OGN significantly reduced the deposition of elastic fibres (p= 
0.019). There was a trend for TGF (32 antisense OGN to reduce cellularity (H / E) and 
collagen production (Picrosirius) compared to PBS control (p> 0.05 Figure 85 and 87). 
No other significant differences were found between treatment at day 21 or day 15 
(Figure 85).
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Figure 81 Effect of intra-operative antisense oligonucleotides
on the outcome of glaucoma surgery
(A) Bleb Survival
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Antisense OGN directed against TGF p2 significantly prolonged bleb survival in this 
model of aggressive scarring (Kaplan meier Survival analysis p= 0.0059).TGF pi 
antisense did not effect outcome. Interestingly, mean bleb area and bleb height were 
not significantly increased by any of the treatments ( Bleb area p= 0.407, bleb height 
p= 0.405). Charts B and C: Mean and SE plotted. Legend codes for charts A,B and C
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Table 17 Effect of antisense oligonucleotides on bleb survival
Log rank Statistics and (significance):
TGF p2 TGF p i BRII Misense
TGF p i 10.930.0009
BRII 2.560.1097
1.94
0.1642
Misense 7.22
0.0072
0.01
0.9291
1.78
0.1821
PBS 8.540.0035
0.41
0.5223
3.22
0.0729
0.56
0.4557
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Table 18 Incidence of bleb failure after treatment with antisense OGN
against TGF P
Treatment Days after Surgery Survival 30 days
0 10 13 14 16 17 20 23 30 / n
TGF p2 0 0 0 0 0 2 0 3 0 0 /5
% survival 100 100 100 100 100 40 40 0 0
TGF pi 0 0 1 0 4 0 0 0 0 0 /5
% survival 100 100 80 80 0 0 0 0 0
BRII 0 0 0 2 0 1 2 0 0 0 /5
% survival 100 100 100 60 60 40 0 0
Misense 0 0 0 4 0 1 0 0 0 0 /5
% survival 100 100 100 80 80 0 0 61 0
PSB 0 1 0 3 0 1 0 0 0 0 /5
% survival 100 80 80 20 20 0 0 61 0
Treatment Days after Surgery Survival 15 days
0 13 15 /n
TGF b2 0 1 0 3 /3
% survival 100 100 100
TGF b l 0 2 0 1 /3
% survival 100 33.33 33.33
BRII 0 1 0 1 /3
% survival 100 66.67 66.67
Misense 100 1 0 1 /2
% survival 100 50 50
PSB 0 2 0 0 /3
% survival 100 33.33 33.33
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Figure 82 Bleb appearance on day 17 after intra-operative 
treatment with antisense OGN directed against TGF p
Antisense OGN TGFp2 PBS
Antisense OGN TGF (31 |  Antisense OGN BRII
Typical appearances of filtration blebs on day 17. TGF-p2 antisense 
OGN was associated with diffuse drainage and normal conjunctival 
vascularity.
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Figure 83 Effect of intra-operative antisense OGN on anterior
chamber depth after glaucoma nitration surgery
(A) Anterior chamber depth
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Anterior chamber (AC) depth reflects the drainage of fluid through the microtube 
into the subconjunctival space. Flat or very shallow anterior chambers are seen in 
the early post-operative period, where the drainage of fluid exceeds aqueous 
production. Bleb failure is defined as the presence of a flat scarred bleb with a deep 
anterior chamber. TGF (32 antisense prolonged the duration of a shallow AC and 
this result approached significance (GLM p= 0.065, Duration; Kruskal wallis p= 
0.065).
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Figure 84 Effect of intra-operative antisense OGN on conjunctival
vascularity
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All treatments were well tolerated with no increase seen in conjunctival 
vascularity (Superior p= 0.3 , nasal p= 0.739 and temporal vascularity p= 0.201)
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Figure 85 Effect of intra-operative treatment with antisense OGN on the
different elements of the scarring response after glaucoma nitration surgery
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On day 21 TGF (32 antisense OGN a significantly reduced collagen density and 
improved collagen orientation as graded by gamoris trichrome staining. TGF (32 
antisense OGN also reduced the deposition of elastic fibres (* p=0.05). At other 
time points trends were demonstrated in which CAT-152 reduced collagen 
deposition (picrosirius red), elastic fibre formation (Oxytalan staining) and 
collagen orientation (Gamoris trichrome) although these did not reach 
significance. There was a trend for TGF b2 antisense OGN to reduce cellularity (H 
/ E) and collagen production (Picrosirius) compared to PBS control although these 
parameters did not reach statistical significance.
242
Figure 86 Effect of intra-operative antisense OGN treatment on
subconjunctival scarring on day 21 after glaucoma filtration surgery
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Histological characteristics of filtration blebs on day 21. Hematoxylin and eosin (A- 
B), Gamoris Trichrome (C-D) and Oxidative aldehyde fuschin (E-F) stained 
sections are shown of one representative animal per group: TGF p2 antisense OGN 
treated (A,C,E) and control group (B,D,F). TGF p2 antisense OGN treatment 
reduced subconjunctival scarring at the microscopic level. The gamoris trichrome 
staining demonstrated a reduction in the density of subconjunctival collagen 
deposition (green) with an improvement in the orientation of collagen fibres in 
TGF p2 antisense OGN treated animals. The oxidative aldehyde fuschin staining 
showed a reduction in elastic fibre formation (purple) after TGF P2 antisense OGN.
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Figure 87 Effect of intra-operative antisense OGN treatment on collagen
deposition on day 21 after glaucoma filtration surgery
Picrosirius red stained sections of the operative wound site from animals 
treated with TGF (32 antisense OGN (A) and PBS (B). There was a trend for 
TGF (32 antisense OGN to reduce collagen density which is stained in green 
and yellow.
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CHAPTER 4. DISCUSSION
4.1 MODULATION OF TGF P AND CONJUNCTIVAL SCARRING IN VITRO
4.1.1 ECM production in human Tenon’s fibroblasts
TGF P2 stimulates collagen production in human Tenon’s fibroblasts in vitro. Two 
different assays were performed to investigate collagen production in this study. The 
Sircol dye method detects all acid soluble collagens. The ELISA for C-terminus 
propeptide of collagen I (CICP), a marker of newly formed mature type 1 collagen was 
also used to assess collagen formation. Total collagen and collagen I production by 
ocular conjunctival fibroblasts was enhanced by TGF p2. The CICP assay was selected to 
study the effect of CAT-152 on fibroblast collagen generation as this assay could be 
performed using multiple replicates of the treatment condition with fewer cells whilst 
maintaining accuracy.
CAT-152 caused a concentration-dependent inhibition of collagen I production; full 
inhibition of this response was observed with 30nM CAT-152. These findings are 
consistent with the fact that CAT-152 has also been shown to significantly inhibit TGF 
p2-mediated collagen contraction by human Tenon’s fibroblasts in vitro with an IC50 of 
0.12mg/ml or InM (Cordeiro et al., 1999a).
Basal stimulation in the CICP assay investigating the effect of TGF p2 on Tenon’s 
fibroblasts induced approximately 1500ng/ml collagen I secretion (Figure 35). Maximal 
TGF P stimulation induced more than a doubling of this response (264% increase over 
basal levels). However, when the experiment was repeated to investigate the effect of 
CAT-152, basal collagen I levels were higher at 2000ng/ml and stimulation with lOOpM 
TGF p consequently only resulted in a 34% increase over basal levels. This between
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assay variation in basal collagen I production is difficult to explain given that the 
experiments were performed using the same cell lines. However, the final set of 4 CICP 
CAT-152 were set up in 24 well plates with a cell density of lx 105, compared to 6 well 
plates with a cell density of 7 x 105 which may have influenced the results. The same 
stock TGF P2 was used in this set of experiments.
Inhibition by CAT-152 reduced collagen I secretion to below basal levels at 
concentrations of 10 nM and above (Figure 41). At high concentrations CAT-152 may 
have induced a degree of cell death which has been demonstrated before in neutralisation 
assays. The concentration range tested was from 0.1 nM to lOOOnM. PBS was the vehicle 
used to dilute CAT-152. In order to achieve this concentration range a large PBS 
component containing stock CAT-152 1 mg/ml was added to the TGF (32 stimulation 
media (e.g. 1 7 0 0 jlx1 117.6pM TGF p2 and 300jil lmg/ml CAT-152 gave 2000pl of a 
solution of lOOpM TGF P2 and lOOOnM CAT-152). The PBS component may have had 
detrimental effects. Finally, the presence of anti-human antibody in the media may have 
interfered with the antibodies in the CICP elisa and affected the final reading.
4.1.2 Cytoskeleton and cell morphology
It is apparent from the results that ocular fibroblasts transform into myofibroblasts that 
express a  SMA on treatment with TGF P2. Concomitant treatment with CAT-152 can 
fully inhibit fibroblast differentiation to the myofibroblast phenotype in this human in 
vitro model of fibrosis.
Fibroblast differentiation to the myofibroblast phenotype is known to be modulated by 
cytokines (Darby et al., 1990). Transformation into myofibroblasts is regulated by the 
environment and is thought to be a two step process in which both mechanical tension
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and the presence of TGF P are required. The formation of stress fibres requires an initial 
up regulation and accumulation of intracellular proteins followed by assembly of these 
into stress fibres. The stress fibres form a terminal fibronexus adhesion complex which 
acts as mechano-transduction unit to functionally generate contractile force.
In the present, study TGF p resulted in concentration dependent increase in a  SMA 
expression with maximum TGF p stimulation resulting in a 200% increase over basal 
levels. Under phase contrast light microscopy changes in cell morphology were clearly 
identified after stimulation with lOpM TGF p. Cells became less spindle shaped and 
linear fibres could be defined with greater degree of cell contact. Immunofluorescent 
microscopy confirmed that the a  SMA had been incorporated into stress fibres. No other 
cytoplasmic a  SMA staining was detected. TGF p therefore appears to increase 
expression and assembly of a  SMA stress fibres in these ocular fibroblasts.
Cells at higher passage were found to have increased expression of a  SMA under serum 
free conditions. TGF p2 still upregulated a  SMA production; however, this was less 
marked. Higher passage cells induced a 190% increase over basal levels compared to 
374.9% by low passage cells. It is generally accepted that low passage cells behave in a 
more reproducible and predictable manner and all cell culture experiments were 
performed on cells between 2 and 6. In addition, it has been shown that fibroblast cell 
populations can be directed into either the fibroblast or myofibroblast phenotype by the 
density at which they are cultured. It is hypothesized that low density culture increases 
the population of myofibroblasts by reducing the degree of cell contact and subsequently 
increasing the number of TGF P receptors. All cells in this experiment were seeded at a 
density of 7x 103 which resulted in approximately 80% confluence. The same cell line 
may vary from passage to passage and higher passage cells are more likely at some stage
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to have been plated at high density. Finally, great care had to be taken when washing the 
monolayers with PBS after seeding in the presence of 1% FCS serum. Occasionally, cell 
loss was detected. This may have affected cell density, the response to TGF P and the 
level of a  SMA expression.
Treatment with CAT-152 completely prevented myofibroblast transformation with an 
IC50 value of 1.5nM. This was comparable to CAT-152 inhibition of collagen formation 
in which the IC50 was 1.3nM. Phase contrast microscopy demonstrated that at 
concentrations of lOnM and above CAT-152 cells became more linear and no 
intracellular fibres could be seen. Immunofluorescent imaging of the CAT-152 treated 
fibroblasts showed complete absence of stress fibres staining with a  SMA. At high power 
(x 60) faint granular cytoplasmic staining for a  SMA was detected. A similar degree of 
staining was also detected on the negative control suggesting that related to background 
staining rather than the presence of cytoplasmic a  SMA. CAT-152 appears to inhibit both 
expression and assembly of a  SMA stress fibres.
In summary, it is known that bleb failure is associated with collagen production and 
conjunctival tissue contraction secondary to myofibroblast activity. We have shown that 
CAT-152 reduces collagen production and prevents myofibroblast transformation in 
isolated Tenon’s fibroblasts. The IC50 values for CAT-152 were comparable for 
inhibition of collagen formation and myofibroblast transformation.
This highlights one of the mechanisms by which CAT-152 may act to improve the 
outcome of glaucoma filtration surgery in vivo.
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4.2 MODULATION OF TGF p AND CONJUNCTIVAL SCARRING IN VIVO
4.2.1 Temporal and spatial expression of TGF p and ECM molecules in 
subconjunctival rabbit tissue after glaucoma filtration surgery
Aqueous flow bathes the wound and provides a unique and changeable concentration of 
inflammatory mediators. In humans latent TGF-p2 is thought to be produced by tissues 
within the eye (ciliary body and trabecular meshwork) prior to activation by plasmin and 
thrombospondin released from blood components after breakdown of the blood aqueous 
barrier (Grainger et al., 1995; Knisely et al., 1991; Schultz-Cherry et al., 1995; Tripathi et 
al., 1994a). After glaucoma surgery it is assumed that elevated levels of activated TGF p2 
at the wound site are therefore likely to be related to aqueous concentration, the flow of 
aqueous and breakdown of the blood aqueous barrier. TGF P is also derived locally from 
degranulating platelets and inflammatory cells at the wound site. In addition TGF p 
displays the ability to auto induce its own production thereby initiating a perpetuating 
cascade of activation (Kelley et al., 1993; Li et al., 1999). This working hypothesis of 
TGF P secretion in GFS has not been experimentally demonstrated to date in the rabbit 
model.
The aims of this study were to identify the ocular source of TGF P in the rabbit, the effect 
of GFS on TGF p levels and how CAT-152 influences ocular TGF p2 mRNA and protein 
expression. In addition we analysed the mRNA and protein expression of ECM in the 
subconjunctival bleb tissue.
The rank order of relative TGFP2 mRNA expression in control eye tissues was ciliary 
body»iris>comea>conjunctiva>sclera.Variation in TGFpl mRNA expression across the 
tissues analysed was small, with greatest expression observed in the iris (rank order of
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expression; iris > ciliary body > conjunctiva > cornea > sclera). The relative levels of 
TGF P2 were higher than that of TGF pi and although this data has to be interpreted 
carefully as they are not absolute values, it does indicate that the overall levels of TGF P2 
are higher that those of TGF p i in the rabbit eye. In addition, the internal ocular 
structures (ciliary body and iris) had the highest relative expression of TGF p2 mRNA. 
These findings are consistent with our current hypothesis of ocular TGF p2 secretion as 
based on the research by Tripathi and others (Tripathi et al., 1994a; Tripathi et al., 1993). 
Relative TGFP2 mRNA expression was significantly upregulated after GFS in the cornea 
(day 14; P<0.05), iris (day 3; PcO.Ol) and ciliary body (day 3, P<0.001 and day 14, 
P<0.05). These increases were modest and mean relative mRNA expression did not 
exceed >four-fold control levels for any tissue The most striking changes in relative 
mRNA expression were observed for the TGF pi gene, which was more than 10 fold 
greater than control levels at day 3 in both conjunctiva and sclera, possibly representing a 
delayed local tissue response to the trauma of the GFS procedure.
TGF P mRNA expression appeared to follow a similar temporal pattern reaching a peak 
on day 3 and gradually returning to pre-operative levels by day 14. This was most clearly 
seen in the conjunctival tissue. This represents an interesting finding and correlates well 
the temporal changes in cellularity, collagen and a  SMA demonstrated histologically in 
the rabbit tissue after GFS, which reached a peak at day 10 and gradually reduced by day 
30 (Section 3.2.4.8). The levels of total TGF p2 observed in the aqueous humour of 
control eyes in this study are consistent with values previously reported for the New 
Zealand White rabbit (i.e. 2.7-4.Ing/mL; Liu, 2002 and 1.4-3.5ng/mL; Cousins et al., 
1991) (Cousins et al., 1991; Liu, 2002). However, active TGF p2 levels in control
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samples were higher in the present results than those published by Liu (2002) who 
highlighted a circadian variation in total and active TGF (32 levels in rabbit aqueous 
humour. This factor was not specifically taken into account when sampling aqueous 
humour in this study and it is not clear to what extent the apparent difference in active 
TGF p2 levels is due to such circadian changes. All samples were taken in the morning 
over a two hour time period.
Total TGF P2 levels were significantly higher in rabbit aqueous humour on the first day 
after GFS and again displayed a stepwise reduction over time. The day 1 result was not 
matched with increased relative TGF p2 mRNA expression in any of the ocular tissues 
assayed until day 3. This may indicate that the initial source of TGF P2 is related to the 
BAB breakdown rather than local production.
The post-GFS aqueous levels of active TGF p2 described in this report are constant at 
approximately 600-700pg/mL and appear to more closely reflect the previously reported 
values derived from normal eyes (i.e. 120-450pg/mL; Liu, 2002 and 320-6lOpg/mL; 
Cousins et al., 1991). It would be logical to predict that active TGF P2 levels would also 
become elevated after GFS. However, at face value, the data presented here indicates that 
there is a sustained reduction in aqueous levels of active TGF p2. A number of 
expanantions can be given to account for this. Firstly, the results may demonstrate a 
spuriously high level of active TGFP2 in control samples, with post-GFS levels that are 
reduced or otherwise unchanged from ‘normal’. Secondly, active TGF P is a very labile 
molecule which is difficult to assay. Finally, and most importantly, it is known that on 
conversion to the active molecule, TGF P becomes bound and sequestered in the tissues. 
Total active TGF P may well have become elevated after GFS, however, free unbound 
TGF P2 available for assay would go down.
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Treatment with CAT-152 did not result in a clear pattern of changes in the expression of 
TGFP mRNA or protein in any of the tissues studied. It was interesting to note and 
hypothesize on the biological significance of the isolated inhibitory effects seen for 
relative mRNA expression for TGF (31 (ciliary body; day 3) and TGF p2 (iris; day 3) In 
this model a tube is positioned in the eye and provides a communication between the 
anterior chamber and the conjunctival bleb tissue. Thorectically, it may be possible for 
some of the drug admninistered adjacent to the bleb to enter the eye and act on the 
internal tissues such as the iris and ciliary body. This would help to explain how 
subconjunctival CAT-152 can reduce iris and ciliary body TGF p mRNA expression. 
Overall, the TGF P data presented suggests that normal rabbit eyes contain high levels of 
TGF P2 protein, which is the most predominant ocular isotype in the rabbit. The source of 
TGF P2 in aqueous humour has not been completely elucidated in this study, however, 
TGF P2 mRNA expression was considerably greater in the ciliary body. This supports the 
theory that TGF P2 is predominantly produced from internal ocular tissues in the 
unoperated eye. After GFS early increases in aqueous TGF P2 may result from BAB 
breakdown. Conjunctival TGF p mRNA demonstrates a temporal expression profile with 
highest levels detected on day 3 and stepwise reduction by day 14.
Following GFS conjunctival a  SMA and collagen III mRNA expression was markedly 
increased over 100-fold increase compared to controls. Expression was greatest on day 3 
and reduced with time. A less marked but similar pattern was also demonstrated in the 
sclera expression of a  SMA and collagen III. Collagen deposition and a-SMA expression 
are known features of the fibrotic bleb seen after GFS in the rabbit and human (Hitchings 
et al., 1983). In this model bleb failure occurs on approximately day 14 without any anti­
scarring agents. It can be postulated that the increase in conjunctival collagen and a  SMA
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expression on day 3 would mediate the increase in the deposition of these proteins with in 
the bleb within this time scale.
After wounding, a fibrin scaffold is formed at the wound site, which is initially replaced 
by collagen type in  and then by collagen type I. In comparison to collagen III, lower 
levels of collagen I were detected within the time course of the experiment. However, 
collagen I expression was also highest on day 3 and decreased with time. From this it can 
be inferred that predominantly collagen III may account for early bleb failure, which may 
then be replaced with collagen I as the scar is organized with time.
Interesting results were seen in the cornea with strong up regulation of a  SMA and 
collagen HI seen up to a maximum of around 100-fold increase on day 14. At this time 
point expression of collagen I (p<0.01) and collagen HI (pcO.OOl) reached significance 
over controls. During the procedure the tube is inserted into the clear cornea beyond the 
limbus before entering the eye. This is the most likely trigger to the wound healing 
response in the cornea and the up regulation of both collagen and a  SMA. The rabbit 
appears to exhibit a very pronounced corneal wound healing response clinically with 
stromal opacification and neovascularisation.
In the iris and cilliary body collagen HI was weakly upregulated from day 3 onwards after 
GFS. During the initial post-operative period the anterior chamber is very flat with close 
apposition of the tube to the iris. One explanation for the results is that the physical 
presence of tube in the eye may have initiated injury and a subsequent localised wound 
healing cascade. However, these tissues were also shown to upregulate the expression 
TGF (32. High local levels of TGF [32 may have resulted in a subsequent increase in the 
expression of collagen and a  SMA.
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CAT-152 was only shown to inhibit the expression of collagen III mRNA in the cornea 
but did not affect the genes tested in the other ocular tissues.
The data has displayed a relationship between GFS and the ECM deposition associated 
with bleb failure. However, again it failed to reveal a convincing relationship between 
changes in ECM expression and the application CAT-152 treatment.
Overall, it seems reasonable to assume that scleral and conjunctival tissue at the site of 
the drainage bleb would be continuously exposed to the high concentration of TGF (32 in 
aqueous humour. Total TGF (32 levels are considerably higher in bleb tissue at day 3 post 
surgery and this may represent accumulation of TGF p2 protein at the site of aqueous 
humour filtration or de novo protein synthesis in the bleb tissue in response to tissue 
injury. Based on the data presented here, accumulation from filtered aqueous humour 
seems the more likely explanation given that total TGF p2 levels were transiently 
increased in aqueous humour at day i) post-GFS, and ii) conjunctival TGF p2 mRNA 
expression is not significantly upregulated after GFS (although there is a trend to 
increased expression at day 3 post GFS). Whatever the origin of the conjunctival bleb 
TGF P2, exposure of the tissues to TGF p2 in this way is likely to contribute to the rapid 
fibrosis and failure of drainage blebs characteristic of the rabbit model. The 
concentration of TGF P2 present in aqueous humour in this study (~ 10-lOOpM) has been 
shown in vitro to promote collagen production in human conjunctival fibroblasts and their 
transdifferentiation to a myofibroblast phenotype expressing a  SMA (As discussed in 
section 4.1). Both TGF p2-evoked effects can be inhibited by CAT-152. The available 
evidence suggests that bleb failure in the rabbit experimental GFS model is mediated by 
fibrotic changes in conjunctival tissue that is exposed to persistently high concentrations
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of TGF 02 present in aqueous humour. Prevention of the fibrotic response can be 
achieved by repeated subconjunctival administration of CAT-152, which neutralises the 
excess TGF 02 within the bleb tissue leading to a reduction in TGF 02 protein levels, 
removal of the drive for the fibrotic response and thereby promotes drainage bleb 
survival.
4.2.2 Modulating effect of Anti-TGF 02 antibody (CAT-152) on the outcome of 
experimental glaucoma filtration surgery
4.2.2.1 Effect of intra-operative CAT-152 The ideal anti-scarring agent would
be administered at the time of surgery as a single treatment. We therefore investigated if 
intra-operative treatment of CAT-152 given immediately before and after surgery could 
reduce scarring after glaucoma filtration surgery.
Unfortunately, this study did not show any benefit of a single dose regimen. The main 
outcome variable was bleb survival. All blebs failed by day 21. Median bleb failure was 
14 days after treatment with CAT-152, PBS and with no treatment. These findings were 
consistent with previous studies using this model, in which untreated control animals 
most commonly fail around day 14. In addition, the fact that the PBS group displayed 
similar rates of failure to the no treatment group suggests that the physical act of the 
subconjunctival injection does not influence bleb outcome.
This finding that is not totally unexpected given knowledge of the timing of peak Tenon’s 
capsule fibroblast activity following injury. Reichel introduced a new model of 
conjunctival scarring in the mouse eye (Reichel et al., 1998). The inflammatory cell 
profile following conjunctival injury was demonstrated by sequential histological
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analysis. The fibroblast population, the third wave of cellular activity, was shown to 
increase during the first three days to reach a peak at day 3. Thereafter, it was found to 
decrease but never quite returned to the control eye activity level. Fibroblast activity was 
closely associated with the deposition of newly laid extracellular matrix. With TGF p 
driving this fibroblast proliferation, inhibitory effects induced by its neutralising antibody, 
CAT-152, are likely to be most demonstrable by administration at times of greatest 
cytokine activity in the immediate post-operative period.
Rabbit models exhibit an exaggerated healing response compared to human tissue. 
Demonstration of efficacy in such models is therefore likely to be reproduced in the 
clinical setting. Conversely, potential clinical benefit may be overlooked when a 
treatment fails to show efficacy in such as aggressive model.
The technique of glaucoma surgery used in this study localises scarring to the level of the 
conjunctiva. This is achieved by maintaining a permanent fistula to drain aqueous into the 
subconjunctival wound site. Previous experience has shown that intraocular pressure is 
not a reliable indicator of filtration in this model of glaucoma surgery. Furthermore, in 
this study no significant differences were detected in IOP between groups. This can be 
explained by the fact that basal pre-operative intraocular pressure in this model of 
glaucoma filtration surgery is within the normal range (this is a model of subconjunctival 
scarring not of glaucoma). Given this, bleb failure rather than intraocular pressure has 
always been defined as the primary outcome variable to represent failure of surgery in 
this model.
Anterior chamber depth was included in the observations as an indirect indicator of the 
drainage of fluid through the tube into the subconjunctival space. The rabbit anterior 
segment is very crowded with a very large lens and small anterior chamber. Therefore in 
practice, this measurement was fairly difficult to grade. In most of the animals the
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anterior chamber was flat on day one and gradually deepened over the next 7 days. No 
significant difference was found between the treatments in the time taken for the anterior 
chamber to deepen. Overall, this observation may not be as true a representation of 
anterior fluid dynamics as had been originally anticipated.
Despite the lack of demonstrable efficacy all the treatments were well tolerated.
4.2.2.2 Effect of prolonged post-operative application of CAT-152: Comparison with 
5-Fluorouracil Continued scarring leading to late failure of glaucoma filtration 
surgery remains a major barrier to long-term intraocular pressure control and arrest of the 
glaucomatous progression. This experiment was designed to see if post-operative 
neutralisation of TGF p alone, could prevent bleb failure and provide a means of 
rescuing failing blebs. 5-FU has been given subconjunctival in the post-operative period 
to treat failing and encysted blebs so CAT-152 was also compared to the gold standard 
post-operative anti-scarring agent.
The results of this study demonstrated that neutralising the effects of TGF-P2 in the post­
operative period, by subconjunctival administration of CAT-152 can improve the 
outcome of glaucoma surgery in this model. In addition, the effect of post-operative 
CAT-152 appears more efficacious than 5-FU and without some of the side effects 
associated with anti-proliferative use.
As with previous experience no significant differences were detected in IOP between 
groups in this study.
We found that isolated post-operative 5-FU had the same bleb survival end point as 
control in this experiment. This model exhibits an extremely aggressive scarring response 
which may explain this finding. However, conversely, all the treatments that have 
improved bleb survival in this model have worked in a subsequent clinical setting. Only a
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limited number of studies have looked at efficacy of 5-FU as an isolated post-operative 
agent in animal experiments. Doyle et al compared the effect of 5 post-operative 
injections of 5-FU with single intra-operative 5-FU, and combined intra and post­
operative 5-FU in rabbit filtration surgery. Control animals received intra-operative 
distilled water only. No significant difference was shown in bleb survival between post­
operative 5-FU treatment and control in this study. However, what can be seen in the 
survival curve from Doyle’s study and our data is that post-operative injections of 5-FU 
appear to shift the survival curve to the right of the control in the early time points, 
without affecting the final endpoint (Doyle et al., 1993b).
The landmark study of the 5-Fluorouracil Filtration surgery Study Group represents the 
only definitive report in which post-operative injections of 5-FU were shown to improve 
surgical outcome (Group, 1989). In this study a total of 21 subconjunctival injections 
were given: 2 injections per day on days 1-7 after surgery and 1 injection per day on day 
7-14 after surgery. If this number of injections had been used we may well have shown 
efficacy of post-operative 5-FU in this model. When designing the protocol we chose a 
post-operative regimen that more closely reflected current clinical subconjunctival 5-FU 
use.
Anterior chamber measurements did not reveal any significant differences between the 
groups. This again highlights that this observation has not proved itself to be a reliable 
indicator of transconjunctival drainage.
Ideally all subconjunctival injections would have been given at the same site. In all the 
pre-clinical and clinical studies of CAT-152 in glaucoma filtration surgery the drug has 
been administered by subconjunctival injection in the superior nasal quadrant adjacent to 
the drainage bleb. The same injection site was therefore selected in this study. Clinically, 
the site of subconjunctival 5-FU administration varies depending on clinical preference.
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Some clinicians favour injections adjacent to the bleb, some 90 degrees and some 180 
degrees from the operation site. The main concern with injecting 5-FU adjacent to the 
bleb relates to the possibility of intraocular penetration as the pH of 5-FU is 9. We 
decided to base our study protocol on the pioneering studies of 5-FU in glaucoma surgery 
performed by The Fluorouracil Filtering Surgery Study Group. In this study 5-FU was 
injected 180 degrees from the site of surgery. Given the different injection sites for the 
CAT-152 and 5-FU groups a universal injection site for a control vehicle was not possible 
so the no treatment control group was introduced.
Aqueous flow bathes the wound and provides a unique and changeable environment 
which influences post-operative healing. Of all the growth factors in the aqueous TGF p 
is the most potent stimulator of human Tenon’s fibroblast activity (Khaw et al., 1994b). 
Latent TGF p2 is produced by tissues within the eye (ciliary body and trabecular 
meshwork) prior to activation by plasmin and thrombospondin released from blood 
components (Tripathi et al., 1994a) (Grainger et al., 1995; Knisely et al., 1991; Schultz- 
Cherry et al., 1995). Aqueous humour in glaucomatous eyes contains increased level of 
TGF-p2 (Tripathi et al., 1994a). After glaucoma surgery elevated levels of activated TGF 
P2 at the wound site are therefore likely to be related to aqueous concentration, the flow 
of aqueous and breakdown of the blood aqueous barrier. In addition, TGF p also displays 
the ability to auto induce its own production thereby initiating a perpetuating cascade of 
activation (Kelley et al., 1993; Li et al., 1999). In a mouse model of conjunctival scarring 
peak levels of TGF p2 have been shown at the wound site at day 7 (Reichel et al., 1998). 
Without treatment the rabbit model fails by day 14. We propose that isolated post­
operative administration of CAT-152, between days 2-14 in this model, can still
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neutralise subconjunctival TGF (32 levels at the wound site below a threshold required to 
mediate downstream effects on the extracellular matrix.
Histological analysis of the rabbit tissues showed that CAT-152 significantly reduced 
subconjunctival collagen deposition compared to both the 5-FU and control groups.
CAT-152 also significantly reduced the population of cells expressing a  smooth muscle 
actin, indicating an inhibition of fibroblast differentiation into the myofibroblast 
phenotype. These histological observations taken together with the effects of CAT-152 in 
isolated Tenon’s fibroblasts suggest that the beneficial effects of CAT-152 in glaucoma 
filtration surgery are mediated by a reduction in collagen production and prevention of 
myofibroblast transformation resulting in reduced contraction of the drainage bleb tissue 
Repeated injections of subconjunctival 5-FU in clinical practice are known to cause 
corneal epitheliopathy. Similar findings were associated with the use of 5-FU in this 
study. The more serious complications of avascular bleb formation, bleb related infection 
and chronic hypotony reflect the cytotoxic mechanism of action of anti-proliferative 
agents. CAT-152 treatment provides a more physiological alternative.
This represents a potentially useful development in the prevention of late surgical failure 
and may provide us with a safer therapy to maintain maximal IOP control.
4.2.2.3 Long term effects of combining intra-operative and prolonged post-operative 
CAT-152 treatment So far the effect of CAT-152 has only been investigated over a 30 
day post-operative period. This experiment was designed to identify if maximum dosing 
with CAT-152 could prevent bleb failure occurring for 45 days. In addition, during the 
project the cell line used to expand the production CAT-152 was modified. The original 
batch of CAT-152 had been used in all the previous in vivo experiments. The new 
antibody was used in this experiment.
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The data clearly shows that administration of CAT-152 at the time of surgery and 
continued post-surgical dosing prevents bleb failure (33% survival at day 45). Survival 
until 45 days in this model is highly significant. By combining the intra-operative with 
the prolonged post-operative regimen maximal efficacy appears to have been achieved. 
Two control groups were included in the study. In half the animals the PBS was given by 
superior subconjunctival injection and in the remaining animals by inferior injection. Bleb 
survival was not significantly different between these groups. The physical effect of the 
subconjunctival injection, therefore, does not appear to influence conjunctival bleb 
scarring. This is an important finding and confirms that the efficacy over 5-FU is not 
related to injection site. This is supported by the finding that there is a similar degree of 
bleb failure in PBS treated animals (median bleb survival 17 days; present study) and 
untreated control animals (median bleb survival 14 days in intra-operative study as 
discussed in section 4.2.21).
No significant differences in IOP survival were detected. However a trend for higher 
mean post-operative pressure was seen in the 5-FU treated group. Significantly higher 
pressures in the 5-FU animals compared to CAT-152 were seen on day 14 (p=0.069), 
day 28 (p=0.096) and day 31 p=0.068) and also compared to PBS on day 28 (p=0.075). 
Mean IOP with CAT-152 was similar to control mean IOP. Care must be taken not to 
place too much value on this data as it is generally accepted that intraocular pressure is 
not a reliable indicator of filtration in this model of glaucoma surgery.
In clinical practice 5-FU is associated with corneal epitheliopathy and avascularity. Side 
effects from administration of 5-Flurouracil were demonstrated in this study. 5-FU 
prolonged the duration of superficial punctate keratitis and the duration of the nasal 
avascular segment. These findings relate to the cytotoxic method by which the drug acts. 
Treatment with CAT-152 did not increase these variables over the control animals.
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CAT-152 was also well tolerated as assessed by anterior chamber activity and 
conjunctival vascularity. However, a new finding of conjunctival chemosis was detected. 
Transient self limiting chemosis is seen in this model in the first 24 hours after surgery 
and is thought to be related to tissue trauma. Early chemosis was seen in all treatment 
groups. However, late chemosis 14 days after GFS has not been seen before and was only 
observed in the CAT-152 treatment group. Chemosis occurred in one third of animals 
treated with CAT-152 but did not appear to influence bleb survival. This response may be 
explained by the administration of multiple injections of a human antibody into the rabbit 
generating an immune response. It must be highlighted that this frequency of injections is 
in excess of any regimen that would be translated into the clinical setting. In addition, 
human administration of a human antibody will not be complicated by such a response. 
However, given this finding it will be important to understand the mechanism driving this 
response.
In summary maximal dosing of CAT-152 can maintain long term bleb function and the 
modifications made in the production of the antibody do not seem to influence efficacy.
4.2.2.4 Effects of a combined course of intra-operative and prolonged treatment with 
the CAT-152 on the immune response in the rabbit Prolonged dosing of CAT- 
152 after GFS caused chemosis in a proportion (33%) of treated rabbits. This study was 
designed to confirm this observation and to investigate the mechanism of CAT-152- 
induced chemosis.
The incidence of chemosis was evaluated in the rabbit model of GFS following treatment 
with CAT-152 and a null control human IgG4, CAT-001 according to the prolonged 
dosing schedule used in 2.7.3 (18 subconjunctival injections of lOOpg over 42 days).
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Vehicle control (PBS) was administered to a third treatment group using the same 
injection schedule.
As previously shown, PBS treatment did not cause late chemosis demonstrating that the 
late response is related to antibody treatment. Early chemosis was seen in the PBS 
treatment group as well as the CAT-152 and CAT-001 groups. Early chemosis is a 
response to GFS and is not treatment related. Furthermore, there is no correlation 
between the incidence of early (induced by GFS) and late (induced by antibody 
treatment) chemosis.
CAT-152 and CAT-001 induced chemosis in a proportion of the rabbits treated (1 of 6 
and 3 of 6 rabbits, respectively). The severity of the chemosis induced by CAT-152 was 
similar to that induced by CAT-001, although the incidence of chemosis was greater in 
the CAT-001 treatment group. The ability of CAT-001, a null control human IgG4, to 
induce chemosis suggests that this response is a consequence of an immune reaction to 
this human protein. The chemosis induced by CAT-152 is therefore likely to be an 
immune reaction to the human IgG4 and appears unrelated to neutralisation of TGF p2. It 
has previously been demonstrated that CAT-001 does not neutralise TGF P2.
Evidence for involvement of immune system is demonstrated by the presence of rabbit 
antibodies directed against CAT-001 or CAT-152. The majority of human antibody 
treated rabbits produced an anti-human antibody response (4 of 6 or 5 of 6 for rabbits 
treated with CAT-152 or CAT-001, respectively). Only those rabbits with anti-CAT-152 
or anti-CAT-001 antibodies (detected within the serum) mounted a chemotic response on 
injection of the human antibodies. However, not all rabbits with serum antibodies to 
CAT-001 or CAT-152 responded to antibody injection with chemosis. Therefore, the 
anti-CAT-152 or anti-CAT-001 response, although essential for generation of chemosis,
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is not the only factor required to elicit this response. The additional factors in the 
chemosis response other than the anti-human antibody response are unknown.
The serum level of the anti-CAT-152 or anti-CAT-001 antibody response does not appear 
to be related to the incidence of chemosis. However, it is important to note that the 
presence of CAT-152 or CAT-001 in the serum can interfere with the anti-CAT-152 or 
anti-CAT-001 detection assay, respectively. The presence of CAT-152 in serum 70 days 
after initiation of CAT-152 treatment (rabbits 5 and 6; see Table 16) may result in an 
underestimate of the anti-CAT-152 antibody response. CAT-001 was not detected at the 
70 day time point; interference is therefore unlikely and so the serum anti-CAT-001 level 
is a true estimate of the immune response. Within the CAT-001 treatment group chemosis 
can clearly be dissociated from the anti-CAT-001 serum level (see rabbit 9, Table 16). 
Subconjunctival injection of CAT-001 and CAT-152 resulted in systemic exposure of the 
rabbits to these human antibodies. This has been observed previously with CAT-152. 
Maximum exposure was observed four days after initiation of treatment (and GFS) and 
serum levels of CAT-001 and CAT-152 were similar at this time point (999 and 
1095ng/ml, respectively). The serum level of CAT-001 declined over time and was not 
detected at the 70 day time point. A similar pharmacokinetic profile was observed for 
CAT-152 in the majority of rabbits. However, in two animals the serum concentration of 
CAT-152 increased between day 24 and 44 and appreciable levels of CAT-152 were 
observed in serum 70 days after the first injection (28 days after the last injection). The 
reason for this profile is unknown.
The chemosis induced by CAT-152 in rabbits is unlikely to be manifest in human patients 
undergoing GFS. The main reason is that the human subjects would not be expected to 
mount a marked anti-human antibody response (since CAT-152 is a human IgG4 protein). 
Moreover, application of a regimen (six doses of lOOpg of CAT-152 given over 7 days)
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in the rabbit model that approximates the clinical regimen (four doses of lOOpg of CAT- 
152 given over 8 days) does not induce chemosis (Cordeiro et al., 1999a).
4.2.2.5 Development and application of CAT-152 as an anti-scarring agent in 
glaucoma filtration surgery Figure 88 summarises the survival curves of the CAT-152 
studies using this model, three of which have been performed in this research project. A 
dose-regimen response is evident. Administration of CAT-152 at the time of surgery 
appears to be important but CAT-152 is only effective when surgical dosing is 
accompanied with post-surgical administration. Post-operative dosing is more important 
than surgical as isolated post-operative CAT-152 can still improve bleb survival. 
Maximum efficacy is achieved by the combination of intra-operative and prolonged post­
operative CAT-152. CAT-152 from the new cell line was used for this combined 
experiment (Section 2.7.3: labelled 4 on the graph) and thus it is clear that this batch is 
also effective in vivo as in vitro testing had indicated. Histologically, CAT-152 reduces 
collagen deposition and myofibroblast transformation in vitro and in vivo, two essential 
elements of bleb failure.
Important considerations can be drawn from this preclinical data in the development of 
this drug as a new anti-scarring agent in clinical glaucoma surgery. Two clinical trials 
have been performed and a multicentre European trial is reporting. The dose regimen 
used in the clinic consists of four subconjunctival injections (1 OOjllI of lmg/ml CAT-152). 
Subconjunctival injections are given at the time of surgery (Immediately before and after 
the procedure), on day 1 and day 7. Experience with this model indicates that 1 day in the 
rabbit equates to approximately 1-2 weeks in human scarring. So the clinical dose 
approximately translates to experimental intra-operative treatment combined with post­
operative treatment on day 1 and day 2 in the rabbit. The clinical dose is kept to the
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Figure 88 CAT-152 Dose Regimen-Response
-C A T -152 
—  CAT-152 
...CAT-152 
CAT-152i___
— i
Time (days)
Exp. Treatment Regimen Dose (jig) No. of 
Injection
Time of Dose (days) 
[Study end (day)]
2 Surgical alone 100 2 0,0 [30]
1 Surgical+Acute post-surgical 100 6 0,0,1,2,3,7 [30]
3 Prolonged Post-surgical 100 7 2,3,4,7,9,11,14 [30]
4 Surgical+Prolonged Post-surgical 100 18 0,0,1,2,3,4,7,9,11,14,17,21,24,28,31,35,38,42 [45]
Figure 88 summarises the survival curves of the CAT-152 studies using this model, three of which have been performed in 
this research project. A dose-regimen response is evident.
minimum to aid acceptance and ease of application. This is balanced with the obvious 
need for the selected regimen to provide efficacy.
The information provided by these experimental studies confirms that this dose regimen 
is close to optimal from the preclinical standpoint. The data also suggests that post­
operative dosing with CAT-152 commenced 2 weeks after surgery and continued at 2 
weekly intervals up to three months may provide a means of rescuing failing blebs. A 
further clinical trial is being planned to test this hypothesis.
CAT-152 has always been shown to be more effective than 5-FU (post-operative or 
maximal dose regimen) as shown in Figure 89. The dose regimen of 5-FU in the 
landmark study performed by the fluorouracil filtering study group included 14 post­
operative injections. Clinically, 5-FU is now given as a single intra-operative dose or by 
subconjunctival injection in the post-operative period on an ad hoc basis. The 
demonstration of enhanced efficacy over 5-FU is extremely important for potential 
acceptance of CAT-152 as a new scarring agent. In addition the development of the 
optimal clinical dose regimen has been extensively investigated before licensing of the 
drug unlike 5-FU.
Finally, in all these experimental studies CAT-152 has been well tolerated. The 
observation of chemosis in the rabbit model was an interesting finding. This response was 
investigated in experiment 2.7.4 and the mechanism driving it identified. No chemotic 
response has been seen clinically and should not be mediated as it was driven by the anti­
human antibody response of the rabbit.
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Figure 89 Comparison of the effect of CAT-152 with 5FU
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Time (days)
Exp. Treatment Regimen Dose (mg) No. of Time of Dose (days)
CAT-152 0.1 mg or 5-FU 5mg Injection [Study end (day)]
3 Prolonged Post-surgical 0.1 or 5 7 2,3,4,7,9,11,14 [30]
4 Surgical+Prolonged Post-surgical 0.1 or 5 18 0,0,1,2,3,4,7,9,11,14,17,21,24,28,31,35,38,42 [45]
CAT-152 has always been shown to be more effective than 5-FU (post-operative or maximal dose regimen)
4.2.3 Modulation effect of antisense oligonucleotides targeting TGF P on the
outcome o f  experimental glaucoma nitration surgery
4.2.3.1 Tolerance to TGF p antisense oligonucleotides
The response of the rabbit to application subconjunctival TGF pi antisense OGN was 
investigated in this study. All three doses of antisense 25 pg, 50 pg and 100 pg were well 
tolerated. This w as not unexpected given the similar antisense molecules had been 
previous tested in the mouse model of conjunctival scarring without adverse effects 
(Cordeiro et al., 2000a).
4.2.3.2 Efficacy of TGF p antisense oligonucleotides
This study showed that antisense OGN directed against TGF p2 significantly prolonged 
bleb survival after glaucoma filtration surgery. All animals failed surgery by day 23. The 
effect of TGF P2 was to extend survival from a median of 14 days in the PBS treated 
group to 17 days in the treated group.
Previous studies have shown that TGF p2 is the most important isoform involved in 
conjunctival scarring (Cordeiro et al., 1999b). The reasons why three homologous TGF p 
isoforms exist in humans is still not fully understood. One possible explanation might be 
that the differential patterns of expression rely on co-ordination of each of the three 
isoforms as mediators of mesenchymal-epithelial interactions; hence in the skin, TGF P2 
and TGF p3 affect epithelialization and keratocyte migration, while the effects of TGF pi 
are predominantly dermal and involve fibroblast functions (Lutty et al., 1993). The 
conjunctival scarring model used in this project does not involve a breach in the 
epithelium. Hence the conjunctival stroma is the target tissue, which appears, from this
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work and that of Pasquale et al, to primarily involve the TGF p2 isoform (Pasquale et al., 
1993). Given that inhibiting TGF p2 appears to be so important in reducing the 
conjunctival scarring response, it is perhaps not surprising that the antisense OGN to TGF 
P2 that was most successful in prolonging bleb survival in this model.
However, antisense OGN would be expected to have maximal effects on the local cellular 
production of TGF P at the wound site and not in the aqueous. Evidence suggests that 
TGF p i is secreted in the conjunctiva by local inflammatory cells including fibroblasts 
and platelets. The expression of TGF p i mRNA from our study in the rabbit eye is 
consistent with this. In general most of the TGF p2 is thought to originate from inside the 
eye with high concentration in the aqueous humour. It was therefore hypothesised that 
antisense OGN towards TGF p i would have showed efficacy in this experiment rather 
than TGF p2. As application of the TGF P antisense OGN is external to the eye it should 
not directly suppress the intraocular production of TGF p2, so we can only postulate that 
it may reduce aqueous TGF p2 by interfering the auto induction pathway from the cells 
within the eye. Alternatively, antisense may infact be able to enter the eye through reverse 
flow down the tube.
Bleb failure was defined as the presence of a flat scarred bleb in association with a deep 
anterior chamber. Mean bleb area and bleb height were not significantly increased by any 
of the treatments. However in animals treated with antisense OGN against TGF p2 the 
time for the AC to deepen was increased, which subsequently influenced and prolonged 
the time to bleb failure. The depth of the AC is thought to reflect the speed and degree of 
transconjunctival drainage of aqueous fluid. As we have gained in experience with this 
model it is becoming apparent that this is a difficult parameter to measure. In the previous 
experiments neutralising TGF p2 with CAT-152 the time taken for the AC to deepen has
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been consistent across the treatment groups. It is difficult to explain why it took longer for 
the AC to deepen in this particular experiment, but it is clear that this clinical observation 
was one of the contributing factors associated with the increase in bleb survival.
Median bleb survival in the TBR II treated group was 17 days and this almost gained 
significance over treatment with PBS (p=0.0729). Most cell types simultaneously express 
the main TGF p receptors, TBR I, II and III, which are all present in the conjunctiva. A 
recent finding has been that TBR HB an alternatively spliced variant of the TBR-II 
receptor, is a TGF p2 binding receptor, which mediates signalling via the smad pathway 
in the absence of TBR III (Rotzer et al., 2001). The expression of TBR IIB is restricted to 
cells originating from the mesenchymal tissues such as bone where the isoform TGF P2 
has the predominant role. It would be interesting to investigate an antisense OGN 
designed against this spliced variant, as it may be more specific in inhibiting TGF p2 
mediated activity.
Histological findings on day 21 correlated with the clinical observations of bleb failure. 
On day 21 TGF p2 antisense OGN a significantly reduced collagen density and improved 
collagen orientation and reduced the deposition of elastic fibres. Reduction in TGF P2 
protein expression inhibited the downstream TGF p mediated effects on extracellular 
matrix deposition thereby preventing bleb failure.
It can be concluded that TGF P2 antisense OGN treatment is effective in reducing the 
scarring response after glaucoma filtration surgery and it appears to be more potent than 
TBR II and TGF p i antisense OGN. In addition it appears to be well tolerated in vivo. 
However, these findings have to be interpreted with care. The mechanism by which TGF 
p2 was down regulated and the influence of the AC depth measurements on bleb survival 
must be considered when interpreting the data. In vitro assays of fibroblast function will
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need to be carried out using these novel agents before further in vivo testing is performed. 
However, these results are encouraging and help to confirm both that modulation of TGF 
p is a very effective way of reducing post-operative subconjunctival scarring and TGF 
p antisense OGN might represent a novel way of achieving this.
4.3 CONCLUSIONS
In conclusion this project has continued to establish the role of TGF p modulation as a 
new anti-scarring strategy in glaucoma surgery.
In vitro, I have demonstrated that CAT-152 inhibits TGF P2 induced human Tenon’s 
fibroblast collagen production and myofibroblast transformation at physiological 
concentrations.
In vivo, this research has added further evidence to suggest that TGF p2 is the most 
predominant ocular isoform and has identified changes in the expression of TGF p and 
ECM molecules associated with glaucoma surgery and TGF p modulation in the rabbit 
eye. Histologically, it appears that collagen deposition and myofibroblast transformation 
are key elements of bleb failure in the rabbit.
I have demonstrated, in vivo, that subconjunctival administration of CAT-152, given at 
the time of glaucoma surgery and in the immediate post-operative period, successfully 
improves surgical outcome, reduces subconjunctival fibrosis and is safe and well 
tolerated. Isolated post-operative administration of subconjunctival CAT-152 can prevent 
late bleb failure and prolonged dosing with CAT-152 appears to modulate the long-term 
scarring response after filtration surgery. Finally, I have shown that the anti-scarring 
effects of CAT-152 compare favourably to one of the gold standard anti-scarring agents 
in clinical use. These results have helped in establishing the potential clinical dose
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regimen and have influenced the design of clinical trials. Overall, these findings have 
helped to move the novel antibody CAT-152 nearer to the clinical arena.
In addition, I have shown for the first time that antisense oligonucleotides directed against 
TGF p may also have a role in the prevention of conjunctival scarring.
New developments and the future The anti-proliferative agents are currently the most 
effective tool available to suppress conjunctival scarring after glaucoma surgery. Basic 
research has provided a greater understanding of how these agents work, which has lead 
to modifications in their use to improve efficacy and safety. This thesis and other research 
have demonstrated that exciting new physiological anti-scarring agents are now on the 
horizon. In the future, a multi-therapy approach may offer the best combination of 
efficacy with minimal side effects analogous to chemotherapy. Continued research and 
further understanding of the molecular events driving the wound healing response are 
essential. Ultimately, this will enable us to achieve optimal long-term intraocular pressure 
control after glaucoma surgery and prevent glaucomatous progression in the majority of 
patients.
Finally, the demonstration that TGF p2 modulation represents a successful anti-scarring 
strategy in the conjunctiva after GFS, may lead to its application in other scarring 
conditions in the eye and potentially throughout the body.
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